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Abstract 
 
The investigation of the web of relationships between the different elements 
of the immune system has proven instrumental to better understand this 
complex biological system. This is particularly true in the case of the 
interactions between B and T lymphocytes, both during cellular development 
and at the stage of cellular effectors functions. The understanding of the B–T 
cells interdependency and the possibility to manipulate this relationship may 
be directly applicable to situations where immunity is deficient, as is the case 
of cancer or immune suppression after radio and chemotherapy.  
The work presented here started with the development of a novel and 
accurate tool to directly assess the diversity of the cellular repertoire 
(Chapter III). Contractions of T cell receptor diversity have been related with 
a deficient immune status. This method uses gene chips platforms where 
nucleic acids coding for lymphocyte receptors are hybridized and is based on 
the fact that the frequency of hybridization of nucleic acids to the 
oligonucleotides on a gene chip varies in direct proportion to diversity.   
Subsequently, and using this new method and other techniques of cell 
quantification I examined, in an animal model, the role that polyclonal B cells 
and immunoglobulin exert upon T cell development in the thymus, 
specifically on the acquisition of a broader repertoire diversity by the T cell 
receptors (Chapter IV and V).  The hypothesis tested was if the presence of 
more diverse peptides in the thymus, namely polyclonal immunoglobulin, 
would induce the generation of more diverse T cells precursors.  The results  
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obtained demonstrated that the diversity of the T cell compartment is 
increased by the presence of polyclonal immunoglobulin. Polyclonal 
immunoglobulin, and particularly the Fab fragments of the molecule, 
represent the most diverse self-molecules in the body and its peptides are 
presented by antigen presenting cells to precursor T cells in the thymus 
during its development. This probably contributes significantly to the 
generation of receptor diversity. 
Furthermore, we also demonstrated that a more diverse repertoire of T 
lymphocytes is associated with a more effective and robust T cell immune 
function in vivo, as mice with a more diverse T cell receptors reject minor 
histocompatiblility discordant skin grafts faster than mice with a shrunken T 
cell receptor repertoire (Chapter V). We believe that a broader T cell receptor 
diversity allows a more efficient recognition and rejection of a higher range of 
external and internal aggressions. In this work it is demonstrated that a 
reduction of TCR diversity by thymectomy in wild type mice significantly 
increased survival of H-Y incompatible skin grafts, indicating decrease on T 
cell function. In addiction reconstitution of T-cell diversity in mice with a 
decreased T cell repertoire diversity with immunoglobulin Fab fragments, 
lead to a increase on TCR diversity and to a significantly decreased survival 
of the skin grafts (Chapter V). These results strongly suggest that increases 
on T cell repertoire diversity contribute to improvement of T cell function. 
Our results may have important implications on therapy and immune  
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reconstitution in the context of AIDS, cancer, autoimmunity and post 
myeloablative treatments. 
Based on the previous results, we tested the clinical hypothesis that patients 
with haematological malignancies subjected to stem cell transplantation who 
recovered a robust immune system would have a better survival compared to 
patients who did not recover such a robust immune system. This study was 
undertaken by the examination of the progression and overall survival of 42 
patients with mantle cell non-Hodgkin lymphoma receiving autologous 
hematopoietic stem cell transplantation (Chapter VI). The results obtained 
show that patients who recovered higher numbers of lymphocytes soon after 
autologous transplantation had a statistically significantly longer progression 
free and overall survivals. These results demonstrate the positive impact that 
a more robust immune system reconstitution after stem cell transplantation 
may have upon the survival of patients with haematological malignancies.  
In a similar clinical research framework, this dissertation also includes the 
study of the impact of recovering normal serum levels of polyclonal 
immunoglobulin on the survival of patients with another B cell haematological 
malignancy, multiple myeloma, after autologous stem cell transplantation 
(Chapter VII). The relapse free survival of the 110 patients with multiple 
myeloma analysed was associated with their ability to recover normal serum  
levels of the polyclonal compartment of immunoglobulin.  These results 
suggest again the important effect of polyclonal immunoglobulin for the 
(re)generation of the immune competence. 
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We also studied the impact of a robust immunity for the response to 
treatment with the antibody anti CD20, rituximab, in patients with non-
Hodgkin’s lymphoma (NHL) (Chapter VIII). Patients with higher absolute 
counts of CD4+ T lymphocytes respond better (in terms of longer 
progression free survival) to rituximab compared to patients with lower 
number of CD4+ T lymphocytes. These observations highlight again the fact 
that a competent immune system is required for the clinical benefit of 
rituximab therapy in NHL patients.  
In conclusion, the work presented in this dissertation demonstrates, for the 
first time, that diverse B cells and polyclonal immunoglobulin promote T cell 
diversification in the thymus and improve T lymphocyte function.  Also, it 
shows that in the setting of immune reconstitution, as after autologous stem 
cell transplantation for mantle cell lymphoma and in the setting of immune 
therapy for NHL, the absolute lymphocyte counts are an independent factor 
predicting progression free and overall survival.  
These results can have an important application in the clinical practice since 
the majority of the current treatments for cancer are immunosuppressive and 
implicate a subsequent immune recovery. Also, the effects of a number of anti-
neoplastic treatments, including biological agents, depend on the immune system 
activity. In this way, studies similar to the ones presented here, where methods to 
improve the immune reconstitution are examined, may prove to be instrumental 
for a better understanding of the immune system and to guide more efficient 
treatment options and the design of future clinical trials. 
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O estudo da rede de inter-relações entre os diversos elementos do sistema 
immune tem-se mostrado um instrumento essencial para uma melhor 
compreensão deste complexo sistema biológico. Tal é particularmente 
verdade no caso das interacções entre os linfócitos B e T, quer durante o 
desenvolvimento celular, quer ao nível das funções celulares efectoras. A 
compreensão da interdependência entre linfócitos B e T e a possibilidade de 
manipular esta relação pode ser directamente aplicável a situações em que a 
imunidade está deficiente, como é o caso das doenças neoplásicas ou da 
imunossupressão após radio ou quimioterapia. 
O trabalho apresentado nesta dissertação iniciou-se com o desenvolvimento 
de um novo método laboratorial para medir directamente a diversidade do 
reportório celular (Capítulo III). Reduções da diversidade do reportório dos 
receptores de células T têm sido relacionadas com um estado de 
imunodeficiência. O método desenvolvido utiliza “gene chips”, aos quais 
hibridizam os ácidos nucleicos codificantes das cadeias proteicas dos 
receptores linfocitários. A diversidade é calculada com base na frequência de 
hibridização do ácido nucleico da amostra aos oligonucleótidos presentes no 
“gene chip”. De seguida, e utilizando este novo método e outras técnicas de 
quantificação celular examinei, num modelo animal, o papel que as células 
policlonais B e a imunoglobulina exercem sobre o desenvolvimento 
linfocitário T no timo, especificamente na aquisição de um reportório diverso 
de receptores T (Capítulos IV e V).  Testei, então, a hipótese de que a  
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presença no timo de péptidos mais diversos, como a imunoglobulna 
policlonal, induzisse a génese de precursores T mais diversos. 
Demonstrámos que a diversidade do compartimento T é aumentado pela 
presença de imunoglobulina policlonal. A imunoglobulina policlonal, e 
particularmente os fragmentos Fab desta molécula, representam as 
moléculas autólogas mais diversas presentes nos organismos vertebrados.  
Estes péptidos são apresentados por células apresentadoras de antigénio às 
células precursoras T no timo, durante o desenvolvimento celular T. Tal, 
provavelmente, contribui para a génese da diversidade dos receptores. 
Também demonstrámos que a presença de um reportório mais diverso de 
linfócitos T se associa a um incremento da função imunológica T in vivo.  
Uma diversidade de receptores T mais extensa parece permitir um 
reconhecimento e rejeição mais eficientes de um maior número de 
agressores internos e externos. Demonstrámos que ratinhos com receptores 
de células T (RCT) com maior diversidade rejeitam transplantes cutâneos 
discordantes para antigénios minor de histocompatibilidade mais 
rapidamente do que ratinhos com um menor reportório T (Capítulo V). Por 
outro lado, uma redução da diversidade do RCT, causada por timectomia de 
ratinhos de estirpes selvagens, mostrou aumentar significativamente a 
sobrevivência de transplantes cutâneos incompatíveis para o antigénio H-Y 
(antigénio minor de histocompatibilidade), indicando uma diminuição da 
função linfocitária T. 
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Além disso, a reconstituição da diversidade dos linfócitos T em ratinhos com 
uma diversidade de reportório T diminuída, induzida pela administração de 
fragmentos Fab de imunoglobulina, conduz a um aumento da diversidade dos 
RCT e a uma diminuição significativa da sobrevivência dos enxertos cutâneos 
(Capítulo V). Estes resultados sugerem que o aumento do reportório de 
células T contribui para uma melhoria das funções celulares T e poderão ter 
implicações importantes na terapêutica e reconstitutição imunológica em 
contexto de SIDA, neoplasias, autoimunidade e após tratamentos 
mieloablativos. 
Baseado nos resultados anteriores, decidimos testar a hipótese clínica de que 
doentes com neoplasias hematológicas sujeitos a transplantação de 
precursores hematopoiéticos e com recuperação imunológica precoce após 
transplante teriam uma sobrevivência mais longa do que doentes que não 
recuperassem tão bem a sua imunidade. 
Analisámos a sobrevivência global e sobrevivência sem doença de 42 doentes 
com linfoma não Hodgkin de células do manto sujeitos a transplante autólogo 
de precursores hematopoiéticos (Capítulo VI). Os resultados obtidos 
mostraram que os doentes que recuperaram contagens mais elevadas de 
linfócitos imediatamente após o transplante autólogo, apresentaram uma 
sobrevivência global e sem progressão mais longa do que doentes que não 
recuperaram contagens linfocitárias tão precocemente. Estes resultados 
demonstram o efeito positivo de uma reconstitutição imunológica robusta 
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após transplante de presursores hematopoiéticos, sobre a sobrevivência de 
doentes com neoplasias hematológicas. 
Do mesmo modo, estudámos o efeito que a recuperação de níveis séricos 
normais de imunoglobulina policlonal tem na sobrevivência de doentes com 
outras neoplasias hematológicas de linfócitos B, como o mieloma múltiplo, 
após transplante autólogo de precursos hematopoiéticos (Capítulo VII). A 
sobrevivência livre de doença dos 110 doentes com mieloma múltiplo 
analizados está associada com a sua capacidade de recuperar níveis séricos 
normais do compartmento policlonal de imunoglobulina. Estes resultados 
pioneiros indicam a importância da imunoglobulina policlonal para a génese 
de competência imunológica. 
Também estudámos o impacto de um sistema imunitário eficiente sobre a 
resposta ao tratamento com o anticorpo anti CD20, rituximab, em doentes 
com linfoma não Hodgkin (LNH) (Capítulo VIII). Os resultados mostram que 
doentes com valores mais elevados de linfócitos T CD4+ respondem melhor 
(em termos de maior sobrevida livre de doença) ao rituximab, do que 
doentes com valores mais baixos. Estas observações ilustram a necessidade 
de um sistema imunitário competente para o benefício clínico da terapêutica 
com rituximab em doentes com LNH.  
Em conclusão, o trabalho apresentado nesta dissertação demonstra que as 
células B e a imunoglobulina policlonal promovem a diversidade das células T 
no timo e melhoram a função linfocitária T periférica. 
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Concomitantemente, também demonstrámos que, no contexto de 
reconstituição imune, por exemplo, após transplante autólogo de precursores  
hematopoiéticos em doentes com linfomas de células do manto, o número 
absoluto de linfócitos é uma factor independente da sobrevivência. Os 
resultados demonstram, também, a importância dos valores de linfocitos T 
na resposta ao tratamento com rituximab no caso de doentes com LNH. O 
mesmo princípio se prova pelo facto de que doentes com mieloma múltiplo 
sujeitos a transplante autólogo de precursores hematopoiéticos que 
recuperam valores normais séricos de imunoglobulinas policlonais, terem 
melhores taxas de resposta em comparação com doentes que não recuperam 
valores normais de imunoglobulinas policlonais. Estes resultados podem ter 
importantes aplicações na prática clínica dado que a maioria dos tratamentos 
de doenças neoplásicas implica imunossupressão e, subsequente, 
recuperação imunológica. Estes estudos podem ser um instrumento 
fundamental para uma melhor compreensão do sistema imune e guiar uma 
escolha mais eficiente de opções terapêuticas bem como contribuir para a 
concepção de futuros estudos clínicos. 
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L'étude du réseau d'interrelations entre les divers éléments du système 
immune s'est montré un instrument essentiel pour une meilleure 
compréhension de ce système biologique complexe. C'est particulièrement 
vrai dans le cas des interactions entre les lymphocytes B et T, soit pendant le 
développement cellulaire soit à l'étape des fonctions cellulaires d'effecteurs. 
La compréhension de l'interdépendance entre des lymphocytes B et T et la 
possibilité de manipuler cette relation peuvent être directement applicables à 
des situations où l'immunité est déficiente, comme c'est le cas du cancer ou 
d’immunosuppression après la radiothérapie et la chimiothérapie  
Le travail présenté dans cette dissertation a commencé avec le 
développement d'un nouveau et précis méthode en laboratoire pour mesurer 
directement la diversité du répertoire cellulaire (Chapitre III). Des 
contractions dans la diversité du répertoire des récepteurs de cellules T ont 
été reliées avec un état d'insuffisance immunologique. Cette méthode utilise 
"gene chips", où les acides nucléiques codificateurs des chaînes protéiques 
des récepteurs lymphocytaires sont hybridés. La diversité est calculée sur la 
fréquence d'hybridation de l'acide nucléique de l'échantillon aux 
oligonucléotides présents dans le "gene chip". En suite, et en utilisant cette 
nouvelle méthode et d’autres techniques de quantification cellulaire, j'ai 
examiné, dans un modèle animal, le rôle que les cellules polyclonales B et 
l'immunoglobuline exercent sur le développement lymphocytaire T dans le 
thymus, spécifiquement dans l'acquisition d'un répertoire divers de  
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récepteurs T (Chapitres IV et V). L'hypothèse évalué était si la présence dans 
le thymus de peptides plus diverses, comme l'immunoglobuline polyclonale, 
induirait la génération de précurseurs T plus divers. 
Les résultats obtenus ont démontré que la diversité du compartiment de 
cellules T est augmentée par la présence d'immunoglobuline polyclonale. 
L'immunoglobuline polyclonale, et particulièrement les fragments Fab de 
cette molécule, représente les auto-molécules les plus divers dans les 
organismes vertébrés. Ces peptides sont présentés par des cellules 
présentateurs d'antigène à cellules précurseur T dans le thymus, pendant le 
développement cellulaire T. Ceci probablement contribue significativement, à 
la génération de la diversité des récepteurs.  
Nous avons aussi démontré que la présence d'un répertoire plus divers de 
lymphocytes T est associée avec une fonction immunologique T plus efficace 
in vivo puisque des petits rat avec des récepteurs de cellules T (RCT) plus 
diverses rejettent des transplants cutanés discordants pour antigènes minor 
de histocompatibilité plus rapidement que des rats avec un répertoire T 
moindre (Chapitre V).  
Une diversité de récepteurs T plus étendue semble permettre une 
reconnaissance et un rejet plus efficaces pour un plus grand nombre 
d'agresseurs internes et externes. Dans cette étude, il est démontré qu'une 
réduction de la diversité de RCT, par tymectomie des rats sauvages, 
augmente significativement la survie de greffes cutanés incompatibles pour 
l'antigène H-Y (antigène minor d’histocompatibilité), indiquant une  
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diminution de la fonction lymphocytaire T. D'autre part, la reconstitution de 
la diversité des lymphocytes T dans des rats avec une diversité diminuée du 
répertoire T, réussie par l’administration de fragments Fab 
d'immunoglobuline, conduit à une augmentation de la diversité de RCT et à 
une diminution significative de la survie des greffes cutanées (Chapitre V). 
Ces résultats suggèrent que l'augmentation de la diversité du répertoire de 
cellules T contribue à une amélioration des fonctions cellulaires T. Ces 
résultats pourront avoir des implications importantes dans la thérapeutique 
et la reconstitution immunologique dans le contexte de SIDA, néoplasies, 
auto-immunité et après traitements myéloablatives. 
Nous d’étudions l'hypothèse clinique de que, chez des malades avec des 
néoplasies hématologiques sujets à la transplantation de précurseurs 
hématopoïétiques qui récupéraient un système immunologique plus robuste 
précocement après transplant, auraient plus longues survies en comparaison 
avec des malades qui ne récupéraient pas aussi bien leur immunité. Nous 
conduisons cette étude en analysant la survie globale et la survie libre de 
maladie de 42 malades avec lymphome non Hodgkin de cellules du manteau 
sujets à transplant autologue de précurseurs hématopoïétiques (Chapitre VI). 
La survie de ces malades a été analysée conformément à compte des 
lymphocytes récupérés au 15éme jour après la greffe. Les résultats obtenus 
ont montré que les malades qui ont récupéré des valeurs plus élevées de 
lymphocytes immédiatement après le transplant autologue, ont présenté une 
survie globale et une survie libre de progression, statistiquement plus longue 
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que malades que n'ont pas récupéré de comptages lymphocytaire aussi 
élevés. Ces résultats démontrent l'effet positif de la reconstitution 
immunologique robuste, après transplant de précurseurs hématopoïétiques 
pour la survie des malades avec des néoplasies hématologiques. 
Dans un cadre de recherche clinique, cette dissertation inclut aussi l'étude de 
l'effet que la récupération de niveaux sériques normaux d'immunoglobuline 
polyclonale sur la survie de malades avec autres néoplasies hématologiques 
de lymphocyte B, comme le myélome multiple, après transplant autologue de 
précurseurs hématopoïétiques (Chapitre VII). La survie libre de maladie chez 
110 malades avec myélome multiple a été associée à la capacité de 
récupération des niveaux sériques normaux du compartiment polyclonale 
d'immunoglobuline. Ces résultats indiquent, à nouveau, l'importance de 
l'immunoglobuline polyclonale pour la génération de la compétence 
immunologique.  
Nous avons aussi étudié l'impact que un système immunitaire robuste aura 
dans la réponse au traitement avec l'anticorps anti CD20, rituximab, chez des 
malades avec lymphome non Hodgkin (LNH) (Chapitre VIII). Ces résultats, 
ici présentés, montrent que les malades avec des valeurs plus élevées de 
lymphocytes T CD4 +, répondent mieux à rituximab, en comparaison avec 
des malades avec basses valeurs de lymphocytes T CD4+. Ces observations 
illustrent que un système immunitaire compétent est nécessaire pour le 
bénéfice clinique de la thérapeutique avec rituximab des malades avec LNH. 
 
 32
Résumé 
 
En conclusion, le travail présenté dans cette dissertation démontre que les 
cellules B et l'immunoglobuline polyclonale promeuvent la diversité de 
cellules T dans le thymus et améliorent la fonction lymphocytaire T 
périphérique. 
Il montre aussi que, dans le contexte de reconstitution immune, par exemple 
après un greffe autologue de précurseurs hématopoïétiques chez des 
malades avec des lymphomes de cellules du manteau, le nombre absolu de 
lymphocytes est un facteur prédictif indépendant de la survie libre de 
progression de la maladie et de la survie globale. Les résultats de ce travail 
démontrent, aussi, l'importance que la robustesse du système immunitaire 
dans la réponse au traitement avec rituximab chez les malades avec LNH. En 
effet, des malades avec des nombre plus élevées de lymphocytes T CD4+ 
présentent des taux de réponse plus haute quand comparés avec des 
malades avec des valeurs plus basses. Le même principe se prouve chez les 
malades avec myélome multiple sujets à transplant autologue de précurseurs 
hématopoïétiques qui récupèrent des valeurs sériques normales 
d'immunoglobulines polyclonales. Ils ont des meilleurs taux de réponse en 
comparaison avec les malades qui ne récupèrent pas de valeurs normales. 
Ces résultats peuvent avoir importantes applications dans la pratique clinique 
puisque la majorité des traitements de maladies néoplasiques implique 
immunosuppression et, ultérieure, récupération immunologique. Aussi, les 
effets d'un grand nombre de traitements antinéoplasiques, agents 
biologiques inclus, dépendent de l'activité du système immune. C’études  
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peuvent être un instrument fondamental pour une meilleure compréhension 
du système immunitaire, et guide un efficace choix d'options thérapeutiques 
et aide un le dessin de futures études cliniques. 
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General Introduction 
 
The role of B cells and immunoglobulin in T cell development  
The immune system is one of the most complex biological systems in 
vertebrate animals and it can be systematically divided in innate and 
adaptive. The innate immunity includes the components of the immune 
system that do not recombine its receptors to produce a diverse repertoire.  
The basic protective strategy of an innate immune system allows the 
organism to constitutively produce generic, germ line-encoded receptors. 
These receptors recognize conserved patterns on different classes of 
pathogens and trigger an inflammatory response that limits pathogen 
invasion [1].  The innate compartment includes cellular elements (natural 
killer cells, macrophages and inflammatory cells) and all the physical barriers 
protecting the body.  
On the other way, the adaptive immune system includes cells that clonally 
generate a diverse repertoire. In this compartment, each cell bears a unique 
antigen receptor. The adaptive immune system is present in all jawed 
vertebrates that assemble their antigen-receptor genes through 
recombinatorial rearrangement of different immunoglobulin or T cell receptor 
gene segments [2]. Lymphocytes, the specialized cell types of the adaptive 
immune system, use their cellular receptors to recognize antigenic 
configurations of specific pathogens and then respond to the antigen by  
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clonal amplification, cellular differentiation, and production of antibodies with 
the same antigen binding specificity [3]. 
Two major lineages of lymphocytes that can specifically recognize and 
respond to antigenic determinants of potentially hazardous pathogens are 
generated in the thymus (the T lymphocytes) and the bone marrow or the 
avian bursa of Fabricius (the B lymphocytes) [4]. T and B cell compartments 
are thought to develop separately. The concept that lymphoid compartments 
develop separately derives from observations made nearly fifty years ago on 
the ablation of lymphoid organs.  Removing the Bursa of Fabricius, an out-
pouching of the gut of birds, by either hormonal or surgical means during the 
first days of life, renders a bird incapable of producing antibodies but able to 
reject an allograft [5].  Removing the thymus of a mouse within 24 h of birth 
abrogates the ability to reject an allograft but leaves the mouse able to 
produce antibodies [6, 7].  These classical experiments established that there 
were “at least two basic levels of immune responses related functionally to 
different primary lymphoid organs”, the thymus and the bursa of Fabricius 
[8].  One level of responses requires thymus integrity and concerns allograft 
rejection and graft-versus host disease while the other, requiring the bursa, 
is necessary for antibody production [4, 8, 9].  With the subsequent 
discovery that lymphoid cells develop in the Bursa of Fabricius and in the 
thymus, the former were referred to as “B” cells and the later as “T” cells 
[10].   
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Several subtypes of T cells have been considered: helper T cells (T cells 
expressing surface CD4 molecules), cytotoxic T cells (T cells expressing 
surface CD8 glycoprotein), memory T cells, regulatory T, NKT cells and γδ T 
cells.  All these cell types have different and specifically recognized functions. 
Helper T cells could be seen as the major driving force and the main 
regulators of the immune defense. Their primary task is to activate B cells 
and cytotoxic T cells [11]. However, the helper T cells themselves must be 
activated. This occurs by means of action of antigen presenting cells, namely 
dendritic cells, macrophages or B cells. Once activated, helper T cells 
proliferate and produce cytokines that activate B and T cells as well as other 
immune cellular elements.  
The cytotoxic CD8+ T cells are specialized in recognizing and killing cells of 
the body infected by viruses and bacteria, and also cancer cells.  
Memory T cells are a subset of antigen-specific T cells that persist for long 
periods after an infection has resolved and rapidly expand if they are 
exposed again to the same antigens. Memory cells may be either CD4+ or 
CD8+, and can be functionally divided in central and effector memory T cells 
[12, 13].  
Regulatory T cells (T regs) are crucial for the maintenance of immunological 
tolerance. Their major role is to shut down T cell mediated immunity and to  
suppress auto-reactive T cells that escaped the process of negative selection 
in the thymus [14]. Naturally occurring T regs (phenotypically characterized  
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as CD4+CD25+FoxP3+ T cells) arise in the thymus, whereas the adaptive T 
regs may also originate during a normal immune response [15, 16].  
Natural Killer T cells (NKT cells) bridge the adaptive with the innate immune 
system. They do not use major histocompatibility complex (MHC) molecules 
to recognize peptide antigens but employ CD1 to recognize glycolipid antigen 
[17].  
γδ T cells represent a small subset of T cells (around 5%) that express a 
surface TCR made up of one γ- and one δ-chain and are mainly found in the 
gut. These T cells are not MHC restricted and seem to be able to recognize 
whole proteins rather than peptides [18]. 
 
A previous study, using mice engineered to express monoclonal T cells with 
or without monoclonal B cells, found that mice producing both T cells and B 
cells (called monoclonal B-T mice or MBT mice) have 2-fold more thymocytes 
and 35-fold more peripheral CD4+ T cells than mice that make only T cells 
(called monoclonal T cell mice or MT mice) [19].  One possible explanation 
for these observations is that B cells might in some way promote the 
development of T cells. This work launched further investigations on T-B 
relationships during cell development. 
To understand how B cells might contribute to the development of T cells in 
the thymus, it is useful to consider how the thymus is thought  
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to promote T cell development (reviewed by Hergen Spits in [20]).  The 
process of T cell development includes not only the generation of thymocytes 
but also their maturation to promote the ability to recognize self-MHC 
without autoimmunity. TCR genes recombine to yield approximately 1015 
different TCRs [21].  From these TCRs, only around 108 to 1011 are selected 
in humans [22, 23] and around 106 in mice [24]. This process is called 
positive selection and allows the survival of the thymocytes in which TCRs 
recognize self-peptides presented by self-MHC molecules with an 
intermediate affinity.  In contrast, thymocytes with TCRs that recognize self-
peptides with a high affinity are negatively selected and die by apoptosis, 
protecting the organism from autoimmunity. Also, thymocytes which TCRs 
not recognizing self peptides-MHC complexes or recognizing them with a very 
low affinity die by lack of stimulus via the TCR (neglect).  The fact that each 
T cell precursor, through its TCR, can only recognize self-peptides presented 
by self-MHC molecules is named “restriction” [25, 26]. These two processes 
(selection and restriction) warrant that only T cells that recognize the self 
and are not highly self-reactive are “selected”, and survive to egress to the 
periphery.   
The process of T cell development is generally divided in phases defined on 
the basis of different surface molecules expressed by the thymocytes.  Also, 
each phase is characterized by distinct molecular events.  The most 
immature thymocytes comprise a small cellular population in the thymus that  
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do not express either CD4 or CD8 and are called double negative (DN).  In 
this phase, thymocytes rearrange the TCR β chain and undergo proliferation 
and expansion.  After rearranging the β chain, through a stochastic process 
of VDJ gene segment recombination, thymocytes begin to express membrane 
CD4 and CD8 molecules, becoming double positives (DP) (see Figure 1).   
 
 
 Figure 1 – T cells development in the thymus.  
The T cells precursors enter the thymus by the cortico-medullar junction 
and, in contact with thymic epithelial cells, undergo processes of selection 
and restriction in order to survive.  Before leaving the thymus as 
mature/naïve T cells, the T cells’ precursors rearrange the DNA encoding 
the TCR chains and acquire different membrane markers.  
(Adapted from Hergen Spits, Nature Reviews Immunology, 2002 [20])  
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Arstila el al. calculated that the β chain rearrangements can originate at least 
106 different β chains and the α chain rearrangement can originate a 
repertoire of ~0.5 × 106 different chains [22].  These different α and β  chains 
pair together to form a heterodimer; it is estimated that one β chain pairs, on 
average, with 25 different α chains, generating a final T cell receptor 
repertoire which diversity was predicted to be around 107 in humans [22].  
Since only one percent of thymocytes that begin development reach 
maturity, the critical step in modelling the T cell repertoire must be positive 
selection.  Positive selection must select T cells capable of recognizing self-
MHC with intermediate affinity and these selected T cells also must be 
capable of recognizing “foreign” peptides associated with that MHC.  Thus, as 
a consequence of T cell development, T cells should be able to interact with 
peptides from the range of bacteria, viruses and toxins that threaten health.  
It is generally believed that the combined diversity of the T cell repertoire 
and positive selection process will enable a response towards any pathogenic 
“challenge”.   
 
Several hypotheses can be formulated to address how this functional T cell 
repertoire is generated.  One hypothesis is that different proteins produced 
within the thymus and, presented by self-MHC, originate diversity.  However, 
only a limited number of different peptides are found in the thymus and 
many of them seem to contribute to negative selection [27].  Another  
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hypothesis is that TCR cross-react with many peptides.  However, too much 
cross reactivity between TCR molecules would promote autoimmunity.  Thus, 
although it happens, cross reactivity per se should be limited.   
A third hypothesis, and the one favoured in this work, is that the immune 
system itself generates diverse peptides that select for diversity.  In this 
setting, potential sources of diversity are B cell receptors and serum 
immunoglobulins.  B cell receptors and circulating immunoglobulins contain 
variable regions as diverse as the TCR [21] and we hypothesized these 
proteins help selecting T cell receptors.  This hypothesis is tested in the work 
presented in this dissertation, in particular at Chapter IV and V.  
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Immune Reconstitution after autologous hematopoietic stem 
cells transplantation and after treatment with rituximab. 
The cases of Non-Hodgkin Lymphomas and Multiple Myeloma 
 
There are several neoplastic diseases where high-dose treatments have 
proved to be more effective than conventional dose therapies in what 
concerns response rate, progression free survival and overall survival. This is 
the case of mantle cell lymphoma and multiple myeloma that were studied in 
Chapter VI, VII, and VIII. When extremely high doses of chemotherapy 
and/or radiotherapy are administered, fatal hematopoietic toxicity needs to 
be prevented by the infusion of hematopoietic stem cells, either autologous 
or allogeneic.  Allogeneic hematopoietic stem cells have the advantage of the 
immunologic effect of graft versus tumor, through the recognition of different 
HLA class I and II antigens and co-stimulatory molecules on tumor cells that 
lead to the generation of alloreactive T cells [28] . 
Autologous HSCT involves harvest and storage of patients’ HSC followed by 
high-dose chemotherapy aiming to eradicate the patient's malignant cell 
population. This occurs at the cost of also eliminating the patient's 
hematopoietic stem cells and is followed by rescue through the re-infusion of 
the patient's stored stem cells. Autologous transplants have the advantage of 
a lower risk of graft rejection and infection, since the immune recovery is  
 43
General Introduction 
 
faster. There is no opportunity for graft-versus-host disease, since the donor 
and recipient are the same. 
Allogeneic HSC donors must have major histocompatibility antigens that, at 
least partially, match the recipient’s. Even when a good match is found, the 
recipient will require high levels of immunosuppression to prevent graft-
versus-host disease. Allogeneic transplant donors may be related (sibling) or 
unrelated volunteers. Allogeneic stem cell transplantation aims, not only to 
the rescue of hematopoiesis, but also to improve the immunological effect 
graft versus tumor, as a means of promoting engraftment, accelerating 
immune recovery and strengthening the anti-neoplastic effects. 
High dose chemotherapy followed by autologous hematopoietic stem cell 
transplantation (ASCT) has been associated with prolonged disease-free 
survival in numerous malignancies including relapsed non-Hodgkin’s 
lymphoma [29], acute myelogenous leukemia [30], multiple myeloma [31] 
and a number of solid tumors [32, 33].  Approximately 105,000 autologous 
hematopoietic stem cell transplants were performed until 2004 for malignant 
diseases based on several American registries published by the Center of 
International Blood and Marrow Transplant Research [34].  Of those, 27,419 
were performed for NHL and 20,423 for plasma cell disorders [34]. 
Non-Hodgkin lymphoma (NHL) is the most frequent hematological tumor, 
representing 4% of all neoplasms; for unclear reasons, its incidence has been 
constantly rising in the Western world. The WHO classification of NHL 
includes more than 30 biologically and clinically distinct entities. B cell NHL,  
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that comprise 90% of those entities, includes indolent (mostly follicular, 
lymphocytic, marginal zone and lymphoplasmocytic) and aggressive (mostly 
diffuse large cell, mantle cell, Burkitt, and lymphoblastic) histological forms 
[35]. Indolent diseases are generally incurable but follow a prolonged course, 
with frequent need for therapy, while aggressive forms can be cured in a 
significant proportion but have a global shorter survival. Currently, treatment 
for most forms of B-cell NHL at diagnosis and/or at relapse includes 
chemotherapy associated with the anti B-cell monoclonal antibody Rituximab, 
a chimeric murine/human monoclonal antibody directed to the CD20 antigen 
that has been shown to induce complement- and antibody-dependent cell 
mediated lysis, as well as apoptosis of tumor cells and sensitization to the 
cytotoxic effects of anti-neoplastic drugs [36]. Another treatment option for 
Non Hodgkin lymphomas is high dose chemotherapy followed by 
hematopoietic stem cells transplant (HSCT), autologous or allogeneic. This is 
usually an option in the case of aggressive non-Hodgkin lymphomas, as it is 
the case of diffuse large B cell and mantle cell lymphomas. 
Multiple myeloma is the second most prevalent hematological cancer and 
represents approximately 1% of all cancers and 2% of all cancer deaths [37].  
Treatment of multiple myeloma is currently tailored to each patient according 
to several patient-, disease- and economical-related factors [38] and include 
chemotherapy, radiation, biological treatments and ubiquitin-proteasome 
pathway inhibitors [39, 40]. In the case of multiple myeloma, high dose 
chemotherapy followed by autologous hematopoietic stem cell transplant is  
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the treatment of choice for the fit and young patients [31, 41, 42]. The use 
of allogeneic stem cell transplants to exploit the effect of graft versus 
myeloma effect has been recently shown effective, as survival of patients 
with newly diagnosed myeloma is superior among recipients of a 
hematopoietic stem-cell autograft followed by a stem-cell allograft from an 
HLA-identical sibling compared to recipients of tandem stem-cell autografts 
[42]. 
Even so, the clinical efficacy of ASCT is limited by delayed immune recovery, 
resulting in infectious complications and probably contributing to high tumor 
relapse rates (40 to 70%) [43-45].   
Besides autologous stem cell transplantation many other treatment options 
exist to treat hematological malignancies.  These options include 
chemotherapy, radiotherapy, radioimmunotherapy and biological agents such 
as antibodies, intracellular molecules inhibitors and immunomodulators.  
As previously mentioned, for the most common subtypes of non-Hodgkin 
lymphomas, treatment at diagnosis and/or at relapse includes poly-
chemotherapy regimens associated with the anti B-cell monoclonal antibody, 
Rituximab [46, 47].  
Rituximab is a chimeric murine/human monoclonal antibody directed to the 
CD20 antigen that has been shown to induce complement- and antibody-
dependent cell mediated lysis, as well as apoptosis of tumor cells and 
sensitization to the cytotoxic effects of anti-neoplastic drugs [48].  
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As a consequence, circulating B cells remain undetectable for at least 6 
months after treatment and recover to normal levels between 6 and 9 
months later [49, 50]. The homeostatic and clinical consequences of these 
changes are not yet clear. 
Several ways to simultaneously increase the activity of rituximab and to 
stimulate immunity have been tried exploring the role of cytokines and 
growth factors like IL-2, IL-4, IL-12, IL-15, TNF-α, G-CSF, GM-CSF [48, 51-
55] [56, 57]. These molecules act on T and B cells, macrophages and NK 
cells activating its proliferation and activity.  
The effects of some of these immunomodulators are outlined in Figure 2 and 
listed in Table 1. 
 
 
Figure 2 - Mechanisms of action of rituximab and ways to 
increase its clinical efficacy. FAMP indicates fludarabine 
monophosphate; CR, complement receptor. [Adapted from Carton G et 
al, 2004 [50]. 
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Table 1 – Cytokines and growth factors exploited to increase patients 
immunity  
 
Molecule Effect 
IL-2 [48, 55] [52] • Increases ADCC by NK cells 
• Promotes activation and expansion of NK cells 
• Increases cytotoxicity by macrophages 
• Induces monocytes’ production of cytokines and 
growth factors and expression of its receptors on 
monocytes; also promotes anti microbicidal and 
anti tumoricidal activity of monocytes. 
• Promotes activation and proliferation of T cells 
• Facilitate proliferation of B cells producing IgG1 
immunoglobulins 
IL-12 [55, 58] • Increases ADCC by NK cells 
• Induces the secretion of IFN g by T and NK cells 
• Promote the development of Th1 helper T cells 
• Inhibits angiogenesis 
• Promotes antimicrobial responses to intracellular 
pathogens 
IL-15 [57] • Stimulate lymphocyte proliferation and activation 
• Promote the development and survival of NK 
cells, NKT cells, and intraepithelial lymphocytes 
TNF-α  [54] [53] • Stimulate T lymphocyte cytotoxicity 
• Stimulate NK activity 
 
G-CSF and  GM-CSF 
[59, 60] 
• Induce monocyte differentiation 
• Enhances the cytotoxicity of neutrophils through 
ADCC 
• Increasing neutrophil counts 
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As previously explained, the ability of the immune system to cope with 
diverse and fast evolving pathogens is achieved by the development of a vast 
and diverse repertoire of antigen receptors in lymphocytes that can 
potentially recognize any possible foreign antigens. Since B cell NHL are 
neoplasms of immune system, this function is usually altered. Furthermore, 
the majority of treatments options per se alter the dynamics of the immune 
system and cause a profound impact, in general decreasing the immunity. In 
fact, NHL patients frequently demonstrate clinical and biological signs of 
immune suppression before treatment. Chemotherapy alone strongly 
contributes to lymphocytopenia, significantly depleting circulating T cells, 
which recovery depends on multiple factors, including the intensity of the 
regimens used.  
 
Several studies described the kinetics of the immune reconstitution after 
ASCT for hematological and other neoplasms, including the comparison of 
immunological reconstitution after transplant of autologous CD34+ peripheral 
blood progenitor cells (PBPC) and autologous unselected PBPC [61-65]. It is 
generally accepted that NK cells are the first population appearing within the 
first 2 months after ASCT. B cells appear afterwards and a low CD4+/CD8+ 
ratio is maintained during at least the first year post-transplant, caused by a 
persistent increase of CD8+ and a constant reduction of CD4+ lymphocytes. 
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This finding, in part, explains the patients’ susceptibility to infections for a 
prolonged period of time post-transplant. 
The reconstitution of the immune system after myelotoxic therapies has been 
mostly studied in the setting of hematopoietic transplantation. It may be 
analyzed from two distinct points of view: (1) the numerical recovery of 
cellular elements; and (2) the functional recovery of cellular interactions.  
Following hematopoietic stem cells transplantation there is a relatively rapid 
reappearance of hematopoietic and lymphoid cells. However, functional 
recovery of immune cells occurs at a much slower rate (Table 2).  Complete 
reconstitution of the normal humoral and cellular (T and B cell) immunity 
may be delayed beyond one year following transplantation or, in certain 
settings, it may never fully recover, specially in what concerns the diversity 
of the T and B cell repertoire [66-71].   
On the other hand serum immunoglobulin levels recovery after ASCT, which 
has been mainly characterized in children, seems to start with the recovery 
of normal levels of IgM at 6 months, followed by IgG. Only 2 to 3 years later 
do the IgA levels reach the normal range [72, 73].   
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Table 2 - Reconstitution of B and T cell numbers and function after 
ASCT (adapted from [74]) 
 
B-cell Reconstitution Post-ASCT T-cell Reconstitution Post-ASCT 
Circulating B 
cells 
Low from 3 to 
18 months 
Circulating T cells  
Serum  CD4 Low for years 
 IgM Low for up to 6 
months 
CD8 Low for 3 to 18 
months 
 IgG Low from 12 to 
18 months 
T-cell proliferation Low for 3 
months to 5 
years 
 IgA Low for up to 36 
months 
Cytokine 
production 
Low for 6 
months to 5 
years 
In vivo antibody 
response: 
 Response to IL-2 Low for 7 
months to 5 
years 
   T dependent 
antigen 
Low for months 
to years 
 
Cytotoxic T cells Low for 2 
months to 5 
years 
   T independent 
antigen 
Low for years   
In vitro B cell 
responses to 
polyclonal 
stimulator 
Low for months 
to years 
  
 
 
The reconstitution of NK cells has been extensively studied (reviewed by 
Porrata et al [74]). This compartment recovers normal absolute and relative 
numbers within 1 month after autologous transplantation. The reconstituted 
NK population seems to be fully functional in terms of gamma-IFN-secreting 
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activated killer cells and cytotoxicity [75-78]. 
The study of immune reconstitution after treatment with rituximab is limited 
to a few very recent published studies. Those studies report that, after 
treatment with the monoclonal antibody and during the reconstitution phase 
(3 to 15 months), the majority of the peripheral blood B cells have both an 
immature, naïve phenotype (CD38hiCD27-CD24hiIgD-/+) and function, 
being less responsive to proliferative stimuli and more prone to apoptosis 
when in culture [49, 50, 79, 80].  Studies of the impact on T cell immunity 
after treatment with rituximab are very scarce in the literature. It was 
recently published that a significant increase in activated CD4+ and CD8+ T 
cells, as well as CD25brightFOXP3+ regulatory cells, happens after treatment 
with rituximab [81]. 
Previous studies of our group at the Mayo Clinic have shown that early 
recovery of lymphocytes post-ASCT is critical to the clinical outcome (disease 
free and overall survival) in several hematological and non-hematological 
malignancies [82-85].  In agreement with others [86, 87], the analysis of the 
recovery of lymphocyte numbers at day 15 post-transplant provided evidence 
that timely host immune system recovery may impact on human tumor cell 
biology.  Therefore, the therapeutic goal in ASCT should be to maximize 
hematopoietic engraftment and to improve immunological recovery.  
Effective methods that allow an accelerated immune reconstitution  
post-ASCT are urgently needed, as they may significantly modify the clinical 
outcomes of treated patients.   
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The possibility of manipulating the immune system with IvIg 
infusion 
 
The therapeutic applications of human immunoglobulins have been 
investigated for decades. The largest clinical impact of intravenous polyclonal 
immunoglobulin therapy (IVIG) probably occurrs in the setting of 
immunodeficiency [88-90], autoimmunity and inflammation [91, 92] and 
infectious disorders [93, 94] [95]. Its rationale was based on studies of the 
mechanisms of action of the molecule, that justified these applications [96, 
97].   
The immunomodulatory effects of immunoglobulins are also related to 
several well established actions, including the modulation of the expression 
and function of Fc receptors, the interference with complement activation and 
cytokine networks, the provision of anti-idiotypic antibodies and the 
modification of the activation, differentiation and effector functions of T and B 
lymphocytes cells and dendritic cells [91, 98].  
Immunoglobulins are a product of B cells. There are several other 
mechanisms by which B cells may modify T cell functions, besides the direct 
effects of immunoglobulin.  Those include B cell antigen presentation [99, 
100], the production of antibodies that may enhance [101] or depress [102] 
cellular immunity, B cell dependent development of follicular dendritic cells in  
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peripheral lymphoid organs [103], and negative effects on regulatory T cells 
[104].   
Regarding the effect of B cells on lymphoid organogenesis, it is recognized 
that expression of CXCL13, a B cell chemokine, can generate organized 
lymphoid tissue including B cells and T cells [105].  B cell expression of 
LTα1β2 contributes to the development and migration of follicular dendritic 
cells [106, 107].  B cell expression of LTα1β2 is also necessary for the 
development of T cell zones in the spleen [108].  In the same way, 
differentiation of the “follicular-associated epithelium” in gut associated 
lymphoid tissue requires the presence of B cells [109].   
It has been recently suggested that B cells have a role on the regulation of 
regulatory T cells. Some reports refer a positive effect of B cells via B7 on 
stimulating regulatory T cells [110], while others point to a negative effect of 
the B cell population, which may block regulatory T cells effect [104]. This is 
a novel field of research deserving further investigation. 
The influence of peripheral compartment of B cells and immunoglobulin is 
also noticed in increasing peripheral TCR stimulation, which may be critical 
for maintenance of the naïve T cell population [111, 112].  These signals 
keep T cells metabolically active and thus contribute to avoid passive death.  
This mechanism may allow the survival of naïve T cells and at the same time 
the maintenance of a diverse repertoire of T cells. The reception of survival  
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signals through immune receptors seems to be a general principle in the 
biology of naïve lymphocytes involved in adaptive immunity [113]. The 
question of whether B cells are needed to initiate and maintain memory 
CD4+ T cell responses have been studied by several investigators [110, 114-
116].  Those studies strongly suggest that, by promoting the initial 
expansion of activated antigen specific T cells, B cells have an essential role 
in determining the size and maintenance of the memory T cell pool and, also 
that, this B cell-dependent enhancement of T cell memory response may be 
independent of B cell antigen presentation. 
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Measurement of T cell receptor diversity 
 
T and B cells generate diverse antigen-specific receptors through gene 
recombination; both cell repertoires are shaped during their development by 
recognizing self-antigens. Several estimations of the T and B cells repertoire 
diversity have been accomplished using various available methods. However, 
the different methodologies have their specific limitations, varying with each 
technical tool applied.  
The availability of an accurate instrument to measure the diversity of the T 
cell repertoire is essential to examine the complexity of the immune system, 
either to understand its ability to recognize a diverse range of antigen 
determinants or to assess its limitation in the setting of lymphopenia and 
other situations of repertoire contractions.   
Also, the availability of an accurate and direct measurement of T cell receptor 
repertoire is crucial for the comparison of different T cell receptor 
population’s repertoires and the testing of different approaches to improve T 
cell development, in particular the generation of TCR diversity.   
 
The more commonly used methods to measure cellular diversity are 
insufficient to directly assess the entire repertoire of T cell receptors, since 
they are based on the analysis of only a subset of this repertoire. The most 
widely used method to assess repertoire diversity is spectratyping analysis 
(also known as immunoscope) and is based on the analysis of the distribution  
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of the size spectrum of the TCR chain CDR3 lengths for each V family [117, 
118]. One drawback of spectratyping is the fact that it is based on 
electrophoretic separation of the amplified lymphocyte receptor V family PCR 
products according to the junctional (J) sequences. Diversity is inferred from 
the number and electrophoretic separation patterns of amplified and re-
annealed V region PCR products. Spectratyping effectively detects clonal 
expansion within a V family. However, since several thousand V-J family 
combinations for lymphocyte receptors exist, the totality of V-J combinations 
cannot be routinely analyzed. Several mathematical improvements have 
been developed for the analysis of this type of data.  In fact, improvements 
in the integration of the parameters’ read out from the sequencer were 
achieved [119-121]. However, all the analysis are, ultimately, based on a 
finite set of the entire possible repertoire and not entirely quantitative.   
Other PCR-based methods, very laborious and with limited sensitivity, were 
developed based on the analysis of DNA encoding lymphocyte receptors by 
PCR amplification using constant region (C) and V-family specific primers 
[122]. A more recent PCR-based technique to assess DNA diversity is 
AmpliCot analysis, which uses DNA hybridization kinetics to assess diversity 
of PCR products [123].  The use of PCR methodology for the study of T cell 
repertoire diversity with primers specific for C and V families of the TCR 
chains does not differentiate among individual clones of the same family and 
may fail to detect balanced narrowing or expansion of the repertoire.  In the 
case of AmpliCot analysis, the fact that this estimation of cellular 
 57
General Introduction 
 
diversity is based on Cot analysis (a method based on the principle that the 
time required for a DNA sample to re-anneal is related to the sequence 
complexity of the sample) and PCR, may lead to serious decreases in 
specificity due to possible erroneous amplifications of impure PCR products. 
Also, amplification cycles might decrease the diversity of the final PCR 
product, owing to the loss of sequences that are amplified less efficiently; the 
consequence may be an erroneous assessment of the true cellular diversity. 
Another method used to assess the T cell repertoire diversity is the frequency 
analysis of a given TCR clone based on techniques of limiting dilution [124]. 
This method is quite laborious and based on the not yet proven hypothesis 
that the frequency of a certain clonotype is representative of the frequency of 
all clones.  
Lastly, a strategy frequently used in clinical research to access diversity is 
the analysis of lymphocyte populations by flow cytometry [125, 126]. This 
method is even less sensitive to detect alterations than the PCR-based 
methods, since the antibodies employed detect only the “constant” antigenic 
determinants shared by many lymphocyte receptor clones. Diversity 
evaluated by flow cytometry is, at best, inferred from the result.   
In conclusion, several are the methods available to assess repertoire 
diversity but a direct, accurate, quantitative and easily used method is 
essential to examine and better understand the complexity of the immune 
system, both in physiologic and pathological situations, as the work  
presented in this dissertation demonstrates.
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Aims of the study 
 
The aims of this work and the hypothesis underneath these objectives were:  
 
1) To develop a quantitative method to directly assess the T cell 
repertoire diversity. 
We hypothesize that it is possible to direct assess a cellular 
repertoire diversity by hybridization of all lymphocyte receptor-
specific RNAs in a given sample to oligonucleotides on a gene 
chip as the number of sites undergoing hybridization out of the 
>400,000 available sites on a gene chip corresponds to the level 
of diversity. 
 
2) To determine the role of polyclonal and monoclonal B cells and 
immunoglobulins upon T cell development, mostly the generation of 
the T cell repertoire diversity, using a mouse model where B cells have 
different levels of BCR diversity. 
We hypothesize that polyclonal B cells and polyclonal 
immunoglobulin have a fundamental role of promoting T cell 
development. This is because the diverse peptides from the 
immunoglobulin molecule can easily be presented to the T cells 
precursors in the thymus throughout the process of T cell 
development. 
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3) To examine the importance of the T cell repertoire diversity to 
peripheral T cells function through in vitro and in vivo testing. 
We hypothesize that the function of T cells may be improved if 
the diversity of the T cell repertoire is increased, since a larger 
range of distinct antigens would be detected by a more diverse T 
cell compartment as compared to a less diverse T cell repertoire. 
 
4) To study the impact of lymphocyte and polyclonal immunoglobulins 
recovery in the survival of patients with certain hematological 
neoplasms, namely mantle cell lymphoma and multiple myeloma 
patients subjected to autologous stem cell transplantation. 
We hypothesize that the kinetics of the recovery of lymphocyte 
number during immune reconstitution may predict the 
robustness of the immune system translating in longer survival 
of the patients under these conditions; autologous 
hematopoietic stem cell transplantation provides a useful model 
to evaluate a regenerating immune system. 
Also, when a B cell neoplasm secreting monoclonal 
immunoglobulins is present (for example multiple myeloma), the 
recovery of a regular production of polyclonal immunoglobulin 
will indicate a better immunity and a better response to 
treatment. 
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5) To analyse the impact of the lymphocytes counts and sub-populations 
before treatment with rituximab in the progression free survival of 
patients with non-Hodgkin lymphoma receiving this antibody.  
We hypothesize that the presence of a strong immune system 
will allow an optimization of the effects of anti-neoplastic 
treatment with rituximab, as the mechanisms of action of this 
antibody depend on the activity of elements of the immune 
system.  So, the improvement of patients’ immunity before 
treatment with rituximab should be actively sought. 
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3.1. Abstract 
 
The ability to mount an immune defense against infectious microorganisms 
and their products and against tumors is believed to be a direct function of 
lymphocyte diversity. Because the diversity of lymphocyte receptor genes is 
>1000-fold more diverse than the entire genome and varies between 
genetically identical individuals, measuring lymphocyte diversity has been a 
daunting challenge. We developed a novel technique for measuring 
lymphocyte diversity directly using gene chips. We reasoned and here 
demonstrate that the frequency of hybridization of nucleic acids coding for 
lymphocyte receptors to the oligonucleotides on a gene chip varies in direct 
proportion to diversity. We applied the technique to detect changes in 
lymphocyte diversity in mice with known B cell alterations and in persons 
with known T cell repertoire defects. This approach is the first to provide 
direct analysis of lymphocyte receptor diversity and should facilitate 
fundamental study of the adaptive immune system and clinical efforts to 
assess immunological diseases. In addition this approach could be more 
broadly applied for example, to measure diversity of viral quasispecies. 
 
Keywords: lymphocyte antigen receptor gene rearrangement, T 
lymphocytes, B lymphocytes, gene chips, oligonucleotide array 
sequence analysis 
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3.2. Introduction 
 
While the total number of lymphocytes in the blood can be directly 
measured, the diversity of the lymphocyte compartment, on which 
immunocompetence is based, cannot. In the absence of direct measures of 
lymphocyte diversity, various indirect means for estimating diversity have 
been used. For example, antibodies against variable (V)-region families have 
been used to characterize lymphocyte populations by flow cytometric 
analysis [125, 127]. Since this approach detects “constant” antigenic 
determinants shared by many lymphocyte receptor clones, diversity is at 
best inferred from the result. As another example, nucleic acids encoding 
lymphocyte receptors can be amplified by PCR using constant region (C) and 
V-family specific primers [122]. Like FACS analysis, this approach does not 
differentiate between individual clones of the same family and may fail to 
detect balanced narrowing (or expansion) of the repertoire. 
Diversity can also be estimated by spectratyping (also called immunoscope) 
or by the heteroduplex method [117, 118, 128]. These methods employ 
electrophoretic separation of amplified lymphocyte receptor V family PCR 
products according to the junctional (J) sequences; diversity is inferred from 
the number and electrophoretic separation pattern of amplified and re-
annealed V region PCR products. Spectratyping and heteroduplex  
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methodologies effectively detect clonal expansion within a V family; however, 
because several thousand V-J family combinations for lymphocyte receptors  
exist, all V-J combinations cannot be analyzed routinely. Since only a small 
fraction of V-J combinations are analyzed, the choice of which is random, the 
actual diversity of the TCR repertoire may not be quantified.   
Still another means to assess lymphocyte diversity is based on the tenants of 
limiting dilution analysis and detects the frequency of a given TCR clone 
[124]. This method is quite laborious and is based on the assumption that 
the frequency of the selected clonotype is representative of the frequency of 
all clones.  
While techniques in current use offer value, they also have limitations, the 
most vexing of which is the inability to directly measure diversity. The 
approach we describe addresses this limitation by directly probing the entire 
population of lymphocyte receptors. This is accomplished by hybridization of 
all lymphocyte receptor-specific RNAs in a given sample to oligonucleotides 
on a gene chip; the number of sites undergoing hybridization out of the 
>400,000 available sites on a gene chip corresponds to the level of diversity. 
This approach sidesteps analysis of specific receptor families or clones and 
the limitations associated therein.   
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3.3. Materials and Methods 
 
3.3.1. Isolation of RNA.  All mouse strains were raised and maintained 
with protocols approved by the institutional animal care and use committee 
of the Mayo Clinic, Rochester, MN. All human samples were obtained in 
accordance with the institutional review board of the Mayo Clinic, Rochester, 
MN. Spleens harvested from mice were placed in RPMI and pushed through a 
70 μm cell strainer. Lymphocytes were isolated from the resulting suspension 
of splenocytes or from peripheral blood using Ficoll-paqueTM (Amersham 
Biosciences, Piscatanaway, New Jersey) gradient. Total RNA was isolated 
from the lymphocytes using the Qiagen RNeasy kitTM (Qiagen, Inc., Valencia, 
California) per the manufacturer’s instructions. Isolated RNA was 
resuspended at a concentration of 2 μg/μl. 
 
 
3.3.2. Generation of lymphocyte receptor-specific cRNA.  First strand 
cDNA was constructed first as follows. In an RNAse-free microcentrifuge 
tube, 10 μl of total RNA (20 μg) was mixed with 1 μl (100 pmol/μl) of either:  
 
T7+Cβ   
(5’-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGCGGGCTGCTCC 
TTGAGGGGCTGCG-3’) for T cell receptor analysis or  
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T7+CJH4  
(5’-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGGAGGAGACGG 
TGACTGAGGTTCCTTG-3’) for B cell receptor analysis. 
 
This mixture was incubated at 70°C for 10 minutes followed by a quick spin 
and chill on ice. To this reaction, 4 μl of 5X first strand cDNA buffer 
(Invitrogen, Inc., Carlsbad, California), 2 μl of 0.1 M DTT, and 1 μl of 10 mM 
dNTP mix were added and incubated at 37°C for 2 minutes. Next, 2 μl of 
SuperScript II Reverse TranscriptaseTM (Invitrogen, Inc.) was added and the 
total mixture was further incubated at 37°C for 1 hour. Following incubation, 
the first strand product was placed on ice. For second strand synthesis, the 
following reagents were added to the first strand product:  91 μl of DEPC-
treated water, 30 μl of 5X Second Strand Reaction Buffer (Invitrogen, Inc.), 3 
μl of 10mM dNTPs, 1 μl of 10U/μl DNA ligase, 4 μl of 10U/μl DNA polymerase 
I, and 1 μl of 2U/μl RNase H. The reaction was incubated at 16°C for 2 hours 
in a cooling water bath. Following incubation, 2 μl of 10U T4 DNA polymerase 
was added and the entire mixture was incubated for an additional 5 minutes 
at 16°C. Finally, 10 μl of 0.5 M EDTA was added to the mixture. The 
completed double-stranded cDNA was purified using phase lock gel followed 
by phenol chloroform extraction. The double-stranded cDNA product was 
then biotinylated with Enzo, BioArray High Yield RNA Transcript Labeling KitTM 
per the manufacturer’s instructions. The IVT product (cRNA) was purified 
using RNeasy spin columns (Qiagen, Inc.) per the manufacturer’s  
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instructions. The purified product was quantified using spectrophotometric 
analysis applying the convention that 1 OD at 260 nm equals 40 μg/ml of 
RNA. cRNA was resuspended at a concentration of 1 μg/μl.  cRNA was then 
fragmented to 50-200 bp sizes by combining with 5 μl of 5X fragmentation 
buffer (Invitrogen, Inc.) in 15 μl of water. The mixture was incubated at 94°C 
for 35 minutes and put on ice following incubation.   
 
 
3.3.3. Application of cRNA to the gene chip.  Equal amounts of cRNA 
from different samples were hybridized to U95B gene chips (Affymetrix, Inc., 
Santa Clara, California). While the ideal gene chip might be constructed using 
random oligonucleotides, we reasoned that chips containing known but 
unselected expressed sequence tags from human genes would share less 
homology with mouse lymphocyte receptor RNA and could be used instead. 
And in fact, duplicate experiments performed on U95C chips yielded 
comparable results, suggesting that a random oligonucleotide chip may not 
add benefit. 
 
 
3.3.4. Data Analysis.  For each gene chip experiment, we obtained raw 
data corresponding to oligo location and hybridization intensity. Data were 
arranged in order of ascending hybridization intensity. The number of oligo 
locations with intensity above background (i.e., number of hits) was  
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summed. First, the standard curve was generated (from hybridization of 
samples with known numbers of different oligos). Next, test samples were 
assessed and based on the number of hits, the diversity was extrapolated 
from the standard curve.   
 
 
3.3.5. ELISA for detection of anti-KLH antibodies.  Mice were 
immunized by intraperitoneal injection with 25 μg of KLH (Keyhole Limpet 
Hemocyanin, Sigma, St. Louis, MO) in incomplete Freund’s adjuvant. A boost 
of 10 μg of KLH was administered 20 days later. After an additional two 
weeks the mice were sacrificed and serum and splenocytes were isolated.  
Purified KLH (3 μg/ml in phosphate buffered saline (PBS); 50 μl/well) was 
added to wells of ninety-six well flat bottom microtiter plates (Nunc-Immuno 
96 Micro well – MaxisorpTM, Nalge Nunc International, Rochester, NY). ELISA 
was developed as described [129].  Plates were read using a microplate 
reader (Power Wave XTM, Bio Tek Instruments, Winooski, VT) and analyzed 
using KC4 – Kineticalc software. Samples were analyzed in triplicate in three 
independent experiments. 
 
 
3.3.6. Statistical Analysis.  Slope and y intercept of the standard curves 
were compared between experiments using a single-factor analysis of 
variance for a random-effects model. Differences were considered significant  
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at a value of p < 0.05. Immune responsiveness was compared between 
control (C57) and various mutant mice (QM, JH-/-) using unpaired Student’s t 
test data. Differences were considered significant at a value of p < 0.05. All 
gene chip experiments were performed twice; representative data are 
shown.  
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3.4. Results 
 
As a first test of the concept, we asked whether the diversity of random 
oligonucleotides is predicted by the number of sites hybridized on a gene 
chip. Since the variable sequences of the complementarity determining 
region of lymphocyte receptors are relatively random, the sequences should 
be represented by random oligonucleotides.  We designed a random 
oligonucleotide and then inserted random point assignments at specific 
locations along the oligonucleotide. For example, to generate a sample with 
~106 different oligonucleotides, we synthesized the oligonucleotide with 10 
sites of random base assignment (410 = 1,048,576). We synthesized samples 
with 1, 103, 106, and 109 different oligonucleotides per sample. The 
oligonucleotides were biotinylated, and then 10 μg of each was hybridized to 
separate gene chips under similar stringency conditions to those for 
conventional applications. As anticipated, the number of hybridized sites 
increased with increasing diversity of oligonucleotides (Fig. 1A). Due to the 
exponential nature of the relationship, the natural logarithm of both variables 
was taken and plotted to yield a linear relationship (Fig. 1B, 1C).  
 
 
 72
Chapter III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   1 different oligo         103 different oligos      106 different oligos      109 different oligos 
 
Figure 1. Establishing the relationship between number of gene chip 
hybridization sites and sample diversity. Samples consisting of 1, 103, 
106, and 109 different oligos were biotinylated and hybridized to gene chips. 
Hybridization intensity data were arranged in ascending order. The number of 
probe locations with intensity above background (i.e., number of hits) was 
summed and compared to the number of different oligos initially applied to 
the gene chip (i.e., number of variants) (a) Relationship between number of 
hits and number of variants. The number of hits increases with the number 
of variants, indicating that the human gene chip can be used to detect 
random oligos. (b) Linear relationship between number of hits and number of  
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variants. The natural log of both axes yielded a linear relationship between 
hits and variants. (c) Visual hybridization of random oligos to gene chips.  
Scans of the gene chips afford rapid inspection of the "hit" profile. 
 
 
 
This relationship represents a standard curve that can be used for 
assessment of diversity in physiologic samples. To our knowledge this 
approach is the only means to generate such a curve in the absence of 
physiologic samples of known diversity. To ascertain the reproducibility of 
this relationship (i.e., the standard curve), we repeated the above 
experiment six times (Fig. 2). The trend (i.e., slope of the standard curve) 
was highly reproducible (p > 0.1), however overall hybridization intensity 
(i.e., y intercept of the standard curve) varied between experiments (p < 
0.05; Fig. 2).  This variability requires use of a standard curve for each 
experiment conducted.       
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Figure 2.  Reproducibility of method for analysis of receptor diversity.  
Samples obtained as described in Figure 1 were studied in six separate 
experiments (black circle,-●-)(white circle, -○-)(black square, -■-)(white 
square, -□-)(black triangle, -▲-)(white triangle, -∆-) to test reproducibility.  
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The slopes of the standard curves were the same statistically; however, the y 
intercept varied from experiment to experiment. 
 
To test whether variations in lymphocyte diversity could be measured 
directly, we the method to the study of B cells in mice. We used murine B 
cells for this purpose because diversity of these cells can be measured, at 
least in principle, through analysis of Ig gene expression and because we 
have available mutant mice with defined variations in B cell antigen receptor 
repertoire.  
 
We compared diversity of B cell antigen receptors in wild type (C57Bl/6) mice 
with the diversity of B cell receptors in quasi-monoclonal (QM) and JH-/- mice. 
The QM mice were generated by gene-targeted replacement of the 
endogenous JH elements with a VDJ rearranged region from a (4-hydroxy-3-
nitrophenyl) acetyl (NP)-specific hybridoma [130]. The kappa light chains in 
these mice are non-functional and, therefore, the knock-in heavy chain can 
only pair with endogenously rearranged lambda chains. All B cells in QM mice 
start out with the same heavy chain (QM B cells); however, secondary 
rearrangements and hypermutation change the specificity of B cell receptors 
(non-QM B cells) [130]. Thus, 80% of the peripheral B cells in the QM mice 
express NP-specific antibodies that contain the same single heavy chain, and 
the remaining 20% express antibodies expressing diverse heavy chains and 
diverse antigen specificities. JH-/- mice have a targeted deletion of the JH and  
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of the J kappa gene segments and, therefore, cannot assemble Ig heavy or 
kappa light chains [131]. These animals are B cell deficient although they do 
have surface Ig-negative precursor B cells (B220+/CD43+ pro-B cells) that 
assemble lambda light chain genes at a low level.   
 
To test changes in lymphocyte diversity, we compared gene chip 
hybridization of B cell heavy chain-specific cRNA from splenocytes of wild  
type, QM and JH-/- mice.  The heavy chain specificity of the cRNA was gained 
via generation of first strand cDNA from isolated RNA using a JH4-specific  
custom primer. A primer to the JH4 region of the heavy chain was used to 
detect diversity in one region of the heavy chain. While the results do not 
represent diversity of the entire heavy chain population they might provide a 
baseline from which a change could be detected. Following second strand 
DNA synthesis, the double-stranded product was biotinylated via in vitro 
transcription (IVT). The IVT product (cRNA) was purified and 10 μg of each 
sample and 10 μg of each standard were hybridized to individual gene chips. 
The hybridization intensities obtained from the JH-/- mice (which lack B cell 
receptors) were used to set the background threshold, above which 
hybridization sites (hits) were counted. Sample diversity was extrapolated 
from the standard curve.  
As the results shown indicate, wild type mice expressed more than 105 (2.8 x 
105) different B cell JH4-positive heavy chain clones and QM mice expressed 
3.9 x 102 different JH4-positive heavy chain clones (Fig. 3A). Thus, as  
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expected, QM JH4-positive heavy chain diversity was much less than wild type 
diversity, though well above background levels.  
 
We then tested the ability of this system to detect changes in diversity 
following antigenic challenge with keyhole limpet hemocyanin (KLH).  
Following immunization with proteins such as KLH, heavy chain diversity is 
thought to decrease due to oligoclonal expansion of high affinity clones. In 
contrast, immunization of QM mice with KLH (an antigen that does not bind 
with the QM antibody) causes diverse non-QM B cells to expand at the 
expense of the predominant QM B cells, thereby increasing heavy chain 
diversity [132]. Consistent with these theoretical concepts, JH4-positive heavy 
chain diversity in wild type mice decreased by greater than one order of 
magnitude, from 2.8 x 105 to 4.0 x 104, and diversity in QM mice increased 
(7.5 x 103) following immunization with KLH  
(Fig. 3A). Immune responsiveness was confirmed by quantitation of anti-KLH 
Ig in the serum (Fig. 3B). 
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Figure 3.  Analysis of B cell diversity using the gene chip method.  
Splenocytes were harvested from 3-4 week old JH-/-, QM and WT mice and 
mononuclear cells were isolated on Ficoll-paque gradients. Total RNA was 
isolated from the lymphocytes and first strand cDNA was generated using a 
primer designed to bind the constant region of the mouse heavy chain JH4 
region plus the T7 polymerase promoter. The custom primer promoted 
amplification of JH4-heavy chain-specific RNA only. Equal amounts of the in  
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vitro transcription product (cRNA) from each mouse and standards were 
hybridized to gene chips and then the chips were stained and analyzed as 
described in the methods.  (a) B cell heavy chain diversity in mutant mice  
before and after immunization with KLH.  Pre-immunization, WT diversity 
(black circle, -●-) was more than two-fold higher than QM (white circle, -○-) 
diversity. Post-immunization, WT diversity (black circle, -●-) decreased (4.0 x 
104 different B cell heavy chain clones) while QM (white circle, -○-) diversity 
increased (7.5 x 103).  Background hybridization was established using JH-/- 
RNA (black square, -■-). (b) Immune responsiveness to KLH.  An ELISA was 
used to detect levels of anti-KLH antibodies in the serum following 
immunization. The QM anti-KLH antibody titer was approximately 40% of the 
wild type following immunization:  * p < 0.05.   
 
 
We next asked whether this approach could distinguish medically relevant 
conditions in humans via assessment of T cell diversity. Peripheral blood 
lymphocytes were isolated from two normal individuals (35 and 55 years of 
age) and from two individuals who had cardiac transplants in infancy (3 and 
5 years of age; transplantation was conducted at < 1 year of age). Those 
who receive cardiac transplants in infancy undergo removal of the thymus as 
part of the surgical procedure and depletion of T cells with anti-T cell  
 80
Chapter III 
 
antibodies [133]. These patients would be expected to have a notably 
contracted TCR repertoire because they lack a source of new naïve T cells.  
RNA was isolated from these lymphocytes and from Jurkat cells and first 
strand cDNA was generated using a primer designed to bind the constant 
region of the TCR beta chain. We could have designed a primer to bind the 
constant region of the TCR alpha chain, or combined the alpha chain and 
beta chain primers to isolate all TCR RNA. However, the majority of 
lymphocyte diversity is conferred by the beta chain [22] and so in an effort 
to maintain the simplicity of the system, here we show beta chain diversity 
only. Jurkat cells express only one TCR (Vβ1.2Vβ8.1), and so the 
hybridization intensities of this sample were used to establish the background 
threshold.  
Normal human T cell receptor beta chain diversity was 4.4 x 106 and 5.1 x 
106 (Normal; Fig. 4). These values are consistent with estimates of beta 
chain diversity deduced by other means [124, 134] and taken with estimates 
of β-chain diversity and pairing [22] would place overall T cell diversity at 
minimally 1.1 x 108 (4.4 x 106 * 25 alpha families). And as expected, the T 
cell receptor beta chain diversity of the thymectomized/T cell depleted 
subjects (2.2 x 103 and 1.8 x 102; Thymectomized/T cell depleted, Fig. 4) 
was more than two orders of magnitude lower than that of normal 
individuals. To determine whether the assay could detect smaller changes in 
T cell diversity, we tested an individual with inflammatory bowel disease (25  
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years of age), which in experimental systems has been associated with 
decreased T cell diversity [135]. We found a decrease in TCRβ diversity of 
more than one order of magnitude in this subject (2.6 x 105; IBD, Fig. 4). 
Our results thus suggest that human inflammatory bowel disease may be 
linked with decreased lymphocyte diversity.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Analysis of human T cell diversity using gene chips.  Total RNA 
was isolated from human peripheral blood lymphocytes or Jurkat cells and 
first strand cDNA was generated using a primer designed to bind the 
constant region of the TCRβ chain. 
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Equal amounts of the in vitro transcription product (cRNA) from each sample 
and standards were hybridized to gene chips and then the chips were stained 
and analyzed as described in the methods. Two normal individuals [(black 
circle, -●-), (white circle, -○-)], two thymectomized/T cell depleted 
individuals [(black square, -■-), (white square, -□-)] and one individual with 
IBD (black triangle, -▲-) were analyzed. The TCRβ chain diversity of the 
normal individuals was 4.4 x 106 and 5.1 x 106 respectively (similar results 
were found even after diluting the normal sample with Jurkat cells at various 
ratios up to 20:80), the thymectomized individuals 2.2 x 103 and 1.8 x 102 
respectively and the individual with IBD 2.6 x 105. Background hybridization 
was established using Jurkat cell hybridization. 
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3.5. Discussion 
 
Here we report the direct measurement of lymphocyte diversity and illustrate 
potential applications. The system we devised can estimate diversity of the 
entire lymphocyte repertoire (i.e., all gene segment combinations) at once 
and avoids the complications of indirect estimates of lymphocyte diversity. 
With only minor adjustments, this approach is equally capable of measuring 
B cell and T cell diversity and can be adjusted via primer design to include or 
exclude lymphocyte receptor subsets. The system is sufficiently simple and 
effective to allow widespread application. 
 
There is much interest in the relationship between lymphocyte diversity and 
immunocompetence. Loss of diversity has been implicated in various disease 
states [124, 136, 137], and so changes in diversity might be used to track 
the progression or remission of disease. For example, this approach might be 
used to monitor immune reconstitution following bone marrow 
transplantation or intensive retroviral therapy. In these settings, a small 
number of clones might expand by homeostatic proliferation to yield normal 
lymphocyte numbers, but diversity might be altered [138]. The technique 
reported here might also be used to track expanded T cell clones or clusters 
of clones over time based on gene chip hybridization pattern. Certainly, the 
numbers of individual T cell clones in normal blood are too few to allow clone 
tracking by any means; however, the expanded T cell clones seen in  
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response to infection, transplantation or homeostatic proliferation might in 
principle be tracked over time with this method. Preliminary experiments 
done in our laboratory support this concept (data not shown).       
 
While we have focused on the measurement of lymphocyte receptor 
diversity, the technique here discussed might also be applied more broadly to 
the daunting task of quantifying biologic diversity of, for example, viral 
quasispecies. Because persistence of some viral infections such as hepatitis C 
is positively related to the diversity of the virus [139], quantifying 
quasispecies diversity may be critical to guide therapeutic choices and 
prognostic assessments. Diversity of hepatitis C virus quasispecies may be 
accomplished by generating viral envelop gene-specific cRNA followed by 
hybridization to gene chips and analysis similar to the one described above 
for the lymphocyte receptor genes.   
 
The primary challenge of using gene chips to measure lymphocyte diversity 
is determining the background correction for analysis of extremely narrow 
repertoires. We are exploring the usefulness of intensity data from non-
lymphoid cells for this purpose as well as enhancing our panel of standards to 
include all single order variations in diversity (i.e., 101, 102, 104, 105, etc.).  
An additional caveat warrants mention.  It is difficult to predict whether the 
number of hits generated by a diverse oligonucleotide mixture is equivalent 
to the number of hits generated by the same diversity of lymphocyte 
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 receptor cRNA.   We controlled for the potential difference in hybridization 
by including a sample of known diversity (i.e., Jurkat with 1 TCR and MBT 
with 1 BCR) in the generation of the standard curve.  Thus the number 
deduced by this approach, while likely not the actual number of different 
receptors in a population, is an approximation of the actual number of 
receptors in a population.  The number therefore serves both as an estimate 
of the receptor diversity within a population and a basis for comparison with 
other populations.   
 
Overall, the advent of high-throughput hybridization technology has made it 
possible to directly assess lymphocyte receptor diversity and thus perhaps  
immune fitness. This approach should facilitate fundamental study of the 
physiology of the adaptive immune system and clinical efforts to asses and 
follow immunological diseases. 
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4.1. Abstract 
 
T cell diversity was once thought to depend on the interaction of T cell 
precursors with thymic epithelial cells.  Recent evidence suggests, however, 
that diversity might arise through the interaction of developing T cells with 
other cells, the identity of which is not known.  In this study we show that T 
cell diversity is driven by B cells and Ig.  The TCR Vβ diversity of thymocytes 
in mice that lack B cells and Ig is reduced to 6 x 102 from wild-type values of 
1.1 x 108; in mice with oligoclonal B cells, the TCR Vβ diversity of thymocytes 
is 0.01% that in wild-type mice.  Adoptive transfer of diverse B cells or 
administration of polyclonal Ig increases thymocyte diversity in mice that 
lack B cells 8- and 7-fold, respectively, whereas adoptive transfer of 
monoclonal B cells or monoclonal Ig does not.  These findings reveal a 
heretofore unrecognized and vital function of B cells and Ig for generation of 
T cell diversity and suggest a potential approach to immune reconstitution. 
 
 
 
Keywords: T cell repertoire, antigen receptor diversity, B cell deficiency, 
immunoglobulin, thymus. 
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4.2. Introduction 
 
The generation of TCR diversity is initiated by recombination of the V, D, and 
J gene segments and originates the variable region of the TCR genes in T cell 
precursors in the thymus [21].  Although V(D)J recombination generates 
billions of different TCRs, only a small fraction of these (5%) is expressed by 
the mature thymocytes [140].  Thymocytes that fail to produce TCR or that 
produce TCR that fails to recognize MHC bearing self peptide die by neglect.  
Thymocytes bearing self-reactive TCR are eliminated (negative selection), 
leaving a small fraction of thymocytes surviving (positive selection) [140].  
Thus, positive and negative selection give rise to a primary T cell repertoire 
that recognizes self-MHC (restriction) with moderate avidity that is not self-
reactive and, in turn, establishes the diversity of naive T cells.  Therefore, 
assuming an equal contribution of V(D)J recombination, the diversity of 
newly made thymocytes reflects the efficiency of selection.  T cell diversity 
has been estimated to be 108 different T cells in humans and 106 in mice [22, 
24].  
Positive selection and T cell restriction have been thought to result from the 
interaction of developing T cells with thymic epithelial cells [141].  This 
conclusion was deduced from experiments in which lethally irradiated 
recipient mice of different MHC haplotypes were reconstituted with bone 
marrow cells obtained from H-2b TCR transgenic mice.  In these chimeras, T 
cells were positively selected only when the thymic MHC was of the H-2b  
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haplotype, indicating that H-2b expression by bone marrow-derived cells 
alone was not sufficient to promote positive selection [15].  The conclusion 
that thymic epithelial cells mediate positive selection was also indicated by 
the work of Benoist and Mathis [142], who showed that the expression of 
MHC class II on cortical thymic epithelium was sufficient to achieve positive 
selection of thymocytes, whereas the expression of the same MHC antigens 
on hematopoietic-derived cells was not.  
While thymic epithelium might be sufficient to mediate positive selection, 
some wondered whether cells other than thymic epithelial cells could also 
participate in positive selection.  Pawlowski et al. [143] and Hugo et al. [144] 
showed in separate experiments that MHC class I- or MHC class II-bearing 
fibroblasts injected into the thymus of MHC class I-deficient or MHC class II-
deficient mice were able to mediate positive selection.  Bix and Raulet [145] 
showed that bone marrow-derived cells in MHC class I-deficient bone marrow 
chimeras promoted positive selection of CD8+ thymocytes.  In contrast, MHC 
class II-positive bone marrow-derived cells did not rescue CD4+ T cells in 
MHC class II-deficient mice [146].  If some experiments establish that 
positive selection can, in some cases, be mediated by nonthymic epithelial 
cells, the question of how physiologic these interactions may be is not 
resolved. Zinkernagel and collaborators generated tetraparental aggregation 
chimeras in which thymic epithelial cells expressed one MHC, and 
hematopoietic-derived cells expressed another [147].  In these chimeras, T 
cells were restricted to the MHC expressed on the thymic epithelial cells as  
 91
Chapter IV 
 
expected, but also to the MHC expressed by the hematopoietic cells.  These 
results indicated that nonthymic epithelial cells as well as thymic epithelial 
cells promote positive selection of thymocytes [147].  Which hematopoietic-
derived cells were responsible for the positive selection of thymocytes was 
not determined.  
Besides the question of which cells mediate positive selection of thymocytes 
is the question of which cells provide the source of peptides.  One speculation 
has been that the peptides originate in the thymic epithelium [148]; 
however, the repertoire of peptides available from this source may not 
suffice.  Selection of a diverse T cell repertoire requires diverse peptides 
presented in the context of self-MHC.  Thus, mice that express MHC 
associated with a single peptide have a markedly constrained T cell repertoire 
[149-151].   
As B cells are normal constituents of the thymus [152] and may present 
peptides derived from the Ig V regions [153] or peptides derived from 
antigens expressed endogenously [154], we hypothesized that B cells would 
potentially serve as a source of peptide diversity in the thymus.  In fact, B 
cells are one of the major cell types expressing MHC class II and are capable 
of presenting antigens to T cells [100].  We tested this hypothesis by 
comparing the diversity of the TCR repertoire in mice with varying B cell 
numbers and varying B cell diversity and by testing whether transfer of B 
cells or immunoglobulin could rescue TCR diversity.  Our studies demonstrate  
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that B cells and immunoglobulin generate a significant fraction of T cell 
diversity.  
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4.3. Materials and Methods 
 
4.3.1. Mice strains. JH-/-, µMT, monoclonal B-T, and quasi-monoclonal 
(QM) mice were previously described [19, 129, 131, 155].  The B cell-
deficient strains consisted of JH-/- mice, obtained by gene-targeted deletion 
of the JH segments [131], and µMT mice, obtained by gene-targeted 
disruption of the µ Ig H chain membrane exons [155].  C57BL/6 and µMT 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  JH-/-, 
monoclonal B-T, and QM mice were bred and all mice were housed in a 
specific pathogen-free facility at Mayo Clinic (Rochester, MN).  All mice were 
between 6 and 16 wk of age and were age-matched.  All animal experiments 
were conducted in accordance with protocols approved by Mayo Clinic 
Institutional Animal Care and Use Committee.  
 
 
4.3.2. Adoptive transfer of B cells. Bone marrow cells were harvested 
from C57BL/6 mice or monoclonal B-T mice, and lymphocytes were isolated 
by Ficoll-Paque gradient (Amersham Pharmacia Biotech, Piscataway, NJ).  
Polyclonal B cells (1 x 107) purified with a Miltenyi Biotec isolation kit 
(Auburn, CA) and monoclonal B cells (6 x 106) purified with a high speed 
sorter FACSVantage SE (BD Biosciences, Mountain View, CA) were injected 
i.p. in newborn mice (20 µl).  The polyclonal B cells contained, on the  
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average, 1% CD3+CD4+ and 1.5% CD3+CD8+ cells, and the monoclonal B 
cells contained 0% CD3+CD4+ and 0.07% CD3+CD8+ cells.  
 
 
4.3.3. Immunoglobulin injections. JH-/- mice were injected i.p. weekly 
with 250 µg of mouse polyclonal IgG (Serotec, Oxford, U.K.) or monoclonal 
anti-keyhole limpet hemocyanin IgG2b (C48-4; BD Biosciences) from birth.  
Serum levels of total Ig were tested 4 wk or more after the first injection.  
 
 
4.3.4. Flow cytometry analysis. Thymocytes were obtained by mincing 
thymi through a 0.70-µm pore size mesh, followed by RBC hemolysis in a 
standard NH4Cl lysis buffer.  Bone marrow cells were prepared by flushing 
femurs with cell suspension buffer, followed by RBC lysis, as previously 
described [129].  Total thymocyte numbers were counted with a Coulter 
counter (Hialeah, FL).  Cells were stained with one, two, or three of the 
following monoclonal antibodies (all the antibodies were from BD 
PharMingen, San Diego, CA) as previously described [129].  FITC-conjugated 
rat anti-mouse CD4 (GK 1.5), rat anti-mouse CD43 (Ly-48, leukosialin), and 
mouse anti-5-bromo-2'-deoxyuridine (anti-BrdU) antibodies; PE-conjugated 
rat anti-mouse CD8 (53-6.7), rat anti-mouse CD19 (1D3), and rat anti-
mouse IgMb (Igh-6b; AF6-78); and biotin-conjugated rat anti-mouse B220 
(16A), rat anti-mouse CD62L (LECAM-1, Ly22), and rat anti-mouse CD3  
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(145-2C11).  Lymphocytes were gated on the light scatter plot by back-
gating onto CD4+CD3+ and CD8+CD3+ cells; the numbers of the thymocyte 
subpopulations were determined by multiplying the percentage, as defined 
by gating on the FACS plot, by their total number.  
 
 
4.3.5. DNA analysis. Thymocytes (106/ml) were washed with ice-cold PBS 
and fixed in 70% ethanol at -20°C for at least 2 h.  After fixation, cells were 
washed twice with PBS and incubated in 50 µl of DNA extraction buffer (0.2 
M phosphate citrate buffer, pH 7.8) at 37°C for 30 min in a shaker.  After 
DNA extraction, the cells were stained with propidium iodide in a solution 
containing 10 ml of 0.1% (v/v) Triton X-100 in PBS, 200 µl of 1 mg/ml 
propidium iodide (Molecular Probes, Eugene, OR), and 2 mg of DNase-free 
RNase A (Sigma-Aldrich, St. Louis, MO), for 30 min at room temperature.  
Detection of propidium iodide fluorescence was read at red wavelength in a 
FACScan flow cytometer (BD Biosciences) and was analyzed with ModFit LT 
software (Verity Software House, Topsham, ME).  
 
 
4.3.6. Immunohistological analysis. Thymi removed from 6- to 8-wk-old 
mice were oriented, covered with OCT (Sakura, Torrance, CA), snap-frozen 
by pre-cooled isopentane, and stored at -85°C.  Four-micron-thick frozen 
sections were mounted on positively charged microscope slides (SuperFrost  
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Plus; Fisher Scientific, Pittsburgh, PA) and stored at -85°C.  Before 
processing, sections were air-dried at room temperature, fixed 10 min in 4°C 
acetone, air-dried for an additional 10 min, then post-fixed for 2 min in 100 
mM Tris-buffered 1% paraformaldehyde containing 1 mM EDTA, pH 7.2, and 
rinsed with PBS (pH 7.2). Before staining, the specimens were incubated in 
0.3% hydrogen peroxide in 0.1% sodium azide (aq) solution to quench the 
presence of endogenous peroxidase.  Specimens were incubated with rat 
monoclonal antibodies to murine CD19 (clone 1D3; BD PharMingen) and to 
CD45R/B220 (clone RA3-6B2; BD PharMingen), rinsed with PBS, then 
detected by mouse serum pre-absorbed, affinity-purified, biotinylated goat 
IgG anti-rat IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), 
followed by PBS rinses and the tertiary application of horseradish-conjugated 
streptavidin (DAKO, Carpinteria, CA).  Slides were developed by incubation 
with a peroxidase substrate NovaRED (Vector Laboratories, Burlingame, CA), 
which resulted in an insoluble reddish-brown precipitate, followed by 
counterstaining with a progressive alum-hematoxylin, dehydrated in graded 
ethanols, cleared in xylene changes, and coverslipped with Cytoseal-Xyl 
(Stephens Scientific, Kalamazoo, MI).  Digital images were obtained using a 
brightfield microscope equipped with a CCD digital camera (SPOT II; 
Diagnostic Instruments, Sterling Heights, MI).  
Apoptotic cells were detected in cryostat sections of thymi by in situ TUNEL, 
performed according to the manufacturer’s instructions (ApopTag Plus 
Peroxidase Kit; Serologicals, Norcross, GA).  
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4.3.7. Determination of TCRVβ diversity 
Isolation of RNA. Thymi harvested from mice were placed in RPMI 1640 
and pushed through a 70-µm pore size cell strainer.  Lymphocytes were 
isolated by Ficoll-Paque (Amersham Pharmacia Biotech) gradient.  Total RNA 
was obtained with RNeasy kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions.  
Generation of diversity standards. Diversity standards were prepared by 
creating oligonucleotide mixtures of known diversity.  For example, to 
generate a standard diversity of 106, 18-mer oligonucleotides were 
synthesized with 10 sites of random assignment, generating 410 = 
1,040,526 different oligomeres.  Similarly, we created oligomer mixtures with 
1, 103, and 109 variants.  Oligonucleotides were biotin-labeled and 
hybridized to the gene chips as explained below.  
Generation of lymphocyte receptor-specific cRNA. First-strand cDNA 
was obtained by RT with a mouse TCR C reverse primer, T7+C (5'-
GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGCTTGGGTGGAGTCACA
TTTCTC-3').  Second-strand synthesis and preparation of biotin-labeled cRNA 
were conducted according to standard protocols (Affymetrix, Santa Clara, 
CA).  
Application of cRNA to the gene chip. Equal amounts of cRNA from 
different samples and diversity standards were hybridized to U95B gene 
chips (Affymetrix).  Gene chips were processed at the Microarray Core 
Facility (Mayo Clinic).  
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Data analysis. For each gene chip experiment, we obtained raw data 
corresponding to oligo location and hybridization intensity.  Data were 
arranged in order of ascending hybridization intensity.  The number of oligo 
locations with intensity above background (i.e., number of hits) was 
summed.  The standard curve was generated from hybridization of samples 
with known numbers of different oligomeres.  The standard oligonucleotide 
mixtures were 18-mer oligomeres synthesized to obtain mixtures containing 
1, 103, 106, and 109 different oligonucleotides.  The diversity of cRNA 
obtained from monoclonal T cells was used to establish the background, and 
the diversity of the test samples was extrapolated directly from the standard 
curve.  We controlled for the TCR specificity of the C reverse primer by 
determining the diversity of cRNA obtained from purified polyclonal B cells 
with the C reverse primer, which was found to be three per 10 µg of RNA and 
indistinguishable from background.  
 
 
4.3.8. Statistical analysis. Statistical analysis for group comparison of 
means of TCR Vβ diversity of thymocytes was performed using log 
transformation of the data, followed by one-way ANOVA.  Groups of two 
comparisons were performed by unpaired, two-sided Student’s t test.  
Comparisons of thymocyte numbers were performed using the Kruskal-Wallis 
test for global differences, followed by the Wilcoxon rank-sum test.  A value 
of p < 0.05 was considered statistically significant.  
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4.4. Results 
 
4.4.1. Thymocyte development is perturbed in mice that lack B cells 
and Ig 
To test whether B cells and/or Ig might contribute to thymic selection, we 
compared the numbers of thymocytes and thymocyte subpopulations in mice 
that lack B cells and Ig (JH-/-) with the numbers in wild-type mice 
(C57BL/6).  Because the thymus atrophies with age, the mice in each group 
were age-matched.  Our results show that JH-/- mice had significantly fewer 
total thymocytes (6.5-fold) than C57BL/6 mice (Fig. 1).  The smaller number 
of thymocytes in JH-/- mice was mainly due to a 3.9-fold decrease in the 
number of CD4+CD8+ thymocytes (Fig. 1), but also reflected a significant 
decrease in the numbers of CD4- CD8-, CD4+ CD8-, and CD4- CD8+ 
populations compared with wild type.  These results suggest that B cells 
and/or a B cell product such as Ig might influence thymocyte development by 
various direct or indirect means.   
To determine whether Ig might on its own contribute to T cell development, 
we examined thymocytes in the µMT mouse, which has a serum Ig 
concentration 4.5% that of the wild-type mouse, but very few B cells [156] 
[157] (Table I).  We found that the number of thymocytes in µMT mice was 
increased significantly by 3.2-fold compared with that in JH-/- mice (Fig. 1). 
These results are consistent with a role for Ig in the development of T cells.  
 100
Chapter IV 
 
 
FIGURE 1. Thymocyte numbers in C57BL/6, µMT, and JH-/- mice.  The 
number of thymocytes corresponding to each sub-population was calculated 
by multiplying the respective percentage of the total events as defined in the 
flow cytometric dot plot analysis by the total number of WBC obtained by 
counting on a Coulter counter.  The number of thymocytes (average ± SD) 
was 1.3 x 108 ± 5.1 x 107 in C57BL/6, 8.9 x 107 ± 6.4 x 107 in µMT, and 3.1 
x 107 ± 1.7 x 107 in JH-/- mice.  The average number of CD4-CD8- 
thymocytes was 5.5 x 106 ± 2.1 x 106 in C57BL/6, 3 x 106 ± 2 x 106 in µMT, 
and 2.2 x 106 ± 2.7 x 106 in JH-/- mice; the average number of CD4+CD8+ 
thymocytes was 9 x 107 ± 4.4 x 107 in C57BL/6, 7.3 x 107 ± 4.7 x 107 in 
µMT, and 2.3 x 107 ± 2.7 x 107 in JH-/- mice; the average number of CD4-
CD8+ thymocytes was 1.2 x 107 ± 1.2 x 107 in C57BL/6, 7.7 x 106 ± 1.3 x 
107 in µMT, and 1.5 x 106 ± 1.4 x 106 in JH-/-mice; and the average number 
of CD4+CD8- thymocytes was 1.9 x 107 ± 2.8 x 107 in C57BL/6, 4.9 x 106 ±  
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2.8 x 106 in µMT, and 3.5 x 106 ± 3 x 106 in JH-/- mice.  Error bars represent 
the SD.  Data were obtained from 10 C57BL/6, 8 µMT, and 10 JH-/- mice for 
the total number of thymocytes and from 8 C57BL/6, 8 µMT, and 7 JH-/- 
mice for thymocyte subpopulations.  Mice were between 6 and 16 wk of age.  
Comparisons of the number of cells in the three strains of mice (indicated by 
global p) were performed by the Kruskal-Wallis test, and comparisons 
between two groups of mice (p values indicated below the diagrams) were 
made using the Wilcoxon rank-sum test. 
 
 
Table 1. Mean concentration of serum Ig ± SD in C57BL/6, QM, µMT, JH-/- 
mice and in JH-/- mice reconstituted with B cells or after administration of 
IgG 
Mice Serum Immunoglobulin 
(μg/ml) 
C57BL/6 163.5 ± 160.6 
μMT 10.7 ± 24.7 
QM 654.5 ± 248.8 
JH-/- 0 
JH-/- with Polyclonal B cells 0 
JH-/- with Polyclonal IgG 832.2 ± 1380.1 
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4.4.2. Increased apoptosis in the thymic cortex of mice that lack B 
cells and Immunoglobulin 
Next we asked whether the fewer thymocytes in JH-/- mice were the result 
of higher levels of cell death.  Consistent with that concept, TUNEL, which 
detects DNA strand breaks in cells undergoing apoptosis, revealed increased 
apoptosis (at least 2.5-fold) in the thymic cortex of JH-/- mice compared with 
µMT or to C57BL/6 mice (Fig. 2).  Increased cell death could be the 
consequence of decreased positive selection and/or increased negative 
selection.  Because defective positive selection is accompanied by cortical 
thymocyte apoptosis [158], our results are compatible with B cells and/or Ig 
promoting thymic positive selection.  As apoptosis in the thymic cortex of 
µMT mice is comparable to apoptosis detected in C57BL/6 mice, and as µMT 
mice produce serum Ig, but few B cells [156] [157], our results suggest that 
serum Ig promotes thymocyte survival.  
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FIGURE 2. Apoptosis in the thymus. Apoptotic cells are stained brown and 
were detected in cryostat sections of thymi by in situ TUNEL.  Photographs 
are representative of four mice per genotype analyzed.  The number of 
apoptotic spots in JH-/- sections was at least 2.5-fold greater than the 
number of spots counted in equivalent areas of C57BL/6 or µMT sections. C, 
cortex; M, medulla. 
 
 
4.4.3. Numbers of recent thymic emigrants are maintained and 
thymocyte proliferation is increased in mice that lack B cells and 
Immunoglobulins 
We next wondered whether decreased numbers and increased apoptosis of 
thymocytes in JH-/- mice would change the numbers of recent thymic 
emigrants.  Recent thymic emigrants were identified based on their tendency 
to take up relatively low levels of BrdU according to the method of Tough and 
Sprent [159, 160].  We defined the recent thymic emigrants’ gate by  
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comparing thymectomized and nonthymectomized mice treated with BrdU.  
The recent thymic emigrants’ gate includes the population of naive T cells 
lost by thymectomy (Fig. 3, B and D).  Using these gates we found no 
differences in the proportions of recent thymic emigrants in CD4+ or CD8+ 
naive (CD62L-positive) T cells analyzed in JH-/-, µMT, and C57BL/6 mice, 
suggesting that thymic output is maintained despite decreased number of 
thymocytes (Fig. 3, A and C).  
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FIGURE 3. Recent thymic emigrants.  The plots represent BrdU incorporation 
by peripheral blood CD4+CD62L+ (naive) T cells (A and B) or CD8+CD62L+ 
T cells (C and D).  The x-axis shows BrdU staining fluorescence intensity; the 
y-axis shows CD62L staining fluorescence intensity.  The recent thymic  
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emigrants are the naive CD4+ or CD8+ lymphocytes that incorporate low 
levels of BrdU [159, 160].  The rarity of CD4+CD62L+ and CD8+CD62L+ T 
cells incorporating low levels of BrdU in thymectomized mice defined the 
recent thymic emigrants’ gates (B and D).  The figure shows that thymic 
output did not differ significantly in C57BL/6, µMT, and JH-/- mice.  The dot 
plots shown are representative of three independent experiments with 
C57BL/6 and JH-/- mice and two experiments with µMT mice. 
 
 
 
To reconcile the decreased number of thymocytes in JH-/-mice with the 
maintenance of thymic output, we hypothesized that these mice have 
increased proliferation of thymocytes.  Increased thymocyte proliferation 
would allow JH-/- mice to maintain thymic output despite increased cell 
death.  Cell cycle analysis of thymocytes of JH-/-, µMT, and C57BL/6 mice 
revealed a 1.5-fold increase in the number of cycling (S+G2/M) thymocytes 
in JH-/- compared with µMT and C57BL/6 mice (Fig. 4).  Our results thus 
suggest that lack of B cells and Ig leads to increased cell death and to 
thymocyte proliferation, perhaps as a compensatory mechanism to maintain 
T cell production.  
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FIGURE 4. DNA content of thymocytes from C57BL/6, µMT, and JH-/- mice.  
Histograms of one representative experiment of a total of four per genotype 
are shown. The x-axis shows the DNA content; the y-axis shows the number 
of cells.  Diagrams depict the number of cells in the G1, S, and G2/M phases 
of the cell cycle.  The fraction of cells in the S+G2/M phase of the cell cycle 
(± SD) were 23 ± 0.12% for C57BL/6, 19 ± 0.14% for µMT, and 35 ± 
0.19% for JH-/- mice.  Twenty thousand events were collected for each 
analysis. 
 
 
 
4.4.4. Contraction of the TCR repertoire in mice that lack B cells 
and/or Ig 
If mice that lack B cells and Ig have fewer thymocytes and normal T cell 
egress, one might predict that the TCR repertoire would be contracted due to  
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clonal expansion of the fewer surviving thymocytes.  As a direct test of this 
idea, we assayed TCR diversity in JH-/-, µMT, and C57BL/6 mice.  
Until recently, quantification of TCR diversity has been accomplished by 
generalization from exemplary sequencing of CDR3 regions obtained from 
spectratyping analysis, a method that has been referred to as quantitative 
immunoscope analysis [161].  Although this method yielded useful estimates 
of TCR diversity in human and mouse [22, 24], it is only accurate as long as 
the number of different sequences obtained for the exemplary V(D)J joints 
chosen is a good estimate of the number for any other V(D)J joint.  The 
extraordinary effort needed to perform this method in multiple individuals or 
mice renders it impractical for quantification of TCR diversity.  These 
problems prompted us to develop a novel method to directly measure TCR 
diversity.  Our method allows direct quantification of TCR diversity and was 
recently published [162].  
 
To measure TCR diversity directly, we determined the number of 
hybridization spots (hits) of TCR Vβ-chain RNA on a gene chip (U95B; 
Affymetrix, Santa Clara, CA).  In brief, TCR Vβ-chain cDNA is produced by RT 
from total RNA with a Cβ-specific primer.  After second-strand synthesis, 
biotinylated cRNA is produced by in vitro transcription according to 
Affymetrix protocols and hybridized to the gene chip (U95B; Affymetrix).  
The diversity of the TCR Vβ-chain in a population is proportional to the 
number of hits above background (defined by the number of hits  
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corresponding to hybridization of monoclonal TCR Vβ-chain RNA) of TCR Vβ-
chain-specific RNAs on the gene chip [162].  Diversity is calculated by 
plotting the number of hits onto a standard curve obtained for each 
experiment by hybridizing oligonucleotide mixtures of known diversity to 
individual gene chips.  The number obtained varies proportionally to the 
actual TCR Vβ diversity, even though it does not represent the number of 
different TCR Vβ-chains, as each TCR Vβ-chain may generate more than one 
hit [162].  To determine whether the TCR Cβ-specific primer cross-hybridized 
with B cell RNA, we determined the diversity of cRNA obtained from purified 
B cells with the Cβ reverse primer.  We found that the number of hits 
obtained from B cell cRNA prepared with the TCR Cβ-specific primer was 
three per 10 µg of RNA and was indistinguishable from background, 
indicating that the TCR Cβ-specific primer does not cross-hybridize with B cell 
RNA.  In addition, the T cell diversity of C57BL/6 splenocytes, which include 
mostly B cells, was 1000-fold lower than the T cell diversity of C57BL/6 
thymocytes (results not shown). Thus, the diversity of TCR Cβ-specific cRNA 
does not reflect contamination with B cell receptor messages.  
 
Fig. 5 shows that the TCR Vβ diversity of JH-/- thymocytes was 6.0 x 102/10 
µg of RNA compared to that of wild type, which was 1.1 x 108/10 µg of RNA 
(p = 0.0002).  By showing profoundly decreased thymocyte diversity in mice 
that lack B cells and Ig (JH-/-), our results indicate that B cells and/or Ig 
promote thymocyte diversity.  In this experiment we compared age-matched  
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JH-/- and C57BL/6 mice that were between 5 and 12 wk old.  The decreased 
thymocyte diversity in JH-/- mice was thus not due to age-dependent 
atrophy of the thymus.  
 
 
 
 
 
FIGURE 5. TCR Vβ diversity. A, TCR Vβ diversity of thymocytes obtained 
from C57BL/6, µMT, and JH-/- mice.  The x-axis shows mouse strains; the y-
axis shows TCR Vβ diversity.  Thymocytes were obtained from 5- to 12-wk-
old mice as previously described [129], and mononuclear cells were isolated 
on Ficoll-Paque gradient (Sigma-Aldrich).  Total RNA was obtained with the 
RNeasy kit (Qiagen). First-strand cDNA was synthesized with a reverse 
primer containing a T7 polymerase promoter 3' overhang that annealed to  
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the TCR constant region, with Superscript II reverse transcriptase 
(Invitrogen, Carlsbad, CA).  The second strand was generated by nick 
translation.  The double-strand cDNA was processed for gene chip 
hybridization according to Affymetrix protocols.  Hybridization hits were 
summed, and the total number was used to calculate TCR Vβ diversity by 
comparison with known diversity oligomer mixtures (standards) run at the 
same time.  Measurement of TCR Vβ diversity was specific, because when it 
was applied to purified diverse B cells (with <0.9% of T cells), it yielded 
background values (three per 10 µg of RNA).  Each open circle represents 
one experiment, and the values indicate the mean of TCR Vβ diversity for 
each strain of mice.  Statistical analysis was performed on each of the log-
transformed numeric values by unpaired two-sided t test. 
 
 
 
Next, we asked whether Ig could promote T cell diversity under the condition 
of B cell deficiency.  To this end we analyzed the TCR Vβ diversity in 
thymocytes of µMT mice that have serum Ig, but very few B cells.  We found 
that TCR Vβ diversity in thymocytes of µMT mice was 4.2 x 104/10 µg of RNA 
and 70-fold greater than TCR Vβ diversity in thymocytes of JH-/- age-
matched mice (6.0 x 102/10 µg of RNA; p = 0.0004).  Our results indicate 
that Ig and/or the few B cells in µMT mice contribute to T cell diversity. The 
reduced TCR diversity in B cell-deficient mice was maintained in the 
periphery as JH-/-, and µMT mice splenocytes had 1000- and 10-fold reduced 
TCR Vβ diversity, respectively, compared with wild-type mice.  
 112
Chapter IV 
 
Selection of a diverse T cell repertoire requires TCR recognition of diverse 
self-peptides in the context of self-MHC [140].  Because the V regions of H 
and L chains of antibodies are a potential source of diverse self-peptides, we 
wondered whether T cell diversity depended on the diversity of the B cells.  
To address this question, we determined TCR Vβ-chain diversity of 
thymocytes obtained from QM mice that have 80% of B cells from a single 
clone and polyclonal serum Ig [129, 130].  In QM mice, the diversity of the 
JH4-containing H chains is only 0.01% that in wild-type [162].  Fig. 5 shows 
that the TCR Vβ diversity of QM thymocytes was, on the average, 1.2 x 
104/10 µg of RNA, not significantly different from that of µMT and 0.01% that 
of WT thymocyte diversity (p = 0.006).  Our findings of comparable TCR 
diversity in QM and µMT age-matched mice indicate that oligoclonal B cells 
do not promote diversification of T cells.  
 
 
4.4.5. B cell precursors in C57BL/6, QM, JH-/- and µMT thymi 
Our results imply that B cells and/or Ig promote the selection of a diverse T 
cell repertoire, presumably in the thymus.  As both mature B cells and B cell 
precursors are found in the thymus [163, 164], we wondered which B cell 
populations were present in the thymus of C57BL/6, QM, JH-/-, and µMT 
mice.  Fig. 6A shows that JH-/- and µMT thymi had fewer CD19+ cells in the 
thymic cortex and fewer CD19+ and B220+ cells in the medulla compared 
with C57BL/6 mice.  In contrast, the numbers of B220+ cells were 
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 comparable in the thymic cortexes of JH-/-, µMT, and C57BL/6 mice (Fig. 
6A).  To discriminate B cell precursors from mature B cells, we analyzed 
thymocytes of JH-/-, µMT, QM, and C57BL/6 mice by flow cytometry.  Fig. 6B 
shows that mature B cells (IgM+ and B220+) are missing from JH-/- and 
µMT thymi and are reduced by half in QM thymi compared with those in 
C57BL/6 thymi.  There were very few pre-B cells (IgM-CD43-B220+) [165] in 
the thymi of mice of all genotypes, whereas they were present in the bone 
marrow (Fig. 6C).  Pro-B cells (IgM-CD43+B220+) [165] did not differ 
significantly in JH-/-, µMT, QM, or C57BL/6 thymi (Fig. 6C).  Our findings 
thus suggest that mature B cells, rather than B cell precursors, promote 
thymocyte selection and the generation of T cell diversity.  
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FIGURE 6. Immunohistochemical and flow cytometric analyses of thymic B 
cells and B cell precursors.  A, Immunohistochemical staining of thymic 
sections of C57BL/6, µMT, and JH-/- mice.  Positive cells are stained brown. 
JH-/- and µMT thymi had fewer CD19+ cells in the thymic cortex and fewer 
CD19+ and B220+ cells in the medulla compared with C57BL/6 mice.  The 
numbers of B220+ cells were comparable in the thymic cortexes of JH-/-,  
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µMT, and C57BL/6 mice.  B, Flow cytometric analysis of mature B cells in the 
thymi of C57BL/6, QM, µMT, and JH-/- mice.  The x-axis shows IgM staining 
fluorescence intensity; the y-axis shows B220 staining fluorescence intensity.  
The dot-plot diagrams identify mature thymic B cells that are B220+ and 
IgM+.  Mature B cells are missing from the thymi of µMT and JH-/-, but are 
present in the thymi of C57BL/6 and QM mice.  Percentages represent the 
proportion of thymocytes that are mature B cells.  The results shown are 
representative of three mice per genotype that were between 6 and 10 wk of 
age.  C, Flow cytometric analysis of pro- and pre-B cells in the thymi or bone 
marrow of C57BL/6, QM, µMT, and JH-/- mice.  The x-axis shows the CD43 
staining fluorescence intensity; the y-axis shows the B220 staining 
fluorescence intensity.  The plots represent IgM- cells.  Upper diagrams 
represent thymocytes; lower diagrams show bone marrow cells.  There were 
no significant differences in the proportions of pre-B cells (IgM-CD43-B220+) 
and pro-B cells (IgM-CD43+B220+) in JH-/-, µMT, QM, or C57BL/6 thymi.  
The percentages refer to the fraction of IgM- cells that corresponds to the 
indicated phenotype.  Pre-B cells were nearly absent in the thymi of mice of 
all genotypes, whereas they were present in the bone marrow. 
 
 
 
4.4.6. T cell diversity in JH-/- mice reconstituted by adoptive transfer 
of B cells or administration of immunoglobulin.   
Next we tested whether providing B cells and/or immunoglobulin could 
increase TCR diversity in JH-/- mice lacking both B cells and immunoglobulin.  
To this end, we injected newborn JH-/- mice with bone marrow-derived wild 
type or monoclonal B cells, or with polyclonal or monoclonal IgG, and 
measured TCR diversity after 4 weeks.  The presence of adoptively  
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transferred B cells was verified by flow cytometry analysis; recipient mice 
had between 10% and 20% of B cells in peripheral blood lymphocytes, at the 
time of sacrifice (unpublished data).  Mice injected with immunoglobulin had, 
on average, serum concentrations greater by 4.7 fold than wild type at the 
time of sacrifice (table I and unpublished data).   
 
Transfer of wild type B cells in JH-/- mice increased thymocyte TCR 
Vβ diversity by 8-fold; however, adoptive transfer of monoclonal B cells did 
not, indicating that B cell diversity is required for the generation of 
thymocyte diversity.  Similarly, injection of polyclonal IgG in JH-/- mice 
increased thymocyte TCR Vβ diversity by 7-fold, while injection of monoclonal 
IgG or ovalbumin did not (table II).  
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 Table 2. Reconstitution of TCR diversity in JH-/- mice after adoptive transfer 
of bone marrow B cells or administration of IgG. 
JH-/- recipient TCR diversity  
of thymocytes 
Variation 
from JH-/- 
Not reconstituted 6.5 x 102 1 
Reconstituted with Polyclonal IgG 4.3 x 103 6.6 
Reconstituted with Polyclonal B cells 5.4 x 103 8.3 
Reconstituted with Monoclonal IgG 1.9 x 101 0.03 
Reconstituted with Monoclonal B cells 5.3 x 102 0.8 
Reconstituted with Ovalbumin 1.6 x 102 0.25 
 
 
 
 These results show that diverse immunoglobulin promotes TCR Vβ diversity.  
In agreement with this function for immunoglobulin in promoting T cell 
diversity, μMT mice with serum immunoglobulin that is 4.8% of wild type, 
had 70 fold greater T cell diversity than JH-/- mice that had no serum 
immunoglobulin (table I).   
 
Since injection of polyclonal IgG alone increases TCR diversity, we wondered 
whether production of immunoglobulin was the mechanism by which 
adoptively transferred B cells promoted T cell diversity.  To find out, we  
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quantified serum immunoglobulin in mice recipients of wild type B cells, 4 
weeks or later post-transfer.  Table I shows that JH-/- mice with adoptively 
transferred B cells had no measurable serum immunoglobulin, while JH-/- 
mice injected with polyclonal IgG had levels of immunoglobulin in the serum 
that were 4.8 fold greater than wild type.  One possible conclusion is that 
polyclonal B cells promote TCR diversification in the absence of serum 
immunoglobulin but we cannot exclude the possibility that antibodies 
transiently present in the serum promoted TCR diversification.   
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4.5. Discussion 
 
Here we report that diverse B cells and polyclonal immunoglobulin drive the 
selection of a diverse repertoire of T cells.  This finding questions the long-
standing idea that T and B cells develop independently [8].  Generation of a 
diverse TCR repertoire relies on the quasi-random recombination of the TCR 
V region gene segments and on positive and negative selection [140].  
Positive selection and MHC restriction are generally thought to depend on 
interaction of T cell precursors with thymic epithelial cells [166]; however, 
this concept is at odds with experimental evidence indicating that mice 
bearing T cells and thymic epithelial cells that are haplo-incompatible are also 
restricted to the MHC of nonthymic epithelial cells [147, 167, 168].  These 
observations could suggest that B cells colonizing the thymus promote 
thymocyte selection and MHC restriction.  
 
Our results showing reduced TCR diversity in mice that lack B cells (JH-/-) or 
that have very few B cells (µMT) could be explained if B cells promoted 
positive selection of thymocytes by decreasing death by neglect. In 
agreement with the concept that B cells promote positive selection is the 
finding of a decreased number of thymocytes and increased cell death in the 
thymic cortex of mice that lack B cells.  We cannot, however, rule out the 
possibility that B cells decrease negative selection of thymocytes.  Against 
this possibility are reports that thymic B cells promote, rather than decrease,  
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negative selection of T cells to murine mammary tumor virus, minor 
lymphocyte-stimulating antigens [169], and I-E expressed only on B cells 
[170].  Another possibility is that B cells may promote colonization of the 
thymus by thymic precursors or early thymocyte development before the 
expression of TCR and thus before selection.  
 
As selection of a diverse T cell repertoire in the thymus is thought to depend 
at least in part on the diversity of peptides presented by self-MHC [140], we 
hypothesized that B cells and Ig may provide an alternative source of diverse 
peptides derived from the V region of Ig or from captured peripheral 
antigens.  We tested this hypothesis in mice with QM B cells that are 1000-
fold less diverse than wild-type B cells [162] and have normal numbers of T 
cells (figure 8 of this thesis).  Our finding of severely reduced T cell diversity 
in QM mice indicates that diversity of B cells may be more important than the 
number of B cells in the generation of a diverse T cell repertoire.  
 
Our results showing increased diversity of T cells after injection of polyclonal 
IgG indicate that some of the effects of B cells in the selection of T cells can 
be mediated by secreted Ig.  However, adoptive transfer of polyclonal B cells 
also increased TCR diversity in JH-/- mice in the absence of detectable serum 
Ig (Tables II and I).  One possible interpretation is that polyclonal B cells 
promote TCR diversification in the absence of serum Ig, but we cannot  
exclude that antigens present transiently in the serum may have contributed  
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to the increased T cell diversity following adoptive transfer of B cells.  Thus, 
whether B cells may contribute to a mature T cell repertoire by means other 
than by producing Ig is not known.  
 
Thymic epithelial cells may produce some of the peptides required for 
positive selection, but these may not be diverse enough to assure the 
survival of thymocytes representing wild-type TCR diversity.  Consistent with 
the requirement that diverse self antigens be presented to developing 
thymocytes by stromal cells, it was recently showed that medullary thymic 
epithelial cells (MECs) express a number of genes coding for ectopic proteins.  
Autoimmune regulator (AIRE) is a nuclear protein identified as the regulator 
of this process promoting central tolerance by negative selection of 
autoreactive thymocytes [27].  The AIRE protein contains several domains 
that function as a nuclear transcription factor, interacting with multiple 
components of the transcriptional complex [171].  AIRE exerts its function in 
a dosage-dependent manner.  This way a slight decrease in AIRE gene 
function may decrease thymic protein expression, allowing delivery of 
autoreactive T cell clones in the periphery.  Mice that lack expression of AIRE 
develop autoimmunity but have normal number of thymocytes, normal 
CD4/CD8 subset distributions and spleen and lymph node cell numbers  [27, 
172].  Thus, the role of AIRE shaping the T cell repertoire occurs through 
negative selection and purging of autoreactive cells from the thymocyte 
repertoire.   
 122
Chapter IV 
 
By means of AIRE-mediated negative selection the immune system must 
avoid aggressive T cell responses against self-antigens. But, paradoxically, 
exposure to self-peptides seems to have an important role in positive 
selection in the thymus and the maintenance of a broad T-cell repertoire in 
the periphery.  T cell precursor’s selection in the thymus seems to depend on 
deleting mechanisms, as negative selection, and on non-deleting 
mechanisms, which help to shape the T cell repertoire.  Non-deleting 
mechanisms may include processes that balance and adjust antigen density 
and T cell avidity, promoting survival of thymocytes. This phenomenon is 
recognized as 'tuning' of the T cell development process and may maximize 
the peripheral T-cell repertoire by allowing the survival of T cells that can 
respond to self.   
The ‘tuning’ process may occur when the density of peptide-MHC complex is 
below that required to induce deletion and is not optimal, immediately 
leading to positive selection. Hypothesis of how the ‘tuning’ may occur 
relates with: 1) alteration of antigen processing by APC in the thymus 
(changing the peptide density on APC); 2) alteration of the T cell avidity for a 
single self peptide-MHC complex, for example, through alter peptide ligands 
or the presence of co-receptores or adhesion molecules that affect 
thymocyte-stromal cell avidity; 3) alteration of key elements in TCR signaling 
pathways that would change T cell activation and survival trigger. 
Immunoglobulins are self, highly diverse molecules constantly present in the 
thymus. This work shows that Ig molecules are used to increase TCR  
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repertoire.  The effect of Ig peptides promoting TCR diversification may 
possibly be explained by the effect of presentation of highly diverse self-
peptides in the thymus (Ig peptides) during the process of T cell 
development.  Furthermore, because of similarities on TCR and Ig molecules 
structure [173, 174], a possible preference of the TCR to Ig-MHC complex 
may be present, facilitating the role of Ig as promoter of positive selection 
and T cell repertoire diversification. 
The mechanisms of TCR-based selection prevent autoimmunity by 
maintaining the avidity of the normal self-reactive T-cell repertoire at a low 
level.  This way, it assures protection against producing a repertoire which, in 
this case, could likely recognize Ig molecules with intermediate to high 
affinity.  These mechanisms would buffer excessive autoreactivity while 
optimizing TCR repertoire usage. The activation of possible self-reactive T 
cells in the periphery would, therefore, require levels of self-peptide–MHC 
complexes that might not be achieved under physiological conditions in the 
thymus.  One hypothesis is that the amount of Ig peptides in the thymus is 
sufficient to activate positive selection via low avidity interactions but the 
same amount of Ig peptides is not sufficient to activate peripheral T cells   
Activation of a pathological autoreactive response would, therefore, require a 
combination of factors that may increase the level of self-antigen that is 
available.  These states seem to be regulated both by positive and negative 
selections, as very restrict TCR repertoires are related to autoimmunity 
[175].   
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Our findings reveal a heretofore unrecognized and vital function of B cells 
and Ig, in promoting TCR diversification, perhaps by contributing to the 
diversity of the peptides that developing T cells encounter.  This function of B 
cells may help to explain the phenotype of B cell-deficient human subjects 
and suggests a potential approach to immune reconstitution.  
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5.1. Abstract  
It is generally accepted in Immunology that while T- and B-cells collaborate 
for the production of antibodies in response to protein antigens, T-cells 
develop and function in the absence of B-cells.  However B-cell deficient 
subjects and mice have unexplained cellular immune defects.  Here we 
examined the contribution of B-cells/Ig for the generation of diversity and 
function of T-cells.  Mice lacking B-cells and Ig (JH-/-) or having oligoclonal 
B-cells (QM) had a profoundly contracted T-cell receptor (TCR) Vβ repertoire: 
0.08% and 1.3% of wild type, respectively.  Rejection of H-Y incompatible 
skin graft in QM and JH-/- mice was significantly delayed (median, 43 and 22 
days, respectively) compared to wild type mice (median, 16 days). 
Furthermore, reduction of TCR V β diversity by thymectomy in wild type mice 
significantly increased survival of H-Y incompatible skin grafts and 
reconstitution of T-cell diversity in QM mice with immunoglobulin Fab 
fragments significantly decreased survival of the skin grafts.  These results 
indicate that B-cells and/or Ig “help” T-cells through the generation and 
maintenance of T-cell diversity, improving T-cell function.  Our results may 
have important implications on therapy and immune reconstitution in the 
context of AIDS, cancer, autoimmunity and post myeloablative treatments. 
Keywords: TCR repertoire, immunoglobulin, T cell function, immune 
reconstitution. 
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5.2. Introduction 
 
It is generally accepted in immunology that T and B cell compartments 
develop separately.  The concept of two lymphoid compartments originated 
from studies in the chicken that established that there were “at least two 
basic levels of immune responses related functionally to different primary 
lymphoid organs”, the thymus and the bursa of Fabricius [8].  One level 
requiring thymus integrity concerned allograft rejection and graft-versus host 
disease while the other, requiring the bursa, was necessary for antibody 
production [8].  Thus bursectomy did not changed cellular immune responses 
such as allograft rejection [4, 8] and thymectomy, causing defective cellular 
immune reactions, maintain plasma cells and circulating immunoglobin [4].  
However, thymectomized birds [4] and thymectomized newborn mice [176] 
had impaired antibody responses to antigens, thus contradicting the first 
concept of two independent lineages.  This contradiction was resolved by the 
discovery of T cell “help” for the production of antibodies [177, 178].   
Apart from development, the separation between the functions of B and T 
cells is no longer accepted.  However, the extent and the mechanisms by 
which B cells “help” T cells is today a matter of controversy.  In B cell 
deficient mice several T cell responses to microorganisms such as Salmonella 
enterica [179], Francisella tularensis [180], Plasmodium chabaudi chabaudi  
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[181], Chlamydia trachomatis [182] are compromised.  Also, patients with X-
linked agammaglobulinemia (Bruton’s syndrome) who don’t have peripheral 
B cells and immunoglobulin and are often said to have normal cell mediated 
immune responses, have an increased risk of developing arthritis and 
respond sub-optimally or not at all to recall antigens in tests of delayed-type 
hypersensitivity [183] suggesting deficient T cell function secondary to the 
lack of B cells and immunoglobulin.  
Several mechanisms have been proposed whereby B cells may modify T cell 
functions. Those include B cell antigen presentation [100], production of 
antibody which may enhance [101] or depress [102] cellular immunity, B cell 
dependent development of follicular dendritic cells in peripheral lymphoid 
organs [184], and effects on regulatory T cells [104].  We proposed recently 
that polyclonal B cells and/or immunoglobulin contribute to development of 
thymocyte diversity possibly by mechanisms related to antigen presentation 
of highly diverse peptides originated from Ig [185].  In this paper we tested 
whether B cells and/or immunoglobulin contribute to the diversity of 
peripheral T cells and whether B cell-dependent T cell diversity influences H-Y 
incompatible skin allograft rejection as an example of T cell function.  We 
compared wild type mice with mice that lack B cells and Ig (JH knockout 
mice) and mice that have oligoclonal B cells (QM mice).  All these strains of 
mice are in the same genetic background, H-2b. 
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5.3. Materials and Methods 
 
5.3.1. Mice. The B cell-deficient strains used were the JH-/- mice that lack 
mature B cells and immunoglobulin [131] and the Quasimonoclonal mouse 
(QM) where 80% of the B cells are monoclonal [129].  C57BL/6 mice were 
purchased from the Jackson Laboratories.  JH-/- and QM mice were bred and 
all mice were housed in a specific pathogen-free facility at the Mayo Clinic.  
All mice were between 0 and 20 weeks of age and all animal experiments 
were carried out in accordance with protocols approved by the Mayo Clinic 
Institutional Animal Care and Use Committee.   
 
 
5.3.2. Determination of TCRVβ diversity  
Isolation of RNA.  Spleens harvested from mice were placed in RPMI and 
pushed through a 70 μm cell strainer.  Lymphocytes were isolated by Ficoll-
paque (Amersham Biosciences, Piscatanaway, New Jersey) gradient.  Total 
RNA was obtained with Qiagen RNeasy kit (Qiagen, Inc., Valencia, California) 
per the manufacturer’s instructions.   
Generation of diversity standards.  Diversity standards were prepared 
through the generation of oligonucleotide mixtures of known diversity.   
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For example, to generate a standard diversity of 106, 18-mer 
oligonucleotides were synthesized with 10 sites of random assignment 
generating 410 = 1,040,526 different oligomeres.  Similarly, we created 
oligomer mixtures with 1, 103 and 109 variants.  Oligonucleotides were biotin-
labeled and hybridized to the gene chips as explained below.   
Generation of lymphocyte receptor-specific cRNA.  First strand cDNA 
was obtained by reverse transcription with a mouse TCR Cβ reverse primer:  
T7+Cβ (5’-
GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGGCTTGGGTGGA 
GTCACATTTCTC - 3’).  Second strand synthesis and preparation of biotin-
labeled cRNA was conducted according to Affymetrix standard protocols 
(Affymetrix, Inc., Santa Clara, California).   
Application of cRNA to the gene chip.  Equal amounts of cRNA from 
different samples and diversity standards were hybridized to U133B gene 
chips (Affymetrix, Inc., Santa Clara, California).  Gene chips were processed 
at the Microarray Core Facility, Mayo Clinic, Rochester, MN.   
Data analysis.  For each gene chip experiment, we obtained raw data 
corresponding to oligo location and hybridization intensity.  Data were 
arranged in order of ascending hybridization intensity.  The number of oligo 
locations with intensity above background (i.e., number of hits) was 
summed.  The standard curve was generated from hybridization of samples 
with known numbers of different oligomeres.  The standard oligonucleotide  
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mixtures were 18-mer oligomeres synthesized to obtain mixtures containing 
1, 103, 106 and 109 different oligonucleotides.  Diversity of the test samples 
was extrapolated from the standard curve.  This assay specifically detects 
TCR Vβ diversity since sorted B cells from C57BL/6 splenocytes containing 
0.09% CD3 positive cells yielded a mean diversity of 136 (standard deviation 
of 89) corresponding to 0.023% of the diversity obtained from equal 
numbers of splenocytes containing 20% CD3 positive cells. 
 
 
5.3.3. Vβ amplification and sequencing. Total RNA isolated from C57BL/6 
and JH-/- mice splenocytes (RNeasy mini kit, Qiagen Inc., Valencia, CA, USA) 
was reverse transcribed into cDNA using a ThermoScript™ RT-PCR System 
(Invitrogen Corporation, USA) according to the manufacture’s instructions.  
The following PCR reaction was done with 2 µl of cDNA from each sample, 
39.5 µl sterile water, 5 µl 10 x cloned Pfu DNA polymerase reaction buffer 
(Stratagene, CA, USA), 10 pmol of Vβ 8.1-specific primer (forward) 
(CATTACGCATATGTCGCTGAC) in a 1 µl vol., 10 pmol of Cß (reverse) 
(GAGACCTTGGGTGGAGTCAC) in a 1 µl vol. and 1.25 U Pfu Turbo DNA 
polymerase (0.5 µl; Stratagene, CA, USA).  The PCR conditions were 94°C, 
30 seconds; 60°C, 30 seconds; and 72°C, 1 min for 35 cycles, followed by a 
final extension of 7 min.  The presence of specific PCR products was 
confirmed by size bands on a 1% agarose gel and the PCR products were  
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cloned using TOPO TA cloning (Invitrogen Corporation, USA) according to the 
manufacture’s instructions.  Sequencing was performed on an ABI PRISM™ 
377 DNA Sequencer at Mayo Clinic Molecular Biology Core Facility using the 
TOPO TA vector primers.  Analysis of the sequences was done using the 
Sequencher™ (Gene Codes Inc.) software. 
 
 
5.3.4. FACS analysis. Splenocytes were obtained by mincing spleens 
through a 0.70 μm mesh followed by hemolysis in a NH4Cl buffer.  Total 
splenocyte numbers were counted with a Coulter counter.  Cells were stained 
with one, two or three of the following monoclonal antibodies (all the 
antibodies were from BD Pharmingen) as described [129].  Fluorescein 
isothyocyanate (FITC)-conjugated: rat anti-mouse CD4 (GK 1.5), rat anti 
mouse CD8α (Ly-2); phycoerythrin (PE)-conjugated: rat anti-mouse CD8α 
(53-6.7), rat anti mouse CD44 (Pgp-1, Ly-24), rat anti mouse CD25 (PC61); 
and biotin-conjugated: rat anti-mouse CD3ε (145-2C11).  Lymphocytes were 
gated on the light scatter plot by back gating onto CD4+CD3+and CD8+ CD3+ 
cells; numbers of the splenocytes sub-populations were determined by 
multiplying the percentage as defined by gating on the FACS plot, by their 
total number.   
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5.3.5. Proliferation assays.  CD4+ splenocytes were purified using an 
automated magnetic activated cell sorter (AutoMACS) system (CD4+ T cells 
isolation kit, Miltenyi Biotec, Auburn, CA).  2 x105 CD4+ T cells were cultured 
for 4 days in round bottom, 96-well culture plates with 10 μg/ml of anti 
CD3ε (clone 145-2C11, eBiosciences, San Diego, CA) and 10 μg/ml of Anti 
CD28 (clone 37-51, BD Pharmingen, San Diego, CA) or with purified B cells 
(CD19+ cells isolation kit, Miltenyi Biotec, Auburn, CA) in the presence of 
several concentrations of OVA 323-329 peptide.  In the case of activation 
with CD3ε/CD28, after being coated for 3 h at 37° C with anti CD3 ε the wells 
were washed 3 times with cold PBS and the cells incubated with soluble anti 
CD28.  Incorporation of [3H]thymidine (1 μCi/well) by proliferating cells was 
measured during the last 16 h of culture. 
 
 
5.3.6. Skin Grafts. Skin grafts were performed according to a modified 
technique of Billingham et al. [186].  Briefly, full thickness tail skin (1 x 1 
cm) was grafted on the lateral flank.  Grafts were observed daily after 
removal of the bandage at day 8 and considered rejected when 90% or more 
of the graft was shed off from the graft bed.   
 
 
5.3.7. Thymectomy. The thymus was exposed by a median sternotomy to 
the second anterior rib, the connective tissue dissected and the thymic lobes  
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removed by suction.  The muscles overlying the trachea and the skin were 
sutured.  The accomplishment of total thymectomy was confirmed for all the 
animals at the time of sacrifice by inspection of the thorax. 
 
 
5.3.8. Reconstitution: Mice injections.  Mice were weekly injected i.p. 
with 250 μg of immunoglobulin Fab fragments or mouse polyclonal IgG 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) since birth to 
graft rejection. 
 
 
5.3.9. Statistical analysis.  Data for each of the immunologic parameters 
of interest were summarized for each of the mouse strains. Differences in 
these measures were explored graphically in addition to their descriptive 
summarization. Where appropriate, comparisons of median measures 
between mouse strain cohorts was limited to nonparametric evaluations; e.g. 
the Wilcoxon rank sum test for comparing medians between two mouse 
strains. Time to graft failure was graphically evaluated using the methods of 
Kaplan and Meier. Differences in the time to graft failure distributions were 
assessed in an exploratory manner using log rank statistics. Statistical 
significance was declared for p-values < 0.05.  
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5.4. Results  
 
 
5.4.1. B cell deficient mice and mice with quasi-monoclonal B cells 
have a severely contracted peripheral T cell receptor repertoire    
To study the role of B cells and immunoglobulin in the establishment and 
maintenance of the peripheral T cell repertoire, we took advantage of several 
B cell deficient mice.  We found previously that B cell deficient mice (JH-/- 
[131] and QM mice [129] have profoundly contracted TCR diversity of 
thymocytes [185].  To determine the extent to which these mice also had 
contracted peripheral T cell diversity, we measured TCR diversity in 
splenocytes of JH-/-, QM and wild type mice according to Ogle et al. [162].  
As reflected in Figure 1, the average TCR Vβ diversity of JH-/- splenocytes 
(mean = 482.8 per 10 μg of RNA) was substantially lower than that of the 
wild type (mean = 603997.3 per 10 μg of RNA).   In addition, we found that 
JH-/- mice have lower numbers of splenic T cells (Figure 2A and [108]) as 
well as defective peripheral lymphoid organogenesis with absent follicular 
dendritic cell network (Figure 2B and [109]).   
To determine whether B cells and/or B cell products (Ig) contribute to the 
diversity of T cells in the presence of normal secondary lymphoid organs and 
similar numbers of CD3+ T cells, we measured TCR diversity on splenocytes 
of QM mice. QM mice have quasi-monoclonal B cells and normal levels of 
immunoglobulin [185, 187], had normal secondary lymphoid structure with a  
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mature follicular dendritic cell network (Figure 2B) and normal number of 
splenic T cells (Figure 2A), contrary to what occurs on the JH-/- mice model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – TCR Vβ diversity quantified in splenocytes.  Were studied 3 
mice lacking B cells and immunoglobulin (JH-/), 4 mice with oligoclonal B 
cells (QM) and 3 wild type mice (C57BL/6). All the mice were age-matched. 
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Figure 2 – Number of T cells (A) and presence of follicular dendritic 
cells network in lymph nodes (B) in C57BL/6, QM and JH-/- mice. A - 
The numbers of T cells were calculated by multiplying the respective 
percentage of the total events as defined in the flow cytometry dot plot 
analysis with specific CD3 monoclonal antibodies, by the total number of 
WBC obtained by counting on a Coulter.  The number of CD3+ splenocytes 
(average ± SD) was 3.2 x 107 ± 3.0 x 107 in C57BL/6 (n=8), 3.5 x 107 ± 2.9 x 
107 in QM (n=4) and 9.1 x 106 ± 7.7 x 106 in JH-/- mice (n=6).  Error bars 
represent standard deviation.  Mice were between 5 and 20 weeks of age.   
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Comparisons between each two groups of mice (p values indicated below the 
diagrams) were calculated by the Wilcoxon test.   
B - Follicular dendritic cells network are stained fluorescent green and were 
detected in cryostat sections of lymph nodes using staining with monoclonal 
antibody directed against murine CD21/CD35.  Photographs are 
representative of three to four different mice per genotype analyzed.   
 
 
 
Similar to what seen for splenocytes of JH-/-, the TCR Vβ diversity of QM 
splenocytes was substantially lower than that for those of wild type (QM 
mean = 7683.2 vs. 603997.3 per 10 μg of RNA, respectively) (Figure 1).  
Because contracted T cell diversity occurs in mice with normal lymphoid 
organs (QM mice) and does not reflect differences in T cell number as QM 
mice have normal numbers of CD3+ T cells, we conclude that the number of 
T cells is not a confounder in the association between peripheral TCR 
diversity and the presence of polyclonal B cells or immunoglobulin.  Severely 
reduced TCR diversity in QM mice that are B cell and immunoglobulin 
proficient indicate that T cell diversity is not a function of B cell number 
and/or of serum Ig concentration [185] but may rather depend on the 
diversity of B cells and immunoglobulin in the serum, i.e., on the 
polyclonality of the B cells/Ig compartment. 
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5.4.2. Oligoclonal expansion on JH-/- T cells 
To examine whether contraction of the T cell repertoire in the JH-/- mice was 
accompanied by oligoclonal expansion we analyzed the joining sequences of 
TCR variable exons containing the Vβ8.1 gene.  To this end we amplified, 
cloned and sequenced 46 and 59 of TCRVβ8.1 rearrangements from cDNA 
obtained from wild type and JH-/- splenocytes, respectively.  We found no 
preferential Jβ segment usage in JH-/- or C57BL/6 mice and that all variable 
exon genes sharing Vβ8.1 and Jβ2.6 or Jβ2.1 (these Jβ segments were the most 
frequent chosen, 10 and 15 for JH-/- and 8 and 7 for C57BL/6, respectively) 
had different VDJ joining sequences and do not show evidence of preferential 
clonal expansion (Table 1 and 2).  Although, clonal expansion of other Vβ 
families besides Vβ8.1 cannot be excluded, the extreme contraction of TCR 
repertoire in JH-/- mice seems to be a consequence of gaps or skewness in 
the repertoire.   
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Table 1 – Number of Jβ families represented in the cloned and 
sequenced TCR Vβ 8.1 – Cβ region in C57BL/6 and JH-/- mice.  The 
sequences of the Jβ families were taken from the literature [21, 188]. 
 
 BL/6 
46 sequences 
JH-/- 
59 sequences 
Jβ 1.1 0 3 
Jβ 1.2 5 8 
Jβ 1.3 0 1 
Jβ 1.4 2 1 
Jβ 1.5 3 0 
Jβ 1.6 1 1 
Jβ 2.1 7 8 
Jβ 2.2 4 6 
Jβ 2.3 3 8 
Jβ 2.4 4 8 
Jβ 2.5 2 5 
Jβ 2.6 15 10 
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Table 2 – Comparison of the sequences between the end of Vβ 8.1 
region and the beginning of the two more frequent Jβ sequences 
(Jβ 2.6 and Jβ 2.1) used for both C57BL/6 and JH-/- strains.  A total of 
20 (in the case of C57Bl/6) and 36 sequences (in the case of JH-/-) were 
studied.  The NCBI BLAST software was used to find the Vβ 8.1 sequence and 
the Jβ sequences were taken from the literature [21, 188]. 
 
Clone End of Vβ 8.1 D+N+P Start of Jβ 2.6 
 TGTGCCAGCAGTG  CCTATGAACAGT 
JH #1 TGTGCCAGCAGTG AAAGGACTGGG              GAACAGT 
JH #2 TGTGCCAGCAGTG AAGGGGGGT CCTATGAACAGT 
JH #3 TGTGCCAGCAGTG CG      TATGAACAGT 
JH #4 TGTGCCAGCAGTG ATAGAAGCT CCTATGAACAGT 
JH #5 TGTGCCAGCAGTG ATGCAGGGACTGGGG GGA        ATGAACAGT 
JH #6 TGTGCCAGCAGTG CG      TATGAACAGT 
JH #7 TGTGCCAGCAGTG ATGCACTGGGGG GGTT           TGAACAGT 
JH #8 TGTGCCAGCAGTG TCCGGGACAGCT CCTATGAACAGT 
JH #9 TGTGCCAGCAGTG TCCACTGCA    CTATGAACAGT 
JH #10 TGTGCCAGCAGTG ACAGATCCTA       TATGAACAGT 
Clone End of Vβ 8.1 D+N+P Start of Jβ 2.1 
 TGTGCCAGCAGTG  ACTATGCTGAGC 
JH #11 TGTGCCAGCAGTG ATCGGGACTGGGGGG         ATGCTGAGC 
JH #12 TGTGCCAGCAGTG GGGGTTATA ACTATGCTGAGC 
JH #13 TGTGCCAGCAGTG AGGACTGGG ACTATGCTGAGC 
JH #14 TGTGCCAGCAGT TCAG ACTATGCTGAGC 
JH #15 TGTGCCAGCAGTG ATGGGGGGTT   CTATGCTGAGC 
JH #16 TGTGCCAGCAGTG ATACCTGGGGGGCCCTCA ACTATGCTGAGC 
JH #17 TGTGCCAGCAG CTGACTGGGGGA ACTATGCTGAGC 
JH #18 TGTGCCAGCAGTG ATGTCTGGGGTA ACTATGCTGAGC 
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Clone End of Vβ 8.1 D+N+P Start of Jβ 2.6 
 TGTGCCAGCAGTG  CCTATGAACAGT 
BL/6 #1 TGTGCCAGCAGTG GGGACAGAT CCTATGAACAGT       
BL/6 #2 TGTGCCAGCAGTG CCCCAGACTGGA    CTATGAACAGT 
BL/6 #3 TGTGCCAGCAGTG ATGGAGGCT CCTATGAACAGT       
BL/6 #4 TGTGCCAGCAGTG ACTTCT CCTATGAACAGT 
BL/6 #5 TGTGCCAGCAGTG ATGCCGGACACT CCTATGAACAGT 
BL/6 #6 TGTGCCAGCAGTG AAG CCTATGAACAGT 
BL/6 #7 TGTGCCAGCAGTG GGGGGGC CCTATGAACAGT 
BL/6 #8 TGTGCCAGCAGTG ACTCCGGGACAGGGTACG         ATGAACAGT 
BL/6 
#9,10,11 
 
TGTGCCAGCAGTG 
 
CTGACTGGGGGGCCT 
 
CCTATGAACAGT 
BL/6 #12 TGTGCCAGCAGTG     GAGGGGGGGGGAT CCTATGAACAGT 
BL/6 #13 TGTGCCAGCAGTG        ATAGGCAGGGCT         ATGAACAGT 
BL/6 #14, 
15 
 
TGTGCCAGCAGTG 
 
AGCAGTGAAGGGAC 
 
CCTATGAACAGT 
Clone End of Vβ 8.1 D+N+P Start of Jβ 2.1 
 TGTGCCAGCAGTG  ACTATGCTGAGC 
BL/6 #16 TGTGCCAGCAGTG CTGACTGGGGCCTTA ACTATGCTGAGC 
BL/6 #17 TGTGCCAGCAGTG ATTACTGGGGGGAAAGG       TATGCTGAGC 
BL/6 #18 TGTGCCAGCAGTG CTCAGATT   CTATGCTGAGC 
BL/6 #19 TGTGCCAGCAGTG ATGCAAGGGGT ACTATGCTGAGC 
BL/6 #20 TGTGCCAGCAGTG AGCCGGGAC ACTATGCTGAGC 
BL/6 #21 TGTGCCAGCAGTG ATTACAGGGG    CTATGCTGAGC 
BL/6 #22 TGTGCCAGCAGTG ATGAGGGGA ACTATGCTGAGC 
 
 
 
 
5.4.3. Increased in vivo proliferation of T cells on B cell deficient 
mice  
In B cell-deficient mice (JH-/-) and in mice with oligoclonal B cells (QM), 
contracted thymocyte repertoires [185] may contribute to the contracted  
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TCR Vβ diversity of splenocytes.  Additional mechanisms, however, such as 
homeostatic proliferation in response to decreased numbers of T cells [189, 
190] may also contribute to contracted peripheral T cell repertoire in B cell 
deficient mice.  Homeostatic proliferation is thought to cause a contraction in 
the TCR repertoire because normalization of T cell numbers is owed to clonal 
expansion rather than to de novo production of T cells [189, 190].   
 
JH-/- mice have reduced numbers of T cells in the spleen (CD3+ T cells are 
33% of wild type, respectively) (Figure 2A) that could, in principle, trigger 
homeostatic proliferation.  T cells that result from in vivo homeostatic 
proliferation acquire phenotypic markers of memory and are for this reason 
often referred to as “memory like”.  “Memory like” T cells express high levels 
of adhesion molecules such as CD44 reflecting specific requirements to enter 
peripheral tissues [191].  To determine whether in vivo peripheral 
proliferation occurs in these mice, we compared the relative numbers of 
“memory like” and naïve CD4+ T cells in JH-/- and QM with those in wild type 
mice.  Figure 3A shows that the proportion of “memory like” CD4+ T cells 
(CD4+/CD44hi) is increased in JH-/- compared to the proportion of these 
cells found in QM and C57BL/6 mice (the mean proportion for JH-/- is 1.74 
and 1.5 times more compared to the mean proportion of CD4+/CD44hi in the 
wild type and QM mice, respectively).  These results do favor homeostatic 
proliferation secondary to a primary reduction in the numbers of peripheral T 
cells and suggest that the reduction of T cell diversity in JH-/- could be also  
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secondary to the compensatory peripheral oligloclonal expansion besides the 
effect of lacking B cells and Ig.  In the QM mice, the contraction of the 
peripheral T cell repertoire may thus reflect accurately the contracted 
repertoire of new T cells and/or a defective maintenance of diverse T cell 
clones in B cell deficient mice or mice with oligoclonal B cells.   
 
The expression of the Ki-67 protein is strictly associated with cell 
proliferation.  During interphase, the antigen is scattered within the nucleus, 
whereas in mitosis most of the protein is relocated to the surface of the 
chromosomes. The fact that the Ki-67 protein is present during all active 
phases of the cell cycle (G(1), S, G(2), and mitosis), but is absent from 
resting cells (G(0)), makes it a sensitive marker for determining proliferative 
cells.  Figure 3B shows Ki-67 staining of spleen sections of JH-/-, QM and 
C57BL/6 mice.  In the case of JH-/- mice, the proliferative ratio given by the 
proportion of positive Ki-67 cells in a spleen section is significantly higher 
compared to what is seen in the QM or C57BL/6 spleens.  To, more precisely, 
quantify the proportion of T cells that were proliferating, cell cycle analysis of 
isolated splenic T cells of age matched JH-/-, QM and C57BL/6 was 
performed.  In JH-/- mice, the average proportion of splenic T cells in phase 
S+G2 was 1.76 and 2.25 times the averages in the wild type and QM mice, 
respectively. In one case, the proportion of T cells proliferating in the JH-/- 
mice was 5 times higher than the proportion of proliferating T cells in  
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C57BL/6 or QM mice.  In QM mice, the proportion of proliferating T cells did 
not differ from the proportion of T cells in C57BL/6 mice (figure 3C). 
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Figure 3 – Memory phenotype and in vivo proliferation studies in the 
spleen of B cell compromised mice compared to wild type. A – CD4+ 
T cell memory phenotype.  y-axis, % of memory CD4+ T cells in the 
spleen.  x-axis, mice strains.   Memory CD4+ T cells were characterized as 
CD4+/CD44hi by FACS analysis.  In the graph each bar represents the mean 
and the error bars represent standard deviation of each distribution. In this 
analysis were used 4 C57Bl/6, 4 QM and 2 JH-/- adult, age-matched mice. 
Statistical comparison was performed using the Wilcoxon test. B – Ki-67 
staining of spleen sections.  B cell compromised mice were compared to 
wild type mice. C – Cell cycle analysis.   DNA content was analyzed by flow 
cytometry in T cells sorted from spleens of 6 C57BL/6, 3 QM and 4 JH-/- 
age–matched mice.  The numbers displayed correspond to the mean ± 
standard deviation of the percentage of T cells on phase S+G2 of cell cycle in  
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each mice strain.  The DNA content charts displayed correspond to one 
example of each mice strain. 
 
 
 
5.4.4. Delayed rejection of H-Y incompatible grafts by JH-/- and QM 
mice  
T cell immunological competence is generally thought to be at least in part, a 
function of T cell repertoire diversity because T cell responses to most 
microorganisms and to minor histocompatibility antigens depend on rare 
precursors expressing antigen specific TCR [192-194].  To determine 
whether contraction of the T cell repertoire impacts T cell function, we 
studied T cell responses to skin grafts in mice, avoiding the impact of 
humoral rejection.  Also testing rejection to minor histocompatibility antigens 
enable the detection of small differences in T cell function that may not be 
possible by testing responses to major histocompatiblity antigens, where 
rejection is usually too fast to allow detection of small variations on T cell 
function. Overall, 12 C57BL/6 and 5 JH-/- female mice were evaluated, 
where all had documented skin graft rejection. Ten QM female mice were 
also evaluated, where 7 of these mice had documented skin graft rejection 
and the remaining 3 were censored at their last evaluation timepoint. The 
median time to skin graft rejection for C57BL/6 female mice was 16 days. 
Figure 4 shows that JH-/- and QM female mice had a significant increase in  
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time to skin graft rejection, with medians of 22 days (p = 0.0006) and 43 
days (p = 0.00001), respectively. These results support that TCR diversity is 
associated with T cell function and thus that a decrease in TCR diversity may 
cause a decrease in T cell function.  However, TCR diversity alone may not 
determine the outcome of skin grafts, where JH-/- mice had a smaller TCR 
diversity than QM mice but rejected skin grafts significantly faster than QM 
mice (p = 0.04).  These results suggest instead that T cells with a low level 
of diversity in the JH-/- stimulated to actively proliferate may acquire 
properties that allow them to reject H-Y incompatible skin grafts earlier than 
QM T cells that have a higher TCR diversity but are not so actively 
proliferating.  
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Figure 4 - Kaplan Meier survival curves for H-Y incompatible skin 
grafts in C57BL/6, QM and JH-/- mice.  x-axis, days following surgery; 
y-axis, skin graft survival fraction.  Rejection was defined by shedding 90% 
or more of the graft from the graft bed.  The median time of rejection was 16 
days in C57BL/6; 43 days in QM and 22 days in JH-/- mice.  QM and JH-/- 
skin grafts survived significantly longer compared to C57BL/6, p< 0.0001 
and p= 0.0006, respectively. Each mice group included 12 C57BL/6, 10 QM 
and 5 JH-/-.  All mice were grafted 5 to 6 weeks after birth.  Statistical 
analysis was done with the Log-rank test.   
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5.4.5. Exclusion of other immunological factors that, besides 
contracted TCR diversity, may decrease T cell function: 
1. Activation potential of T cells of B cell compromised mice. 
To test whether the intrinsic ability of T cells to respond to activation was 
unaltered in JH-/- or QM mice compared to wild type mice we tested in vitro 
proliferation of CD4+ T cells in response to polyclonal stimuli, anti-CD3 and 
anti-CD28.  A lack of responsiveness by the T cells could be, in fact, a reason 
for the delayed rejection of the skin transplants. Figure 5A shows that CD4+ 
T cells obtained from QM and JH-/- mice appear to proliferate as well as cells 
from wild type mice following stimulation.  These results indicate that the T 
cells of JH-/- or QM mice retain wild type primary responsiveness to 
polyclonal stimuli and that the delayed function of T cells in rejection the H-Y 
incompatible skin grafts is not related to lack of ability for these cells to 
respond.  Also, these data can be described as a trend to a higher 
proliferation response of the CD4+ T cells to polyclonal stimuli, although 
statistically not significant, when comparing the CD4+T cells response from 
mice that lack B cells to the CD4+T cells response of strains of mice that are 
B cell proficient.  
2. Antigen presentation ability of quasi-monoclonal B cells. 
Delayed rejection of H-Y incompatible skin grafts could also be due to a 
deficiency of antigen presentation by B cells.  Since JH-/- mice lack B cells, 
we tested this possibility by comparing antigen presenting properties of QM 
and wild type B cells.  To this end, we assessed proliferation of DO11.10 T  
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cells in the presence of specific antigen (the OVA peptide 323-339) in the 
presence of wild type or quasi-monoclonal B cells.  Figure 5B shows that 
proliferation of DO 11.10 T cells is comparable whether the OVA peptide is 
presented by wild type or by QM B cells.  Our results indicate that antigen 
presentation by the QM B cells is not compromised.   
3. Proportion of CD4+/CD25+ T cells in B cell compromised mice 
compared to wild type. 
The presence of T cells with suppressor properties (CD4+CD25+ T cell 
phenotype) are thought to promote survival of allografts [195].  To exclude 
the possibility that the longer survival of H-Y incompatible skin grafts in QM 
and JH-/- mice with contracted T cell repertoires was accompanied by an 
increased percentage of CD4+CD25+ T cells, we assessed the proportion of 
these cells in these mice strains compared to wild type.  Figure 5C shows 
that the frequencies of CD4+CD25+ T cells in the peripheral blood are similar 
in JH-/- mice and QM mice compared to wild type mice, suggesting that 
suppression owing to T regulatory cells may not contribute to the increased 
survival of H-Y incompatible skin grafts in JH-/- and QM mice.   
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Figure 5.  A) In vitro proliferation ability of CD4+T cells against 
polyclonal stimuli in C57BL/6, QM and JH-/- mice. x-axis, mice strains; 
y-axis, counts per minute.  Purified CD4+ T cells from the different strains of 
mice were cultured for 4 days with 10 μg/ml (coated well) and 10 μg/ml of 
anti CD28 and proliferation was assessed by the incorporation of 
[3H]thymidine (1 μCi/well) during the last 16 h of culture. In these 
experiments, background counts in the wells containing just cells or just 
media were all < 250 cpm.  Results are expressed as the mean ± SEM of 
triplicate samples of one example from 4 independent experiments in the 
case of C57BL/6 and QM mice and 2 independent experiments for the JH-/- 
mice.  There is no statistically difference between the groups (p>0.05,  
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Student’s t test). B) In vitro proliferation response of DO 11.10 T cells 
to OVA (323-339) presented by wild type or QM B cells.  2 x 104 
purified CD4+ T cells specific to OVA 323-339 were cultured for 4 days in the 
presence of 2 x 105 irradiated B cells taken from C57BL/6 (dotted line) or QM 
mice (continuous line) with three crescent concentration of soluble OVA 323-
339 peptide.  Proliferation was assessed by the incorporation of 
[3H]thymidine (1 μCi/well) during the last 16 h of culture.  In these 
experiments, background counts in the wells containing just cells or just 
media were all < 150 cpm.  Results are expressed as the mean ± SEM of 
triplicate samples.  
 C) Fraction of CD4+/CD25+ splenocytes measured by flow cytometry 
analysis.  x-axis, % of CD4+/CD25+ splenocytes ; y-axis, mice strains.  Each 
circle represents one experiment, and the values indicate the mean % of the 
CD4+/CD25+ population for each strain of mice.  There is no statistically 
difference between the groups (p>0.05, Student’s t test). 
 
 
 
5.4.6. Recovery of TCR diversity and T cell function  
Our data suggest that B cell-dependent T cell repertoire diversity is a major 
factor determining the kinetics of rejection of grafts across minor antigen 
barriers.  If the magnitude of the T cell repertoire predicts immune responses 
across minor antigen barriers, then increasing diversity in mice with a 
contracted T cell repertoire and normal lymph node architecture should 
hasten rejection of H-Y incompatible skin grafts.  To test this prediction we 
increased T cell diversity of QM mice by administering immunoglobulin Fab  
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fragments or polyclonal IgG.  We previously showed that injecting polyclonal 
Ig on mice with contacted TCR repertoire increase T cell diversity [185]. 
However, treatment with Ig molecules is also known to generate 
immunologic suppression mainly because of the attributes of the Fc fraction 
of the molecule [196].  We tested if the injection of Ig Fab fragments would 
increase TCR diversity without generating immune suppression, but, on the 
contrary, improving T cell function. Figure 6A displays how Fab-injected QM 
mice (n=3) recovered TCR Vβ diversity to wild type mean levels (13.4 x 105 
compared to 6.0 x 105 in C57BL/6).  The QM mice treated with Ig Fab 
fragment (n=6) rejected H-Y incompatible skin grafts significantly faster than 
non injected QM mice (n=10) (medians: 27 vs. 43 days, respectively; 
p=0.007).  The QM mice treated with polyclonal IgG (n=4) also rejected H-Y 
incompatible skin grafts faster than not treated QM mice (n=10), although 
not achieving statistically significance, p= 0.07.  In a complementary 
approach, we tested whether decreasing TCR repertoire in the wild mice 
prolonged survival of H-Y incompatible skin allografts.  We performed 
thymectomies in 5 week-old C57BL/6 mice (n = 8) and measured TCR Vβ 
diversity 6 weeks after the surgery.  Figure 6B shows that thymectomized 
mice have a substantial contraction of TCR repertoire compared with non-
thymectomized C57BL/6 mice (n=3), (means: 60.4 x 104 in non-
thymectomized C57BL/6 vs. 1.5 x 104 in thymectomized C57BL/6). In 
addition, thymectomized females transplanted with male skin 9 weeks after 
thymectomy  (n = 7) allowed survival of the grafts significantly longer than  
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non-thymectomized C57BL/6 females (n=12), with median time to skin graft 
failure of 38.5 days vs. 16 days, respectively (p = 0.0001). This suggests 
that decreasing TCR diversity leads directly to decline of T cell function. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Survival of H-Y incompatible skin grafts in QM mice where 
TCR Vb diversity was reconstituted compared to non-reconstituted 
QM mice (A) and in wild type mice (C57BL/6) where TCR Vβ diversity 
was decreased by thymectomy (B) compared to wild type.  
A) TCR Vβ diversity in QM mice injected with Fab fragment (n=3) 
compared to non injected QM mice (n=4). There is, in mean, an 
increase of 174 times in the TCR Vβ diversity after treatment with Ig 
Fab fragment, what achieved, in mean, wild type TCR Vβ diversity 
values. The grafts survival study show that QM mice treated with Ig  
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B) Fab (n=6) have a faster rejection of H-Y incompatible skin grafts 
compared to non treated QM mice (n=10), p= 0.007, Log rank test.  
There was also a faster rejection of H-Y incompatible skin grafts in QM 
mice injected with polyclonal Ig (n=4) compared to not injected QM 
mice (n=10), although not achieving statistically significance, p= 0.07, 
Log rank test.  B) TCR Vβ diversity in thymecthomized wild type mice 
(n=8) compared to non thymectomized wild type mice (n=3). There is, 
in mean, a decrease of 40 times in the TCR Vβ diversity measured 6 
weeks after thymectomy. The grafts survival study show that 
thymecthomized wild type mice (n=7) have a slower rejection of H-Y 
incompatible skin grafts compared to non-thymecthomized wild type 
mice (n=12), p= 0.0001, Log rank test. 
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5.5. Discussion 
 
The data presented here demonstrate that B cells and/or immunoglobulin are 
a major determinant of diversity and, consequently, of the function of 
peripheral T cells and that immunoglobulin derivatives can be used to 
improve T cell function.   
The effect of Ig promoting TCR diversification previously reported by us [185] 
might be related with the highly diversity of the Fab fragments presented, 
independently of the Fc portion of the molecule.  It is known that the 
repertoire diversity is dependent of the diversity of the antigens presented in 
the thymus [149, 151]. Thus, it would be possible to maintain the positive 
effect on TCR diversity and function without the immunosuppressive activity 
of the Fc portion of the molecule, by using Fab fragments instead of the 
whole Ig molecule. Here we show that in vivo administration of 
immunoglobulin Fab fragments allowed the reconstitution of a T cell 
repertoire similar to the mean wild type diversity, and avoided the 
immunological suppressive effects of polyclonal immunoglobulin.  
In an additional approach we demonstrated that the decrease on TCR Vb 
diversity achieved by surgical removing of the entire thymus led to a 
decrease on T cell function, shown by the significant delayed rejection of skin 
grafts.  This is in agreement with previous studies reported that patients who 
suffered thymus removal consequently achieved a worse function of the T  
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cell compartment [197, 198].  Thymectomies may affect other T functions 
besides decreasing TCR repertoire. For example, thymectomy may decrease 
T cells suppressor functions and may stimulate homeostatic proliferation and 
memory like activity of T cells.  However, the effect of decreasing T cell 
suppression or of promoting homeostatic proliferation with increase of 
memory properties would be expected to have the opposite effect on the skin 
allografts rejection compared to the effect of decreasing TCR diversity.  Thus, 
our results seem to indicate that the decrease on TCR diversity caused by 
thymectomy is dominant over other possible consequences of thymectomy, 
as the ones stated above. 
The effect of TCR diversity was proved independent of other factors that 
entail rejection of skin grafts namely T cell ability to respond to antigens, 
antigen presentation, organogenesis of peripheral lymphoid organs and 
suppressor activity of regulatory T cells.    
Taken together this data demonstrate a new compass of the T-cell -B-cell 
bidirectional cooperation: that B cells and immunoglobulin are fundamental in 
the generation and maintenance of a diverse compartment of T cells, 
affecting T cell function via that mechanism.  Idiotype peptides of B cell 
immunoglobulin may be the driving force for the antigen presenting function 
of B cells to influence the T cell repertoire. This would be another relevance 
of the Jerne’s idiotypic network.  
We suggest that B cell primary immunodeficiencies such as Bruton’s 
syndrome are, in some degree, common B-cell/T-cell immunodeficiencies. 
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Evidence in experimental animals and in man indicated previously that 
immunoglobulin may select pre-immune B cell repertoires in the bone-
marrow and peripheral lymphoid tissues [199, 200].  We previously showed 
that B cells and Ig contributed to the generation of thymocyte TCR 
diversification [185].  The role of Ig as a self molecule used by the body to 
select B and T repertoire is a changing and new model idea that emerges 
from these studies and deserves extended mechanistic and translational 
studies. One mechanistic hypothesis put forward by our studies is that B cells 
acting as antigen presenting cells of secreted or endogenous Ig-derived 
peptides could present an extensive diversity of peptides to T cells 
precursors, generating a wider diverse repertoire of newly formed T cells.   
In the periphery, it is known that newly formed T cells require a constant 
engagement of the TCR with self-ligands to persist in a quiescent state [201, 
202].  B cells, by means of Ig, may continuously allow T cell “tickling” by 
self-peptide/MHC complexes.  This mechanism would warrant survival of 
naïve T cells and maintenance of a diverse repertoire of T cells.  
 
The fundamental role of B cells and Ig is manifest on naïve T cells.  By the 
contrary, memory T cell function is not notable dependent on B and other 
antigen presenting cells.  Once memory is generated, T cells survive and 
proliferate without antigen [203] and memory T cells persist in MHC class I 
[204] and II [205] knockout.  The effect of decrease T cell repertoire on 
memory responses was not the objective of this study, which only examined  
 161
Chapter V 
 
the effect of TCR diversity on primary T cell function, given by the rejection 
of first H-Y incompatible skin grafts.  
This study also shows that in situations where homeostatic proliferation is 
present as a compensatory mechanism for the decrease on the number of T 
cells, the cells acquire properties possibly counterbalancing the deficit in T 
cell function achieved by the contraction of repertoire diversity.  However, to 
which level this compensatory mechanism exert its effect, how differently 
this effect occurs in naïve and memory T cell populations and how can it be 
optimized and exploited  is not yet known. 
 
Futures studies on the mechanism of how Ig peptides promote TCR diversity, 
on the specific role of each fragment of the Ig molecule and on the 
interaction between Ig and TCR molecules should be undertaken with the 
purpose of clearly understanding how Ig derivatives promote T cell function 
by increasing TCR diversity.  This fact brings the possibility of improving 
immunity for a vast number of patient populations undergoing immune 
reconstitution. We believe that our results open a new therapeutic 
perspective in situations where immune reconstitution occurs.  This may 
have profound implications for the adjuvant treatment of conditions 
associated with immune deficiency such as AIDS, autoimmunity, cancer, post 
myeloablative therapy. 
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6.1. Abstract  
 
Autologous stem cell transplantation (ASCT) is an effective treatment 
strategy for mantle-cell lymphoma (MCL) demonstrating significantly 
prolongs progression free survival (PFS) when compared to IFNα 
maintenance therapy of patients in first remission.  The study of ALC-15 after 
ASCT as a prognosis factor in NHL included different subtypes of lymphomas.  
The relationship of ALC-15 after ASCT in MCL has not been specifically 
addressed.  Herein we present data evaluating the impact of ALC-15 recovery 
on survival of patients undergoing ASCT for MCL.  We studied 42 consecutive 
MCL patients who underwent ASCT at the Mayo Clinic in Rochester from 1993 
to 2005.  Based on our previous studies, the ALC-15 threshold was set at 
500 cells/µL.  The median follow-up after ASCT was 25 months (range, 2-106 
months).  The median overall survival (OS) and PFS times were significantly 
better for the 24 patients that achieved an ALC-15 ≥ 500 cells/μL compared 
with 18 patients with ALC-15 < 500 cells/µL (not reached versus 30 months, 
P < 0.01 and not reached versus 16 months, P < 0.0006, respectively).  
Multivariate analysis demonstrated ALC-15 to be an independent prognostic 
factor for OS and PFS.  ALC-15 ≥ 500 cells/μL is associated with significantly 
improved clinical outcomes following ASCT in MCL. 
Keywords: absolute lymphocyte count, mantle cell lymphoma, autologous 
stem cell transplantation. 
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6.2. Introduction 
 
Mantle-cell lymphoma (MCL) is characterized by an aggressive clinical course 
and poor prognosis with a median survival of only 3 to 4 years [206, 207].  
Unlike other aggressive NHL, patients with MCL have a poorer complete 
response rate with standard anthracycline-based or non- anthracycline-based 
regimens [208, 209]. 
High-dose chemotherapy (HDC) followed by autologous stem cell 
transplantation is an effective form of treatment for relapsed non-Hodgkin’s 
lymphoma [29].  In the case of MCL, this type of treatment has been shown 
relatively success, with 50 to 70% of patients free of disease at 2 or 3 years, 
if patients are transplanted in 1st remission [210, 211].  The European MCL 
Network completed the only current available prospective randomized study 
comparing ASCT with IFNα maintenance in 1st remission in patients with 
advanced stage MCL [212].  This multicenter trial demonstrates a significant 
improvement of PFS of patients with advanced stage MCL who were treated 
with myeloablative radiochemotherapy followed by ASCT compared to 
patients on IFNα maintenance.  The outcome of patients with MCL after ASCT 
has been associated with age and levels of C-reactive protein at diagnosis, 
levels of B2-microglobulin at the time of diagnosis or transplantation, 
conditioning regimens including TBI, morphologic variants, tumor score and 
expression of p53 [213-215].   
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The absolute lymphocyte count (ALC) recovery ≥ 500 cells/μL at day 15 
(ALC-15) after ASCT has been reported as a powerful and independent 
prognostic factor for clinical outcomes for patients with NHL [82, 216, 217], 
Hodgkin lymphoma [84, 216], multiple myeloma [82], acute myelogenous 
leukemia [218], amyloidosis [83], breast cancer [86, 219].  The fact that the 
recover of lymphocytes after ASCT affects survival of cancer patients is a 
clinical evidence of the existence of an autologous graft-versus-tumor effect.   
To assess whether absolute lymphocyte count at day 15 post ASCT has 
prognostic significance in MCL post ASCT, we conducted a retrospective 
analysis of consecutive MCL patients undergoing ASCT since 1993 and 2005 
and assessed OS and PFS. 
 
 
6.3. Patients and Methods 
 
4.3.1. Patient population. Forty two consecutive patients with the 
diagnosis of MCL underwent ASCT at the Mayo Clinic between November 
1993 and March 2005. Data from transplant recipients used on this 
retrospective study were collected prospectively and entered into a 
computerized database. Response to therapy, relapse, and survival data are 
updated continuously. No patients were lost to follow-up. All patients gave 
written, informed consent allowing the use of their medical records for 
medical research. Approval for the retrospective review of these records was  
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obtained from the Mayo Clinic Institutional Review Board and was in 
accordance with US federal regulations and the Declaration of Helsinki.  
 
 
6.3.2. End Points. The primary end point of the study was to determine if 
ALC -15 after ACST is a prognostic factor for PFS or  (OS) in patients with 
MCL who underwent ASCT.  The ALC-15 was calculated from the standard 
complete blood cell count at day 15 after ASCT. 
 
 
6.3.3. Prognostic factors. This study used the following prognostic factors 
for patients with MCL: international age-adjusted prognostic index (IPI) [220] 
(age (≥60 vs <60), lactate dehydrogenase (LDH) > normal, performance 
status (PS-ECOG) (≥2 vs <2), extranodal sites (≥2 vs <2) and stage (III/IV 
vs I/II)), in addition to the number of pre-transplant treatments, stem cell 
source (BM vs PBSCs), type of conditioning regimen and disease status (CR1 
/ PR1 vs CR>1 / PR>1) before transplantation. The ALC-15 was determined 
at day 15 after ASCT.  
 
 
6.3.4. Conditioning regimens. The conditioning regimens for patients were 
as follows: 9 patients received BEAC (BCNU [300 mg/m2], Etoposide [100 
mg/m2], ARA-C [100 mg/m2], and Cyclophosphamide [35 mg/kg]), 30  
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patients received BEAM (BCNU [300 mg/ m2], Etoposide [100 mg/ m2], ARA-
C [100 mg/m2], and Melphalan [140 mg/ m2] and 3 patients  received 
Cyclophosphamide [60 mg/ m2] and total body irradiation [12 Gy]. All 
patients underwent stem cell re-infusion after HDC. Hematologic engraftment 
was thought to have occurred when the ANC reached 500 cells/µL or more for 
more than 3 consecutive days.  
 
 
6.3.5. Stem cell source. The stem cell source for the ASCT included bone 
marrow (BM) or peripheral blood stem cells (PBSCs).  41 patients received 
PBSCs, and 1 received a mixture of PBSCs and BM stem cells. The decision to 
change from BM stem cell to PBSC was made when PBSCs became the 
standard for stem cell collection. The patient who did not obtain an adequate 
number of stem cells through PBSCs underwent BM harvest.  
 
 
6.3.6. Response and survival. Complete remission (CR) was defined as 
complete regression of all measurable or evaluable disease including 
radiologically demonstrable disease, BM involvement, or peripheral blood 
involvement. Partial remission (PR) was defined as a reduction in the sum of 
the products of measurable lesions' longest diameters and perpendicular 
diameters of 50% or greater, with a 30% or greater decrease in 
hepatomegaly or splenomegaly (measured from the costal margin), if there  
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was previous known liver or spleen involvement. Disease progression was 
defined as a 25% or more increase in the sum of the products of the longest 
diameter and its perpendicular diameter of measurable lesion(s) from the 
pre-study measurement, the appearance of new lesions, or a 2-cm increase 
in spleen or liver size due to lymphoma.  
OS time was measured from the date of transplantation to the date of death 
or last follow-up. PFS was defined as time from transplantation to disease 
progression, relapse, or death.  
 
 
6.3.7. Statistical analysis. OS and PFS times were analyzed using the 
method described by Kaplan and Meier [221]. Differences between survival 
curves were tested for statistical significance using the 2-tailed log-rank test. 
The Cox proportional hazards model [222] was used to assess ALC-15 as a 
prognostic factor for post-transplant OS and PFS times as well as to adjust 
for other known prognostic factors. Hazard ratios reported are for risks 
associated with patients having high (greater than 500 cells/µL) versus low 
(less than 500 cells/µL) ALC values. The cutoff of an ALC of 500 cells/µL or 
more was based on data from our previous study [82]. Multivariate analysis 
done using Cox regression models tested all variables with a P < 0.2 in the 
univariated analysis.  
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Pearson’s chi-square analysis was used to determine relations between 
nominal variables; nonparametric tests were used for continuous variables. 
All p values represented were 2-sided, and statistical significance was 
declared at p < .05.  
The accuracy of the absolute number of lymphocytes recovered at day 15 
after ASCT as a predictor of PFS during the study follow-up was evaluated by 
the Harrell’s method, i.e., concordance (c)-statistic [223], what is equivalent 
to the area under the receiver operating characteristic (ROC) curve. This 
statistic may vary from 0 to 1, with 1 indicating perfect discrimination and 
0.5 indicating what is expected by chance alone. 
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6.4. Results  
 
6.4.1. Patient characteristics 
A total of 42 patients (9 females and 33 males) were included in the study; 
the median age for the cohort group at transplant was 57 years (range, 37-
71).  Forty of the patients had a histologic type of MCL of intermediate 
variant and 2 had blastic mantle cell type. The analysis of the patients 
baseline characteristics that may impact survival and recovery of absolute 
lymphocytes counts after ASCT show similar distribution of those 
characteristics when comparing the patients who recovered the absolute 
count of lymphocyte at day 15 after ASCT (ALC-15 ≥ 500 cells/µL) and the 
patients who did not (ALC-15 < 500 cells/µL) (Table 1). 
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Table 1 – Baseline characteristics of patients according to the recovery of 
absolute lymphocyte count at day 15 after ASCT (ALC-15). 
Characteristics 
 
ALC ≥ 
500 cells/µL 
N = 24 
ALC < 
500 cells/µL 
N = 18 
p value 
Age 
≥ 60 
< 60 
 
7 
17 
 
5 
13 
p=0.92 
Sex 
Females 
Males 
 
6 
18 
 
3 
15 
p=0.51 
LDH 
≤ Normal 
> Normal 
 
12 
3 
 
9 
3 
p=0.76 
 
PS (ECOG) 
≥ 2 
< 2 
 
1 
23 
 
0 
18 
p=0.38 
Stage (Ann Arbor) 
I/II 
III/IV 
 
5 
19 
 
1 
17 
p=0.16 
Number of pre-transplants 
treatments 
1 
2 
3 
 
 
12 
11 
1 
 
 
10 
7 
1 
p=0.90 
Conditioning Regimen 
BEAC 
BEAM 
Cyclophosphamide/TBI 
 
2 
20 
2 
 
4 
14 
0 
p=0.23 
Disease Status at Transplant 
CR1 or PR1 
>CR1 or >PR1 
 
13 
11 
 
6 
12 
p=0.18 
# CD34+ cells transplanted 
Median  
(range) 
 
4.37 x 106 
(2.28-8.44 x106) 
 
2.87 x 106 
(2.0-10.3 x106) 
p=0.12 
Post-transplant cytokines 
G-CSF 
GM-CSF 
 
3 
21 
 
4 
14 
p=0.40 
 
Abbreviations: ASCT = autologous stem cell transplantation; BEAC = BCNU (300mg/m2), 
Etoposide (100mg/m2), ARA-C (100mg/m2), and Cyclophosphamide (35mg/Kg); BEAM = BCNU 
(300mg/m2), Etoposide (100mg/m2), ARA-C (100mg/m2), and Melphalan (140mg/m2); CR1 = 
complete response 1; PR1 = partial response 1; LDH = lactate dehydrogenase; PS = performance 
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status; 2-CDA = cladribine (3,4mg/m2); CHOP = Cyclophosphamide (750 mg/m2), Doxorubicin 
(50mg/m2), Vincristine (1,4mg/m2), and Prednisone (100mg/m2); R-CHOP = Rituxan (375mg/m2), 
Cyclophosphamide (750 mg/m2), Doxorubicin (50mg/m2), Vincristine (1,4mg/m2), and Prednisone 
(100mg/m2); HperCVAD = Cyclophosphamide (300mg/m2), Doxorubicin (50mg/m2), Vincristine 
(2mg/day), and Dexametasone (40mg/day). 
 
 
 
 
6.4.2. Prognostic factors for progression and survival 
The median follow-up after ASCT was 25 months (range, 2-106 months). At 
the time of analysis, 25 out of the 42 patients were alive and 17 were dead.  
The median survival was 47 months. The causes of death were AML in 1 
case, progression of lymphoma in 14 patients, sepsis in 1 case and not 
known in 1 case. The patient who died with AML had ALC-15 ≥ 500 cell/μL; 
from the 14 patients who died of lymphoma progression only 3 had ALC-15 ≥ 
500 cell/μL and the patient who died in sepsis had ALC-15 < 500 cell/μL. All 
the patients were treated similarly regarding supporting care (antibiotics, 
transfusions, growth factors) according to Mayo Clinic protocols.  
The median OS (figure 1) and PFS (figure 2) times were significantly better 
for patients with an ALC-15 ≥500 cell/μL than for those with an ALC-15 < 
500 cell/μL (not reached versus 30 months, p < 0.01 and not reached versus 
16 months, p < 0.0006, respectively). 
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Figure 1 – Overall survival for 42 patients with mantle cell lymphoma 
after ASCT as a function of recovery of absolute number of 
lymphocytes at day 15.  Median overall survival for patients with ALC ≥ 
500 cells/μL was not reached and median overall survival for patients with 
ALC < 500 cells/μL was 30 months (p=0.01, log rank test). 
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Figure 2 – Progression free survival for 42 patients with mantle cell 
lymphoma after ASCT as a function of recovery of absolute number of 
lymphocytes at day 15.  Median overall survival for patients with ALC ≥ 
500 cells/μL was not reached and median overall survival for patients with 
ALC < 500 cells/μL was 16 months (p=0.0006, log rank test). 
 
 
Prognostic factors were tested as predictors for OS and PFS for the 42 
patients with mantle cell lymphoma studied (Table 2). Age at transplant (≥ 
60 vs < 60), LDH, stage (III/IV vs I/II), IPI ≥ 2 versus < 2, number of pre-
transplant chemotherapy regimens (1 vs 2 or 3) and type of condition 
regimen were not predictor of OS or PFS. Recover of absolute lymphocyte 
count at day 15 after ASCT (≥ 500 cells/μL vs < 500 cells/μL) and being 
transplanted on first CR / first PR versus second or more CR/PR were 
significant predictors of OS and/or PFS on univariate analysis. Age at 
transplant was also tested as a continuous variable and it was not associated  
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to disease progression or patient survival (data not shown). The effect of 
condition regimens were tested comparing patients conditioned with BEAC to 
patients conditioned with BEAM. The 3 patients who did 
Cyclophosphamide/TBI were excluded. Presence of disease at extranodal 
sites and performance status (PS) were not included in the analysis because 
only 1 patient had 2 or more extranodal sites involved and only one patient 
had a PS ≥ 2.  
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Table 2 – Univariate analysis for patients with mantle cell lymphoma 
– overall survival and progression free survival rates were indicated. 
 
Prognostic factors at 
time of 
transplantation 
Overall survival 
HR           95% CI          p  value 
Progression free survival 
HR        95% CI          p  value 
Age (≥ 60 vs < 60) 0.84 (0.23 – 2.43) 0.77 1.06 (0.38 - 2.62) 0.90 
LDH (normal vs  
> normal) 
0.51 (0.03 – 2.89) 0.49 0.73 (0.11 – 2.81) 0.67 
IPI (≥ 2 vs < 2) 1.08 (0.37 – 2.9) 0.87 1.48 (0.60 – 3.51) 0.38 
Stage (III/IV vs I/II) 1.64 (0.31 – 30) 0.61 3.85 (0.79 – 69) 0.11 
Number of pre-ASCT 
chemotherapy 
regimens 
(1 vs 2 or 3) 
0.89 (0.31 – 2.45) 0.83 0.75 (0.31 – 1.80) 0.51 
Condition regimen  
(BEAC vs BEAM) 
1.35 (0.78 – 2.32) 0.27 1.34 (0.83 – 2.11) 0.21 
ALC (≥ 500 cells/μL vs  
< 500 cells/μL) 
0.22 (0.05 – 0.70) 0.0086 0.19 (0.05–0.49) 0.0005 
Disease status at ASCT 
(CR1/PR1 vs 
CR>1/PR>1) 
0.42 (0.11 – 1.21) 0.11 0.25 (0.08–0.65) 0.0037 
HR – Hazard ratio;  
95% CI – 95% Confident interval. 
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Having a recovery of the absolute number of the lymphocytes ≥500 cells/μL 
at day 15 after ASCT is an independent prognostic factor for OS (HR = 0.25,  
p = 0.02) and PFS (HR = 0.18, p = 0.0006) in this group of patients with 
MCL in multivariate analysis adjusted to disease status at transplant (Table 
3).  The hazard risk for death is 4 times less for patients who recover the 
number of lymphocytes to values ≥500 cell/μL by day 15 after ASCT 
compared with MCL patients who do not recover this value of ALC-15.   
 
When the risk of lymphoma recurrence was assessed based on ALC-15, the 
hazard risk of recurrence was 5 times less for patients who recover ALC-15 ≥ 
500 cell/μL.  
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Table 3 – Multivariate analysis for patients with mantle cell 
lymphoma – overall survival and progression free survival rates were 
indicated. Multivariate model contains all the prognostic factors 
listed. 
 
 
Prognostic 
factors at time of 
transplantation 
Overall survival 
HR        95% CI        p  value 
Progression free survival 
 HR          95% CI            p  value 
ALC (≥ 500 
cells/μL vs  
< 500 cells/μL) 
0.24 (0.06 – 0.80) 0.02 0.18 (0.05 – 0.50) 0.0006 
Disease status at 
ASCT (CR1/PR1 vs 
CR>1/PR>1) 
0.54 (0.15 – 1.58) 0.27 0.25 (0.08 – 0.66) 0.005 
HR – Hazard ratio;  
95% CI – 95% Confidence interval. 
 
 
Also, the multivariate analysis demonstrates that the disease status, i.e., 
being in first CR o/ first PR, is an independent prognostic factor for 
lymphoma recurrence, independent of the immune recovery after ASCT in 
terms of ALC-15.  Patients who were transplanted in CR1 or PR1 have a 4 
times less risk of recurrence compared to patients who were transplanted in 
second or more CR or PR (HR =0.25, p = 0.005). 
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6.4.3. Discrimination of ALC-15 in MCL patients as predictor of PFS 
To compare the accuracy of ALC-15 as predictor of recurrence accounting for 
censored data, the Harrell’s method, which yields the concordance c statistic, 
was calculated [223]. The c index estimates the probability that, of two 
randomly chosen patients, the patient with the higher value of the prognostic 
factor will outlive the patients with the lower value. Values of c near 1 
indicate that a higher value of the prognostic factor virtually always 
determine that a patient has a better prognosis.  
This new independent prognosis factor (ALC-15) alone can predict recurrence 
of MCL after ASCT with a discrimination power of 61%. 
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6.5. Discussion 
 
Our study shows that recovery of the absolute number of lymphocytes after 
ASCT is a strong and independent prognostic factor for overall survival and 
progression free survival in patients with MCL who are treated with high dose 
chemotherapy followed by ASCT.  Patients with MCL who recover the number 
of lymphocytes to values ≥500 cells/μL by day 15 after ASCT have a 5 times 
less risk of progression and a 4 times less risk of not surviving compared to 
patients with an ALC < 500 cells/μL by day 15 after ASCT.  
 
A ROC curve provides a graphical representation of the relationship between 
the true-positive and false-positive prediction rate of a test and allows 
physicians and investigators to determine which should be the cut point value 
of the prognostic factors to use in order to best discriminate the expected 
outcome. The c-statistic allows the quantification of the discrimination power 
of prognostic factors of time-dependent events. The quantitative-qualitative 
relationship between the c-statistic and discrimination power of the 
prognostic factor follows a fairly linear pattern.  
The value of 61% represents that the accuracy of ALC-15 predicting 
recurrence of MCL after ASCT in this group of patients is satisfactory.  The 
knowledge of how accurate is a prognostic factor predicting the outcome 
helps physicians to rely on the prognosis factors when proposing treatment 
to their patients.  Also, allow developing of alternative treatment strategies  
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to groups of patients predicted to early recurrence or death. From our data, 
it is clear that patients with MCL who do not recover the lymphocyte number 
by day 15 after ASCT should be offer new and investigative therapeutic 
strategies, as the risk of early recurrence or death is very high. 
 
This is the first time these results are published for patients with MCL 
subtype of NHL.  Before, we had shown the association between ALC-15 and 
overall survival and progression free survival in NHL [82], which included 
several histological subtypes.  In the case of more aggressive NHL, as it is 
the case of MCL, the importance of being aware of prognostic factors that 
could be therapeutically modified and that very clearly divide the group of 
transplanted patients in those who have a bigger overall survival and PFS or 
not, is a key factor to better treat patients.  Our study also shows that ASCT 
does not offer cure to MCL patients as the overall survival curve does not 
reach a plateau if patients are analyzed independent of theirs lymphocyte 
recovery.  Immunotherapy comes as a reasonable treatment option on these 
patients after ASCT as other investigators have been investigating [224, 
225].  However, the benefit of immunotherapy may be investigated in the 
context of the patients own immune system recovery and potential.  One 
hypothesis is that the maximal effect of immunotherapy, including 
monoclonal antibodies or cytokine treatment, depends on the patient’s own 
immune system robustness at the time of treatment.   
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The multivariate analysis indicates that the ALC-15 ≥500 cells/mL after ASCT 
remains a strong prognostic factor when adjusted to the other important 
prognostic factors.  These results contribute to the recent concept of 
autologous graft versus tumor (GVT) effect, which is based on the fact that 
immune recovery after ASCT in several malignancies (hematological and 
non-hematological) has been shown to be an independent prognostic factor 
for survival of cancer patients [85].  The interest in immunotherapy after 
hematopoietic stem cell transplantation has come from the clinical 
observation of the GVT effect. The GVT effect has been recognized in the 
allogeneic context [226-228] where the recognition of allo-major 
histocompatibility complex (MHC) leads to the killing of residual tumor cells 
besides graft versus host disease [229-231].  In the autologous setting, 
patient survival is associated with a rapid recovery of lymphocytes, 
suggesting that the autologous immune system has the ability to fight 
residual tumor cells.  It is fundamental to understand what the precise role 
that each subset of lymphocyte plays is, in the immune response to residual 
tumor cells after autologous hematopoietic transplantation.  
 
A recent report demonstrated that polyclonal immunoglobulin administration 
is able to increase TCR repertoire diversity in an animal model with 
contracted T cell repertoire [232].  This could represent a possible approach 
to be tested in the clinical setting.  The possibility of improving repertoire 
diversity and function of the T cells that populate the immune system after  
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hematopoietic precursor transplant will allow a better immune function and, 
probably a lower rate of recurrence of the tumor.    
In the case of mantle cell lymphoma is particularly important the knowledge 
that ALC-15 is a new independent prognosis factor for survival and 
progression after ASCT. High dose chemotherapy followed by autologous 
hematopoietic precursor transplant in first remission gives an advantageous 
to the patients in terms of PFS [212].  However, longer follow up are needed 
to evaluate the impact of ASCT on overall survival of  
MCL patients.  ALC-15 seems to be a prognostic factor for disease 
progression and survival after ASCT in which intervention is worth and 
possible.  Further basic and clinical investigation is needed to understand 
which specific therapeutic intervention should be used and the magnitude of 
its benefits. 
The retrospective nature of this study limits the response of the fundamental 
question of which subset of lymphocytes led to the observed increase in 
survival.  Our group has already undertaken a prospective study to address 
that question.  However, we published before that the number of 
lymphocytes present in the apheresis product infused into the patients 
correlates positively with the recovery of lymphocytes observed after ASCT in 
patients with NHL and with survival of these patients [233].  More, 
retrospectively we found no strong correlation between T or B cells from the 
apheresis product compared with the ALC at day 15 post-ASCT, but good 
correlation between NK cells from the apheresis product compared with ALC  
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at day 15 post-ASCT (CD16+/CD56+/CD3-, r = 0.77) [234].  Although those 
results were primarily hypothesis generating given the small sample size and 
the design of the study, it sets the foundation to test immunomodulatory 
therapeutic approaches aiming early NK recovery. 
Given the results of the present study and the previous literature showing 
that recover of lymphocytes after ASCT is associated with a better survival of 
patients with cancer [82-84, 86, 87, 218, 219], it is important to further 
investigate approaches to improve immune reconstitution in the ASCT 
setting.   
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7.1. Abstract  
 
Background and Aims:  The ability of the immune system to recover its 
components after autologous stem cell transplantation (ASCT) is known to 
predict survival in patients with neoplasms. Also, our previous work showed 
that polyclonal immunoglobulin can be used to improve T cell diversity and, 
consequently, T cell function.  The aim of this retrospective study was to 
understand if the recovery of the polyclonal compartment of immunoglobulin 
in patients with multiple myeloma (MM) at day 100 (± 40d) after ASCT is a 
predictor factor for survival in MM patients who were subject to ASCT.  
Methods: From 294 patients with IgG-MM subject to ASCT at the Mayo 
Clinic, Rochester, MN since October, 1993 until June, 2004, 110 patients 
were studied.  The rational to select this group of patients was the fact that 
they had levels of serum IgM collected at day 100 ± 40 after ASCT recorded.  
Progression free survival (PFS) was assessed from the day of the transplant.  
PFS was studied using Kaplan-Meier curves and the univariate and 
multivariate analysis were done using proportional Cox regression.  The 
prognostic variables included in the multivariate model were stratified by 
disease status at the time of immunoglobulin evaluation and comprise 
recovered IgM at day 100, β2 microglobulin, age, LDH, plasma cell label 
index and disease status at the time of transplant. 
Results: There are 48 females in the study.  The median age of the cohort 
was 58 y (33-75).  The median follow up of the study was 34 mo (range, 2 -
140). PFS was significantly higher in the group who recovered normal serum  
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levels of IgM at D100 compared to the pts who did not.  This corresponds to 
a survival 1.5 longer in the group of patients who recovered normal levels of 
IgM versus the patients who did not (median: 34 to 23 mo, respectively; 
p=0.048).  By univariate analysis, those who did not recover normal serum 
levels polyclonal immunoglobulin by day 100 after ASCT had a risk of relapse 
1.3 times higher than the risk of the patients who recovered.  Multivariate 
analysis suggests that recover the normal levels of polyclonal 
immunoglobulin after ASCT is an independent prognostic factor for PFS for 
MM patients after ASCT. 
Conclusions: These results suggest that polyclonal immunoglobulin is a major 
factor promoting immunity after ASCT.  
 
Keywords: Immunity, Polyclonal Immunoglobulin, Multiple Myeloma, 
Autologous Stem Cell Transplantation. 
 
 
Running title: Polyclonal immunoglobulin and immunity in multiple 
myeloma 
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7.2. Introduction 
 
MM is the most common primary bone cancer in adults (generally in those 
older than 50) with an annual U.S. incidence of 4.2 cases per 100,000 people 
[235].The median survival for multiple myeloma varies from 3 to 4 years 
[236].  
High-dose chemotherapy followed by transplantation has resulted in 
improvement in response rates and survival compared with conventional 
therapy, but relapse is nearly universal and not all patients are candidates for 
this option of aggressive treatment. High-dose therapy with autologous stem 
cell transplantation (ASCT) has become the treatment of choice for 
symptomatic eligible patients with multiple myeloma (MM). Several studies 
have shown that high-dose chemotherapy with autologous stem cell 
transplantation improves the response rate, event-free survival (EFS), and 
overall survival (OS) in myeloma over that obtained with conventional 
chemotherapy [31, 41, 237-239]. In patients who cannot withstand the 
autologous stem cell transplantation regimen and for treatment of refractory 
or relapsed disease various chemotherapy regimens are employed as initial 
therapy in [240]. 
 
Immunity in multiple myeloma is known to be impaired [241], what is 
considered as an additional factor correlated with prognosis and influencing 
disease progression [242]. Immunological abnormalities, particularly in  
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patients with advanced disease, have been described in B, T and natural 
killer (NK) cells. The CD4:CD8 T cell ratio decreases, related mainly to an 
expansion of the CD8+ lymphocyte subpopulation and a decrease of the CD4+ 
subpopulation [243, 244]. Other studies point to a variety of T cell 
dysfunctions [245] [246-248], including an abnormal expression of cell 
surface molecules, cytokine secretion, high basal activation [249] and an 
impaired response to mitogens [250]. Thus, it has been suggested that the 
immune system might play a role in controlling proliferation of the malignant 
clone and that the disease progresses when the immune system fails [242]. 
The robustness of the immune system given by the recovery of the number 
of lymphocytes after autologous hematopoietic stem cell transplant (ASCT) is 
an independent prognostic factor for survival after ASCT in non-Hodgkin’s 
lymphoma (NHL) and multiple myeloma (MM) [82] and several other 
hematological and non-hematological neoplasms [83, 86, 87, 218, 251]. 
Besides the recovery of lymphocytes and its impact on immunity our 
previous work have also shown that polyclonal immunoglobulin is a self 
molecule that promotes T cell repertoire diversification and improve T cell 
function [232, 252] and that it might be used in the clinical to improve 
immune reconstitution it situations where TCR repertoire diversity is 
contracted [253].  
 
Here we report that the recovery of polyclonal immunoglobulin compartment 
to normal serum levels in MM patients after ASCT predicts disease free  
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survival independently of common considered prognostic factors as β2 
microglobulin, age, LDH, plasma cell label index and disease status at the 
time of transplant. 
 
 
7.3. Patients and Methods 
 
7.3.1. Patient population. We studied all the patients with IgG MM subject 
to ASCT at the Mayo Clinic, Rochester, MN since October, 1993 until June, 
2004, who had levels of serum IgM collected at day 100 ± 40 after ASCT 
were included in the study.  Response to therapy, relapse, and survival data 
were updated continuously. All patients gave written, informed consent 
allowing the use of their medical records for medical research. Approval for 
the retrospective review of these records was obtained from the Mayo Clinic 
Institutional Review Board and was in accordance with US federal regulations 
and the Declaration of Helsinki.  
 
7.3.2. Objective of the Study. The primary objective of this retrospective 
study was to determine if the recovery of the polyclonal compartment of 
immunoglobulin in patients with multiple myeloma at day 100 (± 40d) after 
ASCT is a predictor factor for survival in MM patients who were subject to 
ASCT.   
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7.3.3. Prognostic factors. This study included the following prognostic 
factors: age as a continuous variable, lactate dehydrogenase (LDH) at 
diagnosis as a continuous variable, recovered of normal IgM at day 100 after 
ASCT, serum levels of IgM at day 100 after ASCT, β2 microglobulin at 
diagnosis, CRP at diagnosis, types of conditioning regimen used, bone 
marrow level of plasma cells, plasma cell labeling index and disease status at 
the time of transplant.  
 
7.3.4. Conditioning regimens. All patients underwent peripheral blood 
precursor cells (PBPC) re-infusion after high dose chemotherapy (HDC). The 
conditioning regimens used as HDC for patients were as follows: 62 patients 
received Melphalan [200 mg/ m2], 34 patients received Melphalan [200 mg/ 
m2]/Total Body Irradiation, 12 patients received Melphalan/Samarium, 1 
patient received Melphalan [140 mg/ m2] and another patient received 
Phenylalanine Mustard. Hematologic engraftment was thought to have 
occurred when the ANC reached 500 cells/µL or more for more than 3 
consecutive days.  
 
7.3.5. Response and survival. The stringent criteria specified by the 
European Group for Blood and Marrow Transplant (EBMT) and published by 
Bladé et al [254] were used to assess response at day 100 after ASCT. 
Complete remission (CR) was defined as a stable (more than 6 weeks) 100% 
of reduction in the serum and urine protein electrophoresis, negative  
 195
Chapter VII 
 
immunofixation (serum and urine), less than 5% of plasma cells in the bone 
marrow, normal calcium and stable bone disease. Partial remission (PR) was 
defined as a steady (more than 6 weeks) ≥50% of reduction in the serum 
protein electrophoresis, ≥90 % reduction of urine protein electrophoresis, 
≥50% reduction in plasma cells in the bone marrow, normal calcium and 
stable bone disease. 
Quantification of serum IgM at day 100 ± 40 after ASCT was done by ELISA 
(Enzyme Linked Immuno Sorbent Assay). 
Progression-free survival (PFS) time was assessed from the initial date of 
treatment to date of disease progression, or relapse.  
 
7.3.6. Statistical analysis. Progression free survival times were analyzed 
using the method described by Kaplan and Meier [221]. Differences between 
survival curves were tested for statistical significance using the 2-tailed log-
rank test.  
The Cox proportional hazards model [222] was used to evaluate recovery of 
normal serum levels of polyclonal Ig at day 100 after ASCT in patients with 
MM subject to ASCT as a prognostic factor for PFS as well as to adjust for 
other prognostic factors. Multivariate analysis done using Cox regression 
models tested all variables with a p < 0.02 in the univariate analysis. 
Recovery of normal serum levels of IgM was used as a discrete variable for 
the study of survival impact and as continuous variable for the analysis of 
prognostic factors performed by Cox proportional hazards models. 
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7.4. Results  
 
7.4.1. Patient characteristics 
Patient characteristics prior to ASCT are detailed on Table 1.  
A total of 110 patients with IgG MM (48 females and 62 males) were included 
in the study; the median age of the cohort group at transplant was 58 y 
(range of 33-75).  Sixty nine patients (62%) had a MM IgGk, thirty five 
patients (32%) had MM IgGλ, five patients (4%) had a MM IgGk+λ and one 
patient (0.9%) had a MM IgGk and IgAλ. 
The numbers of prior treatment combination of chemotherapy used varied 
from 1 to 3; the majority of the patients (79%) were subject to just one type 
of chemotherapy regimen before ASCT. Prior treatments included 
Dexamethasone; Thalidomide; VAD (Vincristine, Adriamicin, 
Dexamethasona); VBMCP (Vincristine, Melphalan, BCNU, Cyclophosphamide, 
Prednisone); CHOP (Cyclophosphamide, Adriamicin, Vincristine, Prednisone), 
alone or in combination. 
PFS was assessed from the day of ASCT.  The median follow-up was 34 
months (2-140 months). 
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Table 1 – Patients characteristics (N=110) 
Characteristics 
Age  Median, Range 
58,5, 33-75 
Sex 
      Females 
      Males 
Number of patients (%) 
48 (44%) 
62 (56%) 
Cytogenetics 
     Normal 
     13 inversion 
     Complex 
     Other 
 
91(82%) 
1 (0.9%) 
8 (7%) 
10 (9%) 
Number of prior treatments 
     1 
     2 
     3 
 
87 (79%) 
19 (17%) 
4 (4%) 
Conditioning Regimen 
     Melphalan/ Total Body Irradiation 
     Melphalan 200 mg/m2 
     Melphalan 140 mg/m2 
     Melphalan – SAM 
     L-Phenylalanine Mustard 
 
34 (31%) 
62 (56%) 
1 (0.9%) 
12 (11%) 
1 (0.9%) 
Disease Status at ASCT 
      Relapse 
      Plateau/Response 
 
40 (36%) 
70 (64%) 
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7.4.2. Progression and survival  
Univariate analysis of prognostic factors 
At day 100 after ASCT, 96% (106/110) of the patients were in response (19 
in complete responses and 87 in partial responses) and 4% (4/110) of the 
patients were in progression. All the patients who were in progression at day 
100 after ASCT did not recovered normal levels of IgM at that date.  
The median PFS was significantly better for patients who recovered normal 
levels of IgM (n = 30) vs those who did not recovered (n = 80) normal IgM 
levels at day 100 after ASCT (23 months vs 35 months, p < 0.048, 
respectively) (Figure 1).  Performing a similar analysis only in the sub group 
of patients who were at response (complete or partial) at day 100 after 
ASCT, the patients who recovered normal levels of IgM continue to have a 
longer PFS compared to those who did not recovered normal levels of IgM 
(24 months vs 34 months, p < 0.07, respectively) (Figure 2). 
 
From all the prognostic factors studied here, several were identified as 
significant for PFS (Table 2). Having recovered normal values of serum levels 
of IgM in patients with IgG MM at day 100 after ASCT, was identified as a 
significant prognostic factor for PFS (HR = 0.76, p < 0.04), meaning that the 
patients who recovered the polyclonal compartment of Ig at day 100 after 
ASCT have a risk of relapse that is approximately a third lower for the 
patients who do not recovered normal levels of serum IgM.  Performing a 
similar analysis analyzing the impact of the continuous numeric value of IgM  
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at Day 100 (continuous variable) for PFS, the HR obtained is 0.99, p=0.02; 
meaning that for each increased unit of IgM (mg/dl) at day 100 after ASCT 
the risk of relapse decrease 1%. 
Other factors were found to impact on progression free survival in our cohort 
of MM patients (Table 2), namely β2 microglobulin at diagnosis, LDH at 
diagnosis, percentage of bone marrow plasma cells at diagnosis, plasma cell 
labeling index, disease status at diagnosis and having aneuplodia in the 
cytogenetics evaluation of diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 - Progression free survival analysis of IgG MM patients after 
ASCT.  Analysis was performed based on having or not recovered normal 
serum levels of IgM at day 100 after ASCT. The patients who recovered 
normal levels of polyclonal Ig after ASCT achieved a longer PFS, p=0.048. 
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Figure 2 - Progression free survival analysis in the sub group of IgG 
MM patients who were in response at day 100 after ASCT. The patients 
who recovered normal levels of polyclonal Ig after ASCT achieved a longer 
PFS compared to those who did not recover normal levels of IgM, p=0.07. 
 
 
7.4.3. Multivariate analysis of prognostic factors 
Cox regression models for multivariate analysis of the prognostic factors 
highly significant in the univariate analysis were developed. Having recovered 
normal serum levels of IgM at day 100 after ASCT is an independent 
prognostic factor for progression free survival in a model that considered B2 
microglobulin, recover IgM serum levels, percentage of bone marrow plasma 
cells, plasma cell labeling index and having an aneuploidy cytogenetics 
versus normal (Table 3). 
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Table 2 – Univariate analysis for PFS on patients with IgG MM subject 
to ASCT. 
 
Prognostic factors Progression free survival 
   HR*          95% CI           p  value 
Age 1.00 0.99-1.03 0.99 
β2 microglobulin 1.23 1.07-1.39 0.004 
LDH at diagnosis 1.0 1.0-1.0 0.05 
Recovered normal levels IgM at 
D100 vs not recovered IgM 
0.76 0.57-0.99 0.04 
Level of serum IgM at Day 100 0.99 0.97-0.99 0.02 
Bone marrow plasma cells 1.02 1.00-1.03 0.004 
CRP at diagnosis 1.19 0.92-1.47 0.16 
Conditioning regimen 0.87 0.55-1.38 0.55 
Disease status at the transplant 
(Plateau/Response vs Relapse) 
1.57 0.99-2.47 0.05 
Plasma Cell Labeling Index 1.34 1.15-1.53 0.0009 
Aneuploid vs normal 0.58 0.49-0.78 0.0004 
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Table 3 – Multivariate analysis for PFS on patients with IgG MM 
subject to ASCT. 
 
Prognostic factors Progression free survival 
 HR*         95% CI       p  value 
β2 microglobulin 1.21 1.01-1.44 0.04 
Bone marrow plasma cells 0.99 0.97-1.01 0.63 
Level of serum IgM at Day 100 1.30 0.99-1.76 0.05 
Plasma Cell labeling Index 1.21 0.99-1.45 0.06 
Aneuploid vs normal 2.56 1.31-4.78 0.007 
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7.5. Discussion 
 
Multiple myeloma is a disease where immune deregulation is manifest. 
Several are the clinical situations that illustrate this phenomenon during the 
course of the disease.  Myeloma patients have higher risk of infection [255, 
256], abnormal B cells function and hypogamaglobulinemia [247], altered 
lymphocytes sub population numbers [245], decrease TCR repertoire 
diversity [257], among other changes of the immune system that contribute 
to the elevated number of infections on this patients’ population [258, 259]. 
Some of these authors suggest that myeloma patients, who are at increased 
risk of serious infection, can be identified and may benefit from replacement 
immunoglobulin therapy to reduce the risk of infection. Chapel H et al., from 
the UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma, 
reported significant benefit on the use of intravenous immunoglobulin as 
prophylaxis against infection in plateau-phase multiple myeloma in a multi 
center randomized trial [260].  
 
Given all these immune alterations related with this particular disease, it is 
key to guarantee a high-quality immune recovery after myeloablative 
treatments as ASCT, as the ability to fight minimal residual disease, what is 
highly prevalent in MM patients after autologous transplantation [261]. Also, 
providing that intravenous immunoglobulin protects against life threatening  
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infections and significantly reduces the risk of recurrent infections, it is 
reasoning to expect that recover of polyclonal compartment of Ig during 
immune reconstitution after autologous transplantation in MM patients would 
impact on relapse risk and/or patient survival. 
At baseline and after treatment approaches as ASCT, the levels of immune 
cells and the rate of immune reconstitution were identified as determinant 
factors affecting survival of these patients [82, 85, 262]. 
In Porrata et al’s studies the immune reconstitution after ASCT was analyzed 
using the absolute number of lymphocytes as a surrogate of the immune 
system robustness. Hofer at al. reported as an abstract, that the recovery of 
polyclonal immunoglobulin synthesis after ASCT in MM patients was a 
prognostic factor for event-free survival [263].  Here we studied the recovery 
of IgM levels in IgG MM patients subjected to ASCT.  Our results suggest that 
the recovered of the polyclonal compartment of immunoglobulin during 
immune reconstitution after ASCT in patients with MM is crucial to vigor the 
immune system detecting minimal residual disease, decreasing the risk of 
relapse. This effect seems independent of other predictor factors such as b2 
microglobulin and aneuploidia at cytogenetics analysis. The progression free 
survival of patients who recovered normal levels of IgM at D100 after ASCT is 
prolonged in approximately one year compared to those who did not 
recovered normal levels of IgM at D100, even in the sub analysis of patients 
who were in response at D100 after ASCT. The power of this analysis is 
somehow limited by the fact that only the serum levels of recovered IgM at  
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D100 after transplant were analyzed here.  However, it is predictable that a 
time dependent analysis of recovered serum levels of IgM, collected since the 
date of transplant until the end of follow up, would significantly increase the 
statistical differences already detected by this analysis at one time point, i.e., 
day 100 after ASCT. 
 
The fact that treatment with intravenous immunoglobulin is used widely in 
clinical practice to treat infections [93] and control inflammation [91], and 
given the crescent evidence that is useful during immune reconstitution [252, 
253], it seems reasonable to expand measures to increase serum levels of 
polyclonal immunoglobulin in myeloma patients who underwent autologous 
stem cell transplantation. 
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8.1. Abstract  
 
Background/Objective: Rituximab immune-mediated mechanisms of 
action suggest that it efficacy depends on host immunocompetency. 
Therapies, such as IL-12, that stimulate the immune system may therefore 
increase rituximab efficacy.  We hypothesized that a stronger host immune 
system at the time of rituximab would result in better clinical outcome.  
Herein, we present data supporting that host immune-competence, analyzed 
by absolute lymphocyte count (ALC) and lymphocyte subsets in the 
peripheral blood, predicts a superior survival in non-Hodgkin lymphoma 
(NHL) patients treated with rituximab-based regimens.   
Study Methods: We studied 41 NHL-patients participating in a Phase I study 
of interleukin-12 (IL-12) and rituximab.   
Results: The median follow-up was 42 months.  Patients with ALC ≥ 0.9 x 
109/L experienced superior progression free survival (PFS) compared to 
patients with ALC < 0.9 x 109/L prior to rituximab therapy (21 vs 4 months, 
p < 0.001).  Patients with CD4 count ≥ 500 cells/µl also experienced a 
superior PFS compared to patients with CD4 count < 500 cells/µl (21 vs 9 
months, p < 0.0062). Multivariate analysis demonstrated ALC to be an 
independent prognostic factor for PFS.   
Interpretation and conclusions: Our data denote the value of an immune 
competent host in predicting the efficacy of rituximab therapy in NHL.   
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Keywords: Immunity, Lymphocyte number, Rituximab therapy, Non 
Hodgkin lymphoma. 
 
 
Running title: Response to Rituximab depends on the immune system 
status 
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8.2. Introduction 
 
The exact in vivo mechanism of action of rituximab is not fully elucidated.  
However, the cytotoxic effects of rituximab on CD20-positive malignant B 
cells appear to involve complement-dependent lysis [264], complement-
dependent cellular cytotoxicity (CDC) and antibody-dependent cellular 
cytotoxicity (ADCC) [265], induction of apoptosis [266] and sensitization of 
tumor cells to the effects of chemotherapy through the modulation of 
molecular signal pathways [267].  Thus, rituximab induces responses by 
inducing apoptosis but also by recruiting immune cells to help in the lysis of 
malignant cells. 
As the vast majority of the proposed mechanisms of action of rituximab are 
immune-mediated, we predicted that the efficacy of rituximab therapy would 
depend on the immunocompetency of the host.  Thus, assessing and 
predicting patient immunity before treatment with rituximab would allow a 
better selection of the patients who would benefit from this treatment in 
terms of clinical outcomes. 
Interleukin-12 (IL-12) is a cytokine that has been shown to have a profound 
effect on T and natural killer (NK) cell function [268, 269] and that increases 
ADCC [55]. IL-12 used alone as a therapeutic agent in cases of relapsed and 
refractory hematological malignancies has shown promising results [51, 270, 
271]. This and the fact that the mechanism of action of IL-12 suggested that 
it could have an additive anti-tumor effect when given with rituximab, formed  
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the basis for combining rituximab and IL-12 in an investigational protocol to 
treat non-Hodgkin lymphoma (NHL) [51, 272]. 
The absolute lymphocyte count (ALC) recovery ≥ 500 cells/μL at day 15 
(ALC-15) after autologous stem cell transplantation (ASCT) has been 
reported as a powerful and independent prognostic factor for clinical 
outcomes for patients with NHL [82, 216, 217], Hodgkin lymphoma [84, 
216], multiple myeloma [82], acute myelogenous leukemia [218], 
amyloidosis [83], and breast cancer [86/, 219].  Furthermore, the time-
dependent kinetics to achieve an ALC ≥ 500 cels/μL after ASCT also predicts 
overall survival (OS) and progression free survival (PFS) after ASCT in NHL 
[273], corroborating the importance of lymphocyte recovery as a surrogate 
of immune recovery. 
To assess the significance of an immune competent host in predicting the 
efficacy of rituximab therapy we conducted a retrospective study of NHL 
patients treated with Interleukin-12 and rituximab and assessed lymphocyte 
numbers, lymphocytes subsets, response rate and PFS. 
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8.3. Patients and Methods 
 
8.3.1. Patient population. We studied forty-one NHL patients that 
participated in our Phase I interleukin-12 plus Rituximab study [51].  The 
rationale for selecting this group of patients was that besides having a 
baseline ALC count performed, all patients required baseline flow cytometry 
analysis providing lymphocyte subset data prior to treatment.  Response to 
therapy, relapse, and survival data were updated continuously. All patients 
gave written, informed consent allowing the use of their medical records for 
medical research. Approval for the retrospective review of these records was 
obtained from the Mayo Clinic Institutional Review Board and was in 
accordance with US federal regulations and the Declaration of Helsinki.  
 
 
8.3.2. End points. The primary end-point of the study was to assess 
whether the ALC count prior to rituximab/IL-12 therapy predicted PFS and 
the second end-point was to identify which lymphocyte subset in the ALC was 
responsible for affecting PFS after rituximab/IL-12 therapy.   
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8.3.3. Lymphocyte subset analysis. Immunophenotyping of mononuclear 
cells was performed using a two-color direct staining of cells with mouse 
monoclonal antibodies. Fluorescein isothiocyanate- or phycoerythrin-coupled 
monoclonal antibodies (Becton Dickinson PharMingen, San Diego, CA, USA) 
were directed at human CD3, CD4, CD8, CD16/CD56, CD19. Phenotypic 
analysis was performed with a FACStar PLUS flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA) equipped with CONSORT 40 software 
(Becton Dickinson Biosciences, San Jose, CA, USA). Fluorescein 
isothiocyanate- and phycoerythrin-coupled isotype-matched immunoglobulins 
were used as isotypic controls. 
 
 
8.3.4. Prognostic factors. This study included the following prognostic 
factors: international age-adjusted prognostic index (IPI) [220] (age (≥60 vs 
<60), lactate dehydrogenase (LDH) > normal, performance status (PS-
ECOG) (≥2 vs <2), extranodal sites (≥2 vs <2) and stage (III/IV vs I/II)), in 
addition to the number of lymphocytes (ALC), CD3, CD4, CD8, CD19, 
CD16/56,  number of previous treatments (≥2 vs <2), the dose used of IL-
12, and the histological subtype of lymphoma. The ALC and numbers of 
lymphocytes subset were determined immediately prior to the treatment. In 
the case of follicular lymphomas Follicular lymphoma international prognostic 
index (FLIPI)[274] was also included in the analysis. 
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8.3.5. Response and survival. Response criteria were based on the 
guidelines from the NHL International Workshop [220]. Complete remission 
(CR) was defined as complete regression of all measurable disease including 
radiologically demonstrable disease, BM involvement, or peripheral blood 
involvement. Partial remission (PR) was defined as a reduction in the sum of 
the products of measurable lesions' longest diameters and perpendicular 
diameters of 50% or greater, with a 30% or greater decrease in 
hepatomegaly or splenomegaly (measured from the costal margin), if there 
was previous known liver or spleen involvement. Disease progression was 
defined as a 25% or more increase in the sum of the products of the longest 
diameter and its perpendicular diameter of measurable lesion(s) from the 
pre-study measurement, the appearance of new lesions, or a 2-cm increase 
in spleen or liver size due to lymphoma.  
Progression-free survival (PFS) time was assessed from the initial date of 
treatment to date of disease progression, or relapse.  
 
 
8.3.7. Statistical analysis. PFS times were analyzed using the method 
described by Kaplan and Meier [221]. Differences between survival curves 
were tested for statistical significance using the 2-tailed log-rank test. ALC 
and CD4 were assessed as continuous variable and dichotomized, based on 
the optimal  
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cut-off point based on the log-rank statistic. The ALC and the CD4 values 
analyzed to identify the optimal cut-off point included a range from 0.37-
5.62 x 109/L and 80-2072 cells/µl, as these values were between the 25% 
and 75% quartiles for ALC and CD4, respectively.   The Cox proportional 
hazards model [222] was used to assess ALC and lymphocyte subsets as a 
prognostic factor for PFS as well as to adjust for other prognostic factors. 
Multivariate analysis done using Cox regression models tested all variables 
with a p < 0.008 in the univariate analysis. The p-value cutoff to move 
forward a factor from the univariate into the multivariate was selected based 
on the use the Bonferroni’s correction procedure for multiple comparisons 
with a small number of events.   
In addition to the evaluation of ALC and its prognostic significance for PFS, 
its utility as a marker for CD4 was also assessed.  The choice of the optimal 
cut-off of ALC was based on its utility as a marker for CD4 using ROC curves 
and area under the curve (AUC) analysis. Prediction of CD4 numbers was 
explored further in logistic regression models, univariately assessing 
continuous and dichotomized values of ALC as well as the other potential 
prognostic factors described above. Pearson’s chi-square analysis was used 
to determine relations between nominal variables; the Wilcoxon rank-sum 
tests or the Kruskal-Wallis rank-sum tests were used to determine 
associations between continuous variables and categories, and Spearman 
correlation coefficients were used to evaluate correlation for continuous  
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variables. All p values represented were 2-sided, and statistical significance 
was declared at p< .05.  
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8.4. Results  
 
8.4.1. Patient characteristics 
Patient characteristics prior to treatment with Rituximab/IL-12 are detailed 
on table 1. Of the 41 NHL patients studied, 20 were females. The median age 
of the cohort was 53 years (range: 34-84).  All the patients had performance 
status (ECOG) 0 or 1.  At diagnosis, twenty-four patients had stage 4 
disease, 11 patients in stage 3, 5 patients stage 2 and 1 patient had stage 1 
disease. The numbers of prior treatments varied from 0 to 6. PFS was 
assessed from the initial date of treatment.  The median follow-up was 42 
months (1-62 months).  The median ALC prior to rituximab/IL-12 therapy 
was 0.97 x 109/L (range, 0.37-5.62 x 109/L). 
 
 
 
 
 
 
 
 
 218
Chapter VIII 
 
Table 1 – Patients characteristics (N=41) 
Characteristics 
Age  Median, Range 
53, 34-84 
Sex 
      Females 
      Males 
Number of patients (%) 
20 (49%) 
21 (51%) 
Lymphoma histology 
     Follicular 
     Diffuse large cell 
     Mantle cell 
     Lymphoplasmacytic 
     Lymphocytic 
     T-cell rich B-cell 
Number of patients (%) 
21 (51%) 
10 (24%) 
5 (12%) 
2 (5%) 
2 (5%) 
1 (3%) 
Number of prior treatments  Median, Range 
1, 0-6 
Treatment 
      Rituximab* alone 
      Rituximab* plus IL-12** 
               IL-12 30 ng/Kg 
               IL-12 100 ng/Kg 
               IL-12 300 ng/Kg 
               IL-12 500 ng/Kg 
Number of patients (%) 
6 (15%) 
 
6 (15%) 
9 (22%) 
13 (31%) 
7 (17%) 
Lymphocyte subset prior to treatment/μL 
      CD4+ T cells  
      CD8+ T cells 
      NK cells 
      B cells  
Median, Range 
359, 80-2072 
304, 65-2677 
204, 32-1338 
87, 3-1027 
* Rituximab 375 mg/m2 i.v. weekly for 4 weeks 
**IL-12 was done s.c. twice weekly at different doses as detailed, for a 
maximum of 24 weeks. 
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8.4.2. Progression and survival  
Univariate analysis of prognostic factors 
At the time of this analysis, 78% (32/41) patients had progressed and 41% 
(17/41) patients had died. ALC, as a continuous variable, was identified as a 
prognostic factor for PFS (HR = 0.99, p < 0.001) (Table II).  The use of ALC 
≥ 0.9 x 109/L as a cutoff value was selected as it yielded the highest 
difference in the survival by χ2 when different cut points were analyzed from 
0.37-5.62 x 109/L. The median PFS was significantly better for patients with 
an ALC ≥ 0.9 x 109/L (n = 23) vs an ALC < 0.9 x 109/L (n = 18) from the 
time of rituximab/IL-12 therapy (21 months vs 4 months, p < 0.001, 
respectively) (Figure 1). At the study date, 14/23 (60%) patients with ALC ≥ 
0.9 x 109/L had progressed while all the 18 (100%) patients with ALC < 0.9 
x 109/L had progressed, p< 0.003.  
The lymphocyte subset analysis revealed that CD4, as continuous variable, 
was also identified as a prognostic factor for PFS (HR = 0.99, p = 0.02) 
(Table II).  The use of CD4 ≥ 500 cells/µl as a cut-off value yielded the 
highest difference in survival by χ2 when different cut points were analyzed 
from 80-2072 cells/µl. The median PFS was significantly better for patients 
with a CD4 ≥ 500 cells/µl (n = 19) vs a CD4 < 500 cells/µl (n = 22) from the 
time of rituximab/IL-12 therapy (21 months vs 9 months, p < 0.006, 
respectively) (Figure 2). At the time of this analysis, 9 of the 16 patients with 
CD4 ≥ 500 cells/µl (56%) had progressed while 22 of 25 patients with CD4 < 
500 cells/µl (88%) had progressed, p< 0.0005.  
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In addition, PFS was not affected by the different doses of IL-12 
administered (p = 0.18).  However, in patients that received IL-12 doses of 
100ng/kg, 300ng/kg, and 500ng/kg, a superior PFS was observed in those 
patients with an ALC ≥ 0.9 x 109/L compared to patients with an ALC < 0.9 x 
109/L [100ng/kg group (median: 21 vs 10 months, p < 0.04); 300ng/kg 
group (median: 31 vs 4 months, p < 0.01); and 500ng/kg (median: not 
reached vs 7 months, p < 0.02)].  
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Table 2 – Univariate analysis for PFS in patients with NHL subject to 
treatment with rituximab/IL-12.  
 
Prognostic factors Progression free survival 
 HR              95% CI          p  value 
Age 1.00 0.98-1.03 0.74 
LDH (normal vs > normal) 3.62 1.45-8.34 0.008 
Number of prior treatments  
(≥ 2 vs <2) 
5.8 2.5-15.3 <0.0001 
Stage (III/IV vs I/II) 0.94 0.36-3.21 0.90 
Extra-nodal sites (≥ 2 vs 
<2) 
2.48 0.83-6.09 0.10 
Histology (follicular vs 
other) 
1.32 0.93-1.91 0.12 
Disease status prior to 
rituximab (NR vs CR/PR) 
2.25 1.44-3.45 0.0006 
IL-12 dose* 0.67 0.46-1.00 0.05 
ALC/μL prior to rituximab  0.99 0.998-0.999 0.001 
NK cells prior to rituximab 1.00 0.99-1.00 0.96 
CD4+ T cells prior to 
rituximab 
0.99 0.997-0.999 0.02 
CD8+ T cells prior to 
rituximab 
0.99 0.99-1.00 0.48 
CD19+ cells prior to 
rituximab 
0.99 0.99-1.00 0.20 
HR – Hazard ratio. 
95% CI – 95% Confident interval. 
* Natural Log transformation. 
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Figure 1 – Progression free survival for 41 patients with non Hodgkin 
lymphoma from the time of rituximab/IL-12 therapy as a function of recovery 
of absolute number of lymphocytes. 
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Figure 2 – Progression free survival for 41 patients with non Hodgkin 
lymphoma from the time of rituximab/IL-12 therapy as a function of recovery 
of CD4 lymphocyte. 
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P < 0.006 
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Multivariate analysis of prognostic factors 
Only prognostic factors that fulfilled the criteria of a p < 0.008 were analyzed 
in the multivariate analysis.  This value was found using the Bonferroni’s 
correction for multiple comparisons.  ALC remained an independent 
prognostic factor for PFS (HR = 0.56, p < 0.03) when compared to LDH, 
number of prior treatments and disease status prior to rituximab (Table 3).   
 
 
 
Table 3 – Multivariate analysis for PFS in patients with NHL treated 
with rituximab/IL-12. 
 
Prognostic factors Progression free survival 
   HR                 95% CI           
p  value 
LDH (normal vs > normal) 1.44 0.87-2.37 0.15 
Number of prior treatments  
(≥ 2 vs <2) 
2.47 0.86-7.45 0.09 
Disease status prior to 
rituximab (NR vs CR/PR) 
1.85 1.14-2.98 0.01 
ALC prior to rituximab  0.56 0.27-0.96 0.03 
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8.4.3. Sub-analysis of follicular lymphomas 
Due to the heterogeneity of the histologies analyzed in this study, we 
analyzed the role of ALC and CD4 in patients with follicular lymphomas. In 
the 21 patients with follicular lymphoma, the univariate analysis 
demonstrated that CD4 numbers (HR = 0.996, p < 0.008) and ALC (HR = 
0.35, p < 0.002) were prognostic factors for PFS. Besides these two 
parameters, LDH at diagnosis (HR=5.72, p = 0.02), the number of prior 
treatments (HR=5.01, p = 0.01), disease status prior to rituximab (HR=2.23, 
p = 0.03), FLIP>2 (HR=3.57, p = 0.045) and IL-12 dose (HR=0.32, p = 
0.003), were also predictive factors for PFS. In contrast, for non-follicular 
lymphomas, LDH and IL-12 dose were not significant predictors for PFS (p = 
0.12 and p = 0.75, respectively).  In addition, stage at diagnosis and 
presence of extra nodal disease were statistically significant as predictors for 
PFS for non-follicular lymphomas (p = 0.04 and p = 0.01, respectively). 
The multivariate analysis shows, in the sub-group of patients with follicular 
lymphoma, that CD4+ T cells counts prior to rituximab (HR = 0.996, p < 
0.03) is a significant independent predictor factor for PFS after rituximab, 
adjusting for the Follicular Lymphoma International Prognostic Index at the 
time of treatment.   
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8.4.4. The role of ALC on CD4 counts 
Due to the fact that CD4 counts are not routinely ordered in every patient 
treated with rituximab, we assessed the utility of ALC (obtained from the 
available and standard complete blood cell count) as a marker of CD4. ROC 
curves and AUC analysis showed that ALC was a significant marker for CD4 
(AUC =0.82, p < 0.0009) and a sensitivity of 95% with a specificity of 68%.  
With regard to the association between ALC and CD4, these dichotomized 
variables were found to be significantly correlated with each other (p < 
0.0005) as were their continuous counterparts (rs=0.65, p < 0.0001).  
Logistic regression models for predicting CD4 further indicate that ALC is 
significantly correlated with this clinical outcome (p < 0.0025).  These results 
increase the generability and external validity of this study.   
Another significant factor for CD4 in the univariate setting was the number of 
prior treatments (p < 0.0007), as patients that received more than two prior 
treatments had less CD4 count compared to those who did not prior to 
rituximab therapy (median: 0.77 vs 1.38 cells/µl, p < 0.04, respectively).  
When these factors were accounted for in a multivariate logistic regression 
model, ALC remained significantly correlated with the CD4 count (p < 0.01).  
An ALC ≥ 0.9 x 109/L was associated with an adjusted odds ratio for CD4 
count of 6.74 (95% CI, 1.49-38.1).  Despite the different histologies, no 
association was identified between histology and ALC (as continuous variable, 
p = 0.77, or dichotomized variable, p = 0.76) or CD4 count (as continuous 
variable, p = 0.77, or dichotomized variable, p = 0.76).  In addition, no 
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association was identified between histology and lymphocyte subsets, as 
continuous variables (CD3, p = 0.1; CD8, p = 0.23; CD19, p = 0.55, and NK 
cells, p =0.11). 
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8.5 Discussion 
 
The underlying immunologic mechanisms of rituximab therapy suggest that 
the host immune status plays an important role of in the therapeutic efficacy 
of rituximab [36].  Therefore, we set out to investigate whether the host 
immune system, as defined by the ALC (as a surrogate marker for host 
immune status) and lymphocyte subsets, affects the clinical outcome of 
patients treated with rituximab.  We analyzed patients that participated in a 
phase I trial of rituximab and IL-12 as it was mandatory in this study to 
obtain baseline lymphocyte subset numbers besides ALC prior to therapy. 
This study shows that patients with a higher ALC at the time of rituximab 
therapy experienced better progression-free survival compared to those who 
did not.  This finding concurred with a recent report showing that ALC was an 
independent prognostic factor for event-free survival in patients with 
follicular or mantle cell lymphoma treated with single agent rituximab [275].  
Our study differed in the fact that we identified that not only ALC is a 
prognostic factor for progression-free survival, but also that patients with 
higher numbers of CD4 cells in the peripheral blood have a superior clinical 
outcome.  This finding is significant because the presence of activated CD4+ 
T-cells infiltrating the tumor bed of lymphoma patients has been reported to 
affect survival [276].  The authors argued that a possible mechanism leading 
to the better outcome of patients with higher numbers of CD4+T-cells  
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infiltrating the tumor bed is that CD4+ T-cells may be responsible for 
stimulating antigen-presenting cells, thereby up regulating the immune 
response; and enhancing the anti-tumor immune response.  Further research 
of sub-sets of CD4+ T cells, namely characterizing TH1 or TH2 cytokine 
profile production, and also regulatory phenotype and activity of CD4 T cells 
may better elucidate the precise immunological role of CD4+ T cells prior to 
treatment with rituximab-combined antineoplastic treatments in the clinical 
outcome of NHL patients. 
Patients in this study were also received IL-12 with the intention of 
enhancing the immune response against the tumor. Regarding the dose of 
IL-12 concomitantly administered with rituximab therapy, which was found to 
be associated with PFS, it is important to comment on the way this analysis 
was performed. The analysis of the dose of IL-12 used was done by 
comparing the natural logarithm of the dose increment of IL-12 as predictor 
factor for PFS, by Cox analysis. This type of analysis allowed us to compare 
the importance of using higher increments versus smaller increments of IL-
12 dose to achieve a better clinical response. Because, there was no 
escalation of dose within the same patient in the study, this result suggests 
that patients who started IL-12 at a higher dose achieved a better clinical 
outcome compared to patients who were treated with IL-12 at smaller doses. 
However, the Phase I trial was not powered for this specific analysis [51]. 
This predictor factor was found to be dependent on the ALC prior to 
diagnosis, suggesting that IL-12 treatment itself achieve better results in  
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patients whose immune system is in a better shape, as defined by the 
number of lymphocytes in the peripheral blood. This report gives grounds to 
hypothesize that the clinical results of NHL immunotherapy depend on the 
robustness of the patient’s immune system and predicts that very immune 
depressed patients may not be the best candidates for this type of approach.  
This is exemplified by the fact that the number of prior treatments was a 
poor prognostic factor for progression-free survival in this study.  Patients 
who received more than 2 prior treatments had lower peripheral CD4 count 
and ALC prior to rituximab therapy.  Thus, the immunosuppressive effect of 
chemotherapy should be taking into consideration in the future planning of 
immunotherapeutic studies in the light of these findings. 
The routine lymphocyte subset analysis by flow cytometric analysis in 
patients treated with rituximab is not standard of practice and the application 
of this technique might be hampered by its cost and restricted availability in 
clinical practice.  Thus, we studied ALC as a surrogate marker for CD4 
counts.  This study showed a strong correlation between ALC and CD4, 
suggesting that ALC is a good marker of the immune status of the patient.  
Since ALC is obtained from the standardized complete blood count, ALC is a 
more practical, less costly, and more available prognostic factor to assess the 
immune status of the patient prior to rituximab therapy. 
This study included NHL patients who participated in our Phase I interleukin-
12 plus rituximab study and that had flow cytometry analysis performed 
immediately before the treatment.  This selection of patients limited the  
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potential findings of this study as only a small number of patients were 
selected.  Besides this limitation, this study highlights the fact that a 
competent immune system is required for clinical benefit with rituximab 
therapy in NHL patients. More studies are warranted to analyze the status of 
the host immune system as a potential variable affecting outcome as 
immunological therapies are tested in the clinic setting. 
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Discussion, General Conclusions and Future Directions 
 
The data presented in this dissertation originated several novel scientific 
conclusions and, may point to a new paradigm concerning the way 
immunologists and physicians perceive B and T lymphocyte interdependence 
and the immune system web of relationships.  
In collaboration with Dr. Jeffrey Platt’s group at the Mayo Clinic, I developed 
a new quantitative method to directly assess lymphocyte diversity and 
applied this method to B and T cell populations. This novel technique uses 
gene chips arrays and its rational, demonstrated in Chapter III, is based on 
the fact that the frequency of hybridization of nucleic acids coding for 
lymphocyte receptors to the oligonucleotides on a gene chip varies in direct 
proportion to diversity. We applied the technique to detect changes in 
lymphocyte diversity in mice with known B cell alterations and in people with 
known T cell repertoire defects. This approach is the first to provide a direct 
analysis of lymphocyte receptor diversity and has already facilitated 
fundamental studies of the adaptive immune system and clinical efforts to 
assess immunological diseases. 
 
This work shows that B cells and polyclonal immunoglobulin are essential 
elements driving T cell receptor diversity generation and, subsequently, 
peripheral T cell function.  As demonstrated in Chapter IV, polyclonal 
immunoglobulins have an essential role in the development of T cells in 
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the thymus as promoters of TCR diversification. This may happen through 
the presentation of diverse immunoglobulin’s peptides by B cells and other 
antigen presenting cells existing in the thymus, to the developing T cell 
during the process of TCR diversification. The result is to promote positive 
selection of thymocytes and to decrease death by neglect. This hypothsis is 
reinforced by the finding of an increased apoptosis in the thymic cortex of 
mice that lack B cells or immunoglobulin. Since apoptosis in the thymic 
cortex of wild type mice is comparable to apoptosis detected in mice that 
produce serum immunoglobulin but have few B cells (μMT mice), our results 
indicate that serum immunoglobulin also promotes thymocyte survival 
besides its effect on promoting TCR diversification.  
These observations may have great implications to the way scientists and 
physicians perceive the immune system and its deregulations. Thus help to 
elucidate the phenotype of B cell-deficient human individuals and suggest a 
potential approach to immune reconstitution using immunoglobulin. 
As a consequence of these results, we decided to examine the role of 
immunoglobulin in the function of peripheral T cells. Polyclonal 
immunoglobulin is used for the treatment of several diseases. However, the 
impact of its use on the function of the T cell compartment needs further 
characterization. With this purpose we developed mouse models that allow 
the investigation of the role of B cells and immunoglobulin to the function of 
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T cells at the periphery.  
In vivo testing of T lymphocyte function was performed using H-Y 
incompatible skin grafts; the survival time of the grafts was used as a 
measurement of the function of T cell lymphocytes. Skin grafts are rejected 
by CD4+ and CD8+ T cells, so an impairment of T lymphocyte function would 
allow a longer survival of the grafts. Rejection of H-Y incompatible skin graft 
in mice with oligoclonal B-cells and in mice lacking B-cells was significantly 
delayed compared to wild type mice, indicating that the presence of B cells 
and/or immunoglobulin are essential to an enhanced T cell function. The 
assessment of TCR V β diversity on these mice (all strains with the same MHC 
background) demonstrated that the presence of B cells or polyclonal 
immunoglobulin was determinant for the diversity of the T cell repertoire. 
To verify these rational and results, we induced a reduction of the TCR V β 
diversity by thymectomy in wild type mice and observed a significant 
increase of the survival of H-Y incompatible skin grafts.  Also, the 
reconstitution of T-cell diversity in mice with oligoclonal B-cells with 
immunoglobulin Fab fragments significantly decreased survival of the skin 
grafts.  These results indicate that B-cells and/or Ig “help” T-cells through 
the generation and maintenance of T-cell diversity, improving T-cell function.  
These results, again, may have important implications on therapy and 
immune improvement in the context of AIDS, cancer, autoimmunity and 
post-myeloablative treatments, where immune reconstitution occurs. 
The T cell repertoire may be influenced by the immunoglobulin idiotypic  
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peptides presented either by B cells or by other antigen presenting cells. The 
presence of polyclonal immunoglobulin or of immunoglobulin Fab fragment 
seems to overcome the impact of the absence of B cells in what concerns the 
diversity of TCR Vβ, since their administration to mice lacking B cells 
significantly enhance TCR Vβ diversity.  
The impact of immunoglobulin idiotypic peptides on TCR cell diversification 
and function could be seen as a further development of Jerne’s idiotypic 
network theory and as another potential usefulness of immunoglobulin, in 
addition of its recognized roles on the treatment of B cell immunodeficiencies 
and autoimmune, inflammatory and infectious disorders. Thus, the 
development of strategies that increase the diversity of the T cell repertoire 
may improve T cell function in those situations and others characterized by a 
contracted TCR repertoire, such as AIDS, cancer and following chemotherapy 
and hematopoietic precursors transplantation. 
In addition, the experimental data obtained in animal models and described 
in this work give a new perspective to the way primary immunodeficiencies 
are generally interpreted. In the light of these new findings, the separation of 
B and T cell immunodeficiencies may not be adequate. In fact, a B cell 
immunodeficiency implicates a decrease in T cell function, through 
impairment upon TCR repertoire diversity. Also, a T cell immunodeficiency is 
known to originate an impairment of B cell function since a vast number of 
antigens depend upon T cells for their presentation to B cells. The present 
work proposes that B and T cell immunodeficiencies should be seen as  
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common deregulations of adaptive immunity. Also, the therapeutic approach 
for those situations should take into account the influence exerted by the 
cellular and humoral immune compartments upon each other. This could be 
done, for instance, through the use of polyclonal immunoglobulin, which 
would improve both B and T cell functions.  
The clarification of the mechanism of action of immunoglobulins in various 
clinical settings can be extremely relevant. It should be noted that recently 
the infusion of polyclonal immunoglobulin as an adjuvant treatment for 
sepsis was re-assessed. This was a consequence of a meta-analysis including 
all randomized, controlled trials of patients with sepsis who received 
polyclonal immunoglobulin therapy or placebo or no intervention [277].  The 
conclusions of this meta-analysis were that a survival benefit was observed 
for critically ill patients with infections receiving polyclonal immunoglobulin 
compared to those who received placebo or no intervention. This result 
shows the immune modulator effect carried out by polyclonal 
immunoglobulin and is an example of the clinical relevance of the 
experimental work presented here.  
Polyclonal immunoglobulin represents another bond between B and T cell 
compartments at the development stage and at functional level of mature 
cells. Also, immunoglobulin derivatives, like Fab fragments, can be used to 
improve T cell function in vivo during immune reconstitution, avoiding some 
immunosuppressive effects of polyclonal immunoglobulin. The in vivo 
administration of the whole molecule of immunoglobulin may have  
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immunosuppressive properties since Fc receptors, present in a vast number 
of immunological cells and having crucial functions on the activation of those 
cells, are blocked by the binding of the Fc portion of the immunoglobulin 
molecule. 
 
The second part of the work presented in this dissertation, applies this new 
view of interactions within the immune system to the clinical setting. More 
specifically, the immune reconstitution after myeloablative treatments in 
onco-hematology was evaluated, based on preliminary data published by Dr. 
Porrata et al [82, 84, 234]. This evaluation was performed in patients with 
haematological tumours (lymphomas and myelomas) undergoing high dose 
anti-neoplastic therapy with autologous haematopoietic support. The data 
obtained establish that the robustness of the reconstituted immune system 
after autologous stem cell transplantation is a major determinant predicting 
progression free survival and overall survival in those patients.  In particular, 
I examined a series of patients with mantle cell lymphoma undergoing 
autologous hematopoietic stem cell transplantation and another series of 
patients with non-Hodgkin lymphoma treated with rituximab.  In the case of 
MCL patients, the early recovery of higher absolute lymphocytes numbers 
after ASCT predicts a significantly longer survival (overall and without 
relapse). This suggests that a robust immune system would offer an 
advantage in situations of immune reconstitution.  When patients with NHL  
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were treated with rituximab, the presence of sufficient numbers of 
lymphocytes before the treatment, in particular of CD4+ T cells, predicted a 
lower risk of relapse.  
Also, in agreement with the results from the experimental models showing 
that treatment of immunodeficient mice with polyclonal immunoglobulin was 
able to increase TCR repertoire diversity and to improve T cell function. I 
showed that, in the case of multiple myeloma patients in remission after 
autologous hematopoietic stem cell transplantation, the recovery of the 
polyclonal immunoglobulin compartment is an independent factor predicting 
relapse free survival.  This effect was shown to be independent of other well 
known predictive factors in multiple myeloma such as β2 microglobulin and 
cytogenetic abnormalities. These data suggest that the recovery of the 
polyclonal compartment of immunoglobulin during immune reconstitution 
after autologous stem cell transplantation in patients with multiple myeloma 
is crucial to re-inforce the immune system, decreasing the risk of relapse. 
These observations set the ground for future clinical studies testing the 
impact of treatment of these patients with IVIg as a way of boost their 
immune system. 
 
The work presented here represents, in my view, a step forward on the 
knowledge of T cell development, B cell-T cell interdependency and 
relationship, the function of immunoglobulin and its effect on T cell immunity.   
 
 240
Chapter IX 
 
Understanding the effect of immunoglobulin following autologous stem cell 
transplantation in vivo will potentially creates an opportunity to modulate this 
process in patients after autologous stem cell transplantation, facilitating T 
cell immune recovery in this setting.   
Also, the use of polyclonal immunoglobulin (i.e., IVIg) in patients with B cells 
primary immunodeficiency, hypogammaglobulinemia or viral infections 
might, not only restore the serum level of IgG, decrease autoimmunity and 
inflammation but also improve T cell functions. 
 
As a consequence of the results already obtained in animal models and in the 
setting of autologous transplantation, my areas of interests are now mainly 
the application of the fundamental immunological concepts studied.  Two new 
scientific projects were started and are under development.  The first is a 
prospective laboratorial study aiming to determine the association between 
the recovery of serum immunoglobulin levels and T cell immunity 
(characterized in terms of measurement of recent thymic emigrants, 
proportion of naïve versus memory CD4+ and CD8+ T cells and TCR 
diversity) following ASCT for non-Hodgkin’s lymphoma.  The project is being 
conducted at the Mayo Clinic, Rochester, MN, USA with Dr. Luis Porrata and 
Professor Svetomir Markovic and is funded by a research grant from the 
University of Iowa/Mayo Clinic Lymphoma SPORE Developmental Research 
Grants.  We hypothesized that T cell immune reconstitution after ASCT may  
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be dependent on post-ASCT immunoglobulin recovery. Higher serum 
immunoglobulin levels may be associated with a more effective de novo T  
cell reconstitution, an increase in the number of recent thymic emigrants in 
the peripheral blood, an enlargement of the compartment of naïve T cells and 
an increase in T cell repertoire diversity. The study is designed to accrue 30 
non-Hodgkin’s lymphoma adult patients who are candidates to ASCT.  
Peripheral serum levels of immunoglobulin, recent thymic emigrants, the 
proportion of naïve versus memory CD4+ and CD8+ T cells and TCR diversity 
will be analysed longitudinality.  We will analyze the relationship between the 
variables, indicating to which extent one variable can be predicted by 
knowing the others, including the examination of potential confounding 
factors (as age and baseline levels).  Our goal in this study is generation of 
preliminary, hypothesis generating data that will be the subject of further 
clinical and laboratory investigations.    
This study is a significant step in the field of lymphoma clinical research as it 
integrates basic knowledge about immunoglobulin/T cell interactions with 
clinical observations of post-ASCT immune reconstitution.  If successful, the 
data may further support our argument that early immune recovery following 
ASCT may be one of the most important clinical goals in autologous 
hematopoietic stem cell transplantation.    
The other project is being developed at IGC, Oeiras and started in 2006. The 
goal is to determine whether immunoglobulin or its derivatives, such as Fc or 
Fab fragments, contribute to an improved immune reconstitution after ASCT,  
 242
Chapter IX 
 
and to determine whether injections of immunoglobulin or fragments can 
improve in vivo T cell immune function in mice after ASCT.  The T cell 
functions will be tested using graft rejection and, possibly, an infection 
model.  Because diversity of the T lymphocytes is directly related to T cell 
function [190, 278], this work will examine whether critical defects in 
immunity can be repaired by increasing TCR diversity and T cell function 
following treatment with immunoglobulin or derivatives. This research will 
directly address the immune reconstitution after ASCT but may also provide 
clues of central interest for the fields of AIDS and aging, where immune 
function is an essential determinant for survival [190, 279].  The project is 
funded by Associação Portuguesa Contra a Leucemia and Fundação para a 
Ciência e Tecnologia. 
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